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According to the World Health Organization (WHO), Malignant Melanoma is the most 
aggressive form of skin cancer. Melanoma accounts for only about 4% of skin cancer 
cases but for as many as 74% of all deaths caused by skin cancers. The development of 
regional and/or distant metastases and the lack of promising therapies for the treatment 
of Melanoma are the principal causes of extremely poor survival of Melanoma patients. 
Recently, enormous efforts are taken to unravel the molecular mechanisms that lead to 
tumour development and metastasis. A new class of small non-coding RNAs, the 
microRNAs (miRNAs), has been involved in tumour progression and metastasis. 
MiRNAs are able to modulate the expression of specific target genes binding to their 3’-
UTRs through Ago proteins complex and usually causing transcript degradation.  
The ability of miRNAs to achieve simultaneous fine-tuning of numerous different 
targets makes them a fundamental system for cell regulation but, despite their biological 
importance, the identification of their targets is still a challenging research task. 
The aim of my project is the identification of real functional miRNA-target interactions 
involved in pathways that control Melanoma metastasis. 
The experiments were performed using the metastasis model developed by Xu and 
colleagues (Xu et al., 2008) composed by a low metastatic Melanoma cell line (LMCs), 
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its derivative high metastatic cell lines (HMCs) and the lung metastases (Mets) arisen 
after these cell lines are injected into immunodeficient mice. This model mimics the 
behaviour of cancer cells during metastasis progression. 
To reach proposed aims, I have set up a meta-analysis approach first and a genome wide 
biochemical approach later. The combination of the two approaches have been allowed 
the experimental validation of results obtained by meta-analysis and the identification of 
new miRNA interactors. 
I first performed miRNA microarray experiments on LMCs, HMCs and Mets samples 
observing that miRNA expression profiles are able to distinguish the three different 
grade of metastasis. Since the evidence of miRNAs involvement in metastasi, I used a 
meta-analysis approach to evidence the influence of miRNA in pathways involved in 
the extravasation processes: WNT signalling pathway, Adherens Junction pathway, and 
VEGF signalling pathway. Moreover, I identified important miRNA clusters (e.g. miR-
106a~363 cluster) involved in the regulation of metastatic hallmarks such as the cell 
protrusion formation, cell-cell signaling, and the tissue vascularization. 
In order to validate all the interactions identified by meta-analysis, I set up conditions 
for the simultaneous experimental identification of miRNA-target interactions through 
the high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation 
(HiTS-CLiP). This method uses ultraviolet irradiation to covalently crosslink RNA–
protein complexes, in our case Ago proteins, that are in direct contact (approximately 
over single ängstrom distances) within cells. Through the immunoprecipitation 
complexes are purified allowing the identification of interacting RNA through high-
throughput sequencing methods. 
This technique validated several miRNA-mRNA interactions identified by meta-
analysis and by literature. In particular, has been observed the involvement of miR-106a 
in Adherens junction and VEGF signaling pathways where seems to act as metastasis 
suppressor inhibiting pro-metastatic genes as WAVE3 and VEGFA. Moreover, 
sequencing analyses have confirmed the metastatic powerful for miR-214 and let-7c in 
Melanoma metastasis. 
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The importance of miR-214 was confirmed by results obtained by our collaborator Dr. 
Taverna of University of Torino, while I used let-7c inhibition to confirm that it 
interacts with two targets (FNDC3B and FOXN) identified by AGO-Hits-CLIP 
experiment and that can be studied in future functional studies. 
Finally, I have also discussed the involvement of a new class of miRNA regulators: the 
long non-coding RNAs (lncRNAs). I identified a lot of lncRNAs with the ability to 
regulate miRNA availability. 
Taken together, these findings demonstrate the strong involvement of miRNAs in 
metastasis. In fact, several functional miRNA-transcript interactions could regulate 
extravasation pathways during the Melanoma cells spreading. My experimental 
approach successfully guides us towards important biological results with interesting 
therapeutic implications in Melanoma. 
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Il Melanoma è una delle forme più aggressive di tumore cutaneo. Pur rappresentando 
soltanto il 4% dei tumori della pelle causa quasi il 74% dei decessi dei pazienti che 
presentano neoplasie cutanee. Lo sviluppo di metastasi e la mancanza di terapie efficaci 
sono la causa di una mortalità così elevata. 
Recentemente, grazie a metodiche di medicina molecolare, i ricercatori hanno cercato di 
capire i meccanismi che portano allo sviluppo della massa tumorale e delle metastasi  
individuando nei microRNA (miRNA) dei possibili regolatori coinvolti nella 
progressione tumorale del Melanoma. Questi corti trascritti non codificanti hanno la 
capacità di regolare l’espressione di molti mRNA degradandoli o bloccandone la 
traduzione. Il processo di regolazione guidato dai miRNA è basato sul legame degli 
stessi a specifiche sequenze presenti nei trascritti target grazie all’ausilio di un 
complesso proteico formato prevalentemente dalle proteine della famiglia Argonaute 
(AGO).  
Lo scopo di questa tesi è di identificare queste interazioni miRNA-mRNA coinvolte 
nelle vie di segnale che controllano lo sviluppo di metastasi nel Melanoma. 
Gli esperimenti presentati in questo lavoro sono stati effettuati sfruttando un modello 
cellulare che mima lo sviluppo metastatico (Xu et al., 2008). Il sistema vede l’utilizzo di 
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una linea cellulare a basso potenziale metastatico (LMC), delle linee cellulari derivate 
dalla stessa ma con maggiore potenziale metastatico (HMC) e delle metastasi polmonari 
originate dall’iniezione di queste linee cellulari in topi immuno-deficienti. 
Per raggiungere lo scopo di questa tesi ho messo a punto due approcci che mirano al 
raggiungimento del medesimo risultato permettendo così anche di validare gli stessi. Il 
primo approccio, prettamente di tipo bioinformatico, sfrutta i dati di espressione dei 
miRNA e degli mRNA ottenuti da esperimenti di microarray per individuare le coppie 
miRNA-mRNA coinvolte nello sviluppo del Melanoma. Il secondo approccio, invece, si 
basa su una nuova metodica (AGO-Hits-CLIP) per l’identificazione genome-wide di 
interazioni miRNA-mRNA. Questa metodica sfrutta l’immunoprecipitazione delle 
proteine AGO e il recupero delle molecole di RNA ad esse associate (in questo caso i 
miRNA e i messaggeri bersaglio a cui erano legati). Successivamente, l’RNA 
precipitato viene sequenziato per permetterne l’identificazione. 
L’integrazione dei dati ottenuti dall’analisi con i microarray (meta-analisi) e dall’AGO-
Hits-CLIP mi hanno permesso di individuare delle interazioni miRNA-bersaglio 
coinvolte nello sviluppo di metastasi generate dal Melanoma. 
Innanzitutto mi ha permesso di individuare una serie di vie di segnale strettamente 
correlate all’extravasazione delle cellule dal torrente circolatorio. Queste vie sono 
probabilmente regolate da alcuni membri di un cluster policistronico di miRNA: il miR-
106a~363. In particolare grazie alla metodica AGO-Hits-CLIP ho validato due 
interazioni del miR-106; una con il trascritto WAVE3 e l’altra con VEGFA. Questi 
sono rispettivamente coinvolti nella formazione delle protrusioni che la cellula utilizza 
per invadere i tessuti (l’invadopodium) e nella permeabilizzazione della parete dei vasi 
sanguigni,. 
Inoltre è stata confermata l’importanza del miR-214 e di let-7c nello sviluppo 
metastatico. L’effetto di miR-214 è stato confermato anche dagli studi di una nostra 
collaboratrice, la Professoressa Daniela Taverna dell’Università di Torino mentre per 
let-7c ho validato due interattori (FNDC3B e FOXN) identificati mediante la metodica 
AGO-Hits-CLIP. 
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Oltre alla relazione miRNA:mRNA, la tecnica AGO-Hits-CLIP ha permesso di 
evidenziare una nuova classe di interattori: i lncRNA. Questi sono dei trascritti non 
codificanti lunghi più di 200 nt che sembrano funzionare da “spugna” per i microRNA, 
sequestrandoli e impedendone la loro funzione regolativa. 
Concludendo, i risultati ottenuti sostengono l’importanza dei miRNA nello sviluppo del 
Melanoma e nella sua metastatizzazione evidenziandone il ruolo cardine per un futuro 
sviluppo di nuovi farmaci che consentano la riduzione del rischio di sviluppare 
metastasi e, di conseguenza, di diminuire l’alta mortalità. 
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1 Introduction 
 
 
 Malignant Melanoma 1.1
Malignant Melanoma is a fatal form of cancer that develops from melanocytes, 
dendritic cells that are normally expressed in the skin basal layer. It represents the fifth 
most common malignancy for men and the seventh most common neoplasia for women 
and it is considered one of the most invasive, therapy-resistant, and metastatic tumor, 
with only about 10% survival, 5 years after diagnosis (Parkin et al., 2005). Over the past 
decades, its incidence has been increasing by 3% to 8% per year in Western countries 
while mortality has stabilized. Melanoma patients show localized disease in 82-85% of 
the cases, regional involvement in 10-13% of the cases, and distant metastases in 2-5% 
of the cases. 
The development of Melanoma starts rapidly through a radial growth of melanocyte 
cells in the epidermis followed by a vertical growth phase. High-risk Melanomas are 
characterized by this vertical growth phase that involve invasion of the epidermis upper 
layer, deep infiltration in the dermis and subcutaneous tissues, and development of 
lymph-nodal, cutaneous, and visceral metastases in the majority of the cases (Melnikova 
and Bar-Eli, 2008). 
Malignant Melanoma etiology is heterogeneous. It results from the interplay of 
environmental, genetic, and host factors (Hill et al., 2013).  
UV radiation is the major environmental risk factor for Melanoma with geographical 
parameters (latitude and altitude) that influences incidence. The incidence tends to be 
higher in geographic areas with higher sun exposure as in Australia (Armstrong and 
Kricker, 2001). Approximately from 8% to 12% of Malignant Melanomas happen in 
people with a familial predisposition. The reasons for familial Melanoma are that family 
members share similar host characteristics, such as nevi and/or freckling, hair and eye 
color, and skin type (Hayward, 2003). Individuals with non-Melanoma skin cancer are 
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also at increased risk for cutaneous Melanoma because some diseases occur by chance 
(Hayward, 2003). 
Several genes have been implicated in Melanoma pathogenesis with functions both at 
the germline and somatic levels. For instance, melanocyte transformation, that is 
responsible for the initiation of Melanoma and for its progression, is caused by genetic 
mutations of genes implicated in cell cycle regulation, cell differentiation, and signal 
transduction. Thus, mutations in tumor suppressor genes as cyclin-dependent kinase 
inhibitor 2A (CDKN2A) and less commonly mutations in cyclin-dependent kinase 4 
(CDK4) occur in 25-40% of Melanoma cases (Nagore et al., 2000; Berwick et al., 
2006).  Furthermore, gain-of-function mutations affecting the RAS-RAF-MAPK 
pathway (e.g mutations in v-Raf murine sarcoma viral oncogene homolog B1, BRAF 
and neuroblastoma v-ras oncogene homolog, NRAS genes) is responsible for nearly 
75% of malignant Melanomas (Aladowicz et al., 2013). In some patients, phosphatase 
and tensin homolog (PTEN), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog (C-Kit), tumor protein p53 (TP53) and β-catenin are among the most common 
mutations that occur concomitantly to BRAF or NRAS mutations (Bennett, 2008). 
During Melanoma progression there are also alterations in genes codifying for 
transcription factors that control melanocyte development during embryogenesis, as 
twist family bHLH transcription factor 1 (TWIST1), snail family zinc finger 2 (SLUG), 
microphthalmia-associated transcription factor (MITF) and neural precursor cell 
expressed developmentally down-regulated 9 (NEDD9). In particular MITF, the master 
regulator of the melanocyte lineage during development, is able to modulate 
proliferation, differentiation, invasion and metastasis in Melanoma (Garraway et al., 
2005) while TWIST and SLUG are involved in the detachment of Melanoma cancer 
cells through the repression of E-cadherin (Wels et al., 2011; Hao et al., 2012). Finally, 
NEDD9 is amplified in approximately 50% of Melanomas and promotes mesenchymal 
motility by activating the Rho family GTPase RAC1 (Ahn et al., 2012). 
Genomic analyses identified two major patterns of gene regulation. The proliferative 
gene pattern is characterized by the expression of the WNT/β-catenin/MITF-regulated 
genes, while the invasive pattern is characterized by the genes involved in transforming 
growth factor- β (TGF-β) related pathway. The mechanism is not based on differential 
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expression of TGF-β gene but, probably, by microenvironmental changes mediated by 
hypoxia or inflammation. These changes drive the expression of factors that inhibit Wnt 
signalling and promote TGF-β signaling resulting in cells that are lesser proliferative 
but have higher metastatic potential (Hoek et al., 2006).  
Moreover, epigenetic factors such as DNA hypomethylation and hypermethylation 
events affecting the expression of oncogenes and tumor suppressors, have been shown 
to be implicated in Melanoma progression (Schinke et al., 2010; Ecsedi et al., 2013). 
Also the expression alteration of microRNAs (miRNAs) that act as tumor suppressors 
or oncogenes, have also been found in Melanoma specimens. The involvement of 
miRNAs is summarized in (Kunz, 2013) and it will be discussed in depth in the 
“miRNAs and Melanoma” section. 
Considering all these evidences, it is very important to better understand the molecular 
events that regulate Melanoma aggressiveness and metastatic dissemination. Indeed, 
there are no valid treatments for this neoplastic event. Treatment is essentially based on 
surgical wide excision of the primary tumor including all of the subcutaneous tissue 
down to the fascia. However, after complete resection of Melanoma, some patients 
remain at high risk for recurrence. The decision to treat Melanoma with adjuvant 
therapy is a balance between the risk of disease recurrence and the significant toxicity 
and cost associated with adjuvant treatment. Researchers have tested the use of 
Interferon-α as adjuvant therapy over the past few years. Three different trials showed 
an improved 5-year relapse-free survival, but it was demonstrated that Interferon-α does 
not confer a significant long-term survival advantage. Interferon-α has significant side 
effects and morbidity, for instance, the effects identified were primarily fatigue (16%), 
liver toxicity (11%) and depression (6%) (Petrella et al., 2012). 
 
 Metastasis 1.2
Cancer metastasis is the process where cancerous cells escape from the primary tumor 
and spread to other parts of the body in order to form new cancerous masses in distant 
regions from the original. Metastasis are responsible for around 90% of human 
cancerous mortality (Hanahan and Weinberg, 2011). Although metastasis formation is 
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very dangerous for human health, this process is very inefficient. Indeed, only  few cells 
(around <0.01% of primary tumor cells that enter into the systemic circulation) are able 
to develop metastases (Chambers et al., 2002). The most common tissues for the 
metastases to occur are the lungs, liver, brain, and the bones. 
The main steps that cancer cells carry out during metastasis formation are: invasion 
through basement membrane, intravasation into the blood stream, surviving during the 
transport through blood and lymphatic circulation, arrest at distant organ sites, 
extravasation to distal tissues/organs, initially surviving in foreign microenvironments, 
and restarting the cells proliferative programs in new sites (Valastyan and Weinberg, 
2011). 
In order to form metastases, cancer cells twice cross the endothelial cells that line blood 
vessels. It occurs once during intravasation and once during extravasation and this 
process is known as transendothelial migration (TEM). Although the intravasation and 
extravasation of cancer cells require the disruption of endothelial junctions, they are 
fundamentally different because the cancer cells approach the endothelium from 
opposite sides. 
In order to intravasate, tumor cells need to induce local angiogenesis by the actions of 
vascular endothelial growth factors (VEGFs) (Leung et al., 1989). Generally, formed 
capillaries are tortuous, prone to leakiness, and in a state of continuous reconfiguration. 
Cancer cells can enter the vasculature thanks to the weak cell–cell junctions between 
adjacent endothelial cells in these type of vessels (Carmeliet and Jain, 2011). Moreover, 
in addition to VEGF, there are other factors that synergistically promote cancer cells 
intravasation - cyclooxygenase-2 (COX-2), epiregulin (EREG), matrix 
metalloproteinase MMP-1, and MMP-2 – stimulating neoangiogenesis and the 
formation of leaky blood vessels (Gupta et al., 2007).  
During carcinoma metastasis initiation, cancer cells undergo a morphological change 
known as epithelial-mesenchymal transition (EMT). EMT is characterized by a 
disassembly of cell–cell junctions, loss of epithelial polarity, and reorganization of actin 
cytoskeleton. During this process cancer cells improve their motility and invasiveness 
repressing the E-cadherin expression in order to separate from surrounding epithelial 
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cells (Thiery et al., 2009). EMT is important in metastasis also because seems to lend 
stem cells properties to cancer cells increasing their resistance to cellular senescence 
and their self-renewal ability at distant sites (Ansieau et al., 2008; Mani et al., 2008; 
Chang and Mani, 2013). 
Once carcinoma cells have successfully intravasated into circulation system, they can 
spread through the circulatory system surviving a variety of stresses in order to reach 
distant sites. Cancer cells seem to lose the integrin-dependent adhesion to ECM 
components. This interaction is essential for normal cells which, in their absence, 
undergo in anoikis, a form of apoptosis triggered by loss of anchorage to substratum. In 
addition, cancer cells interact with many other circulating cells in the bloodstream, 
including platelets, monocytes, neutrophils and natural killer cells, in order to increase 
endothelial barrier permeability and therefore increase the efficiency of cancer cell 
extravasation (Guo and Giancotti, 2004). 
Cancer cell extravasation usually occurs in small capillaries, where the cells can be 
physically trapped by size restriction and can then form stable attachments to 
endothelial cells. Furthermore, cancer cell adhesion to the endothelium requires the 
expression of cognate ligands and receptors on cancer cells and endothelial cells 
including selectins, integrins, cadherins, CD44 and immunoglobulin (Ig) superfamily 
receptors. (Reymond et al., 2013) 
After extravasation cancer cells must change the local microenvironment in order to 
survive in the distant organ. Indeed, the high proliferation rate of cancer cells needs 
more oxygen than normal cells establishing a hypoxic microenvironment. Hypoxia-
inducible factors (HIFs) are the most important transcription factors that respond to 
hypoxia promoting tumor cell survival and creating new capillary-like structures 
(Semenza, 2013). Recently, several studies have observed another local 
microenvironment change that occur during metastasis: the mesenchymal-epithelial 
transition (MET), the reverse process of EMT (see  Gunasinghe et al., 2012 for a 
review). MET seems to be required during metastasis to allow re-differentiation of the 
stem-like cancer cells obtained after EMT transition in order to obtain a new cancer 
mass in a distant site from the original one (Ocaña et al., 2012). 
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1.2.1 Extravasation associated pathways 
Extravasation is one of the most important steps during metastases formation. The 
processes that lead to the extravasation of cancer cells from the blood vessels act 
together in order to increase the permeability of the membranes, remodel actin 
organization, create a microenvironment suitable for the invasion, disassembly the 
junctions, secrete factors for the cell-cell communication, and form protrusions 
structures like invadopodia and lamellipodia. 
All these processes are summarized in Figure 1.1. The Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database (http://www.genome.jp/kegg/pathway.html) allow a 
better visualization of processes involved in a pathology and it allow their bioinformatic 
analysis. In the specific case of extravasation processes described in figure 1.1 in the 
KEGG database are defined by WNT, Adherens junction, and VEGF signaling 
pathways. 
 
Figure 2.1 Processes involved in cancer cells extravasation. In order to cross the endothelial 
barrier, cancer cells: a) drive protrusion extension through genes of Adherens junction; b) 
cause junction disassembly thanks to ROCK kinase involved in WNT signalling pathway; cause 
endothelial retraction through VEGFA signals that occur also in VEGF signalling pathway. 
Adapted from (Reymond et al., 2013) 
For instance in order to cross the endothelial barrier and to invade the organ, cancer 
cells are able to cause junction disassembly of the epithelial cells thanks to the action of 
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ROCK kinase that is a central gene in WNT signalling pathway, Furthermore, cancer 
cells are able also to drive protrusion extension through genes involved in Adherens 
junction and to cause endothelial cells retraction through VEGFA signals that occur in 
VEGF signalling pathway. 
1.2.1.1 WNT signalling pathway 
The Wnt signaling pathway is highly conserved in eukaryotes and is one of the most 
important signaling pathways. Wnt proteins are secreted morphogens that are required 
for basic developmental processes, as cell-fate specification, progenitor-cell 
proliferation and the control of asymmetric cell division. There are at least three 
different Wnt associated pathways: the canonical pathway, and the two non-canonical 
pathways (the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway). 
WNT ligands family activates the WNT canonical pathway in order to regulate the 
stabilization of the cytoplasmatic β-catenin. In absence of the Wnt proteins the β-catenin 
degradation complex is located in the cytoplasm where the serine threonine glycogen 
kinase GSK-3β phosphorylates β-catenin. Then the ubiquitin protein ligase β-TrCP 
ubiquitinates the phosphorylated β-catenin that will be degraded by proteasome. In 
addition, β-catenin degradation mediated by the SCF(TBL1) E3 ligase complex is 
induced by p53 activation occurring under genotoxic stress conditions. Here, TBL1 and 
its related gene TBL1R function as E3 ubiquitin ligase adaptors for the recruitment of 
specific ubiquitin/proteasome machinery in order to degrade β-catenin (Li and Wang, 
2008).  
On the other hand, when Wnt ligands bind to frizzled (FZD) receptors, β-catenin 
degradation complex formation is inhibited. Thus, β-catenin is accumulated in the 
cytoplasm allowing its entrance into the nucleus and the activation of Wnt-regulated 
genes. These are activated thanks to interactions between β-catenin, T-cell factor 
transcription factors family (TCF) and coactivators involved in cell cycle regulation 
(Valkenburg et al., 2011). 
One of the non-canonical pathways is the planar cell polarity (PCP) signaling pathway. 
It is involved in several processes of vertebrate cells as convergent extension 
movements of mesenchymal cells during gastrulation and arrangement of hairs, cilia 
and sterocilia in mammals (Wang, 2009). PCP signaling cascade activates the small 
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GTPases RHOA and RAC1. These proteins activate the stress kinase Jun N-terminal 
kinase (JNK) and RHO-associated coiled-coil-containing protein kinase 1 (ROCK) 
leading to cytoskeleton remodeling and changes in cell adhesion and motility (Staal et 
al., 2008). Actin cytoskeleton remodeling is essential for tumor cell invasion and 
metastasis. Altered expression of actin cytoskeleton components may also have some 
role in cell transformation and tumourigenesis (Pawlak and Helfman, 2001; Yamaguchi 
and Condeelis, 2007)  
Finally, in Wnt/Ca2+ signaling Wnt proteins interact with Frizzled receptors leading the 
activation of phospholipase C via G proteins and the consequent increase of 
intracellular Ca2+ concentration. The intracellular calcium concentration regulates 
downstream effectors as protein kinase C (PKC). In cancer diseases, this non-canonical 
pathway plays an important role in regulating Melanoma metastasis through the 
induction of epithelial to mesenchymal transition (EMT) (Dissanayake et al., 2007). 
 
1.2.1.2 Adherens junction 
Adherens junctions are the most common type of intercellular adhesions. They are 
important to maintain tissue architecture and cell polarity also limiting cell movement 
and proliferation.  
Structure of adherens junctions is characterized by a pair of plasma membranes with an 
intercellular space of around 10–20 nm that is occupied by rod-shaped molecules 
bridging the membranes, while on the cytoplasmatic side there is the presence of 
condensed actin filaments (Miyaguchi, 2000). F-actin filaments are associated with α 
and β-catenin through a cadherin bridge dependent. These allow producing changes in 
the strength of cell-cell binding changing cytoskeleton organization. Cadherin-catenin 
complex is dissociated and inhibited through the receptor tyrosine kinases (RTKs), 
cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src) and casein kinase II that 
phosphorylate the β-catenin. On the other hand, the complex is positively regulated 
through β-catenin dephosphorylation by protein tyrosine phosphatases (Meng and 
Takeichi, 2009).  
The involvement of β-catenin in this pathway indicates the strong connection between 
adherens junction and WNT signaling pathway. Changes in the phosphorylation state of 
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β-catenin by WNT signaling pathway affect cell-cell adhesion, cell migration and the 
level of signaling β-catenin (Amin and Vincan, 2012). Also cadherins negatively 
regulate β-catenin signaling sequestering it from the nucleus.  
Nectin is another important regulator of adherens junction. In association with the Rho 
family of GTPases, Rho, Rac, and Cdc42 is able to regulate the formation of adherens 
junction reinforcing cell-cell adhesion (Fukuhara et al., 2004; McCormack et al., 2013). 
Adherens junctions also have an important role in the vascular permeability controlling. 
Indeed, changes in the regulation of adherens junction pathway lead to loss of 
endothelial cell apical-basal polarity causing the formation of cavernomas and 
alterations of vascular morphology seen in tumors (Dejana and Orsenigo, 2013). 
In tumor cells, adherens junctions are responsible also for actin polymerization 
processes. In cancer cells there is the presence of actin-rich structures that are 
specialized for matrix degradation known as invadopodia. These structures protrude 
from the basal region of the cell facing the extracellular matrix where they adhere to and 
degrade the matrix thus facilitating invasive processes (García et al., 2012; Hoshino et 
al., 2013). Several proteins of the adherens junction pathway as proto-oncogene 
tyrosine-protein kinase (SRC), Wiskott-Aldrich syndrome protein family (WAVE) and 
Wiskott-Aldrich syndrome-like (NWASP) are involved in cancer cells protrusions 
formation like invadopodia and lamellipodia (Yeatman, 2004; Spence et al., 2012; 
Gligorijevic et al., 2012). 
 
1.2.1.3 VEGF signalling pathway 
Vascular endothelial growth factor (VEGF) is the master regulator of the VEGF 
signaling pathway. It is an endothelial cell-specific mitogen factor that has the capacity 
to induce physiological and pathological angiogenesis (Leung et al., 1989). VEGFA is 
the main angiogenic factor and it is a member of a larger family of growth factors that 
also includes VEGFB, VEGFC, VEGFD and placental growth factor (PLGF). Vascular 
endothelial growth factor receptor 2 (VEGFR-2) is the major mediator of VEGF-driven 
responses and it is a crucial signal transducer in both physiologic and pathologic 
angiogenesis. Based on the fact that angiogenesis is one of the most important factors 
needed for Melanoma progression and metastasis, Mehnert and colleagues discovered 
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that VEGF and VEGFR expression is higher in Melanomas and advanced Melanomas 
than in benign nevi (Mehnert et al., 2010). 
The VEGFs-VEGFR-2 binding leads to a cascade of different events that result in the 
up-regulation of genes involved in proliferation regulation, migration of endothelial 
cells and promotion of cell survival and vascular permeability. For instance, VEGFA-
VEGFR-2 interaction leads to dimerization of the receptor followed by the activation of 
the phospholipase PLCγ and MAPK kinase pathway. This process leads to initiation of 
DNA synthesis and cell growth and, simultaneously, it increases endothelial-cell 
survival through the activation of the phosphatidylinositol 3'-kinase (PI3K)-Akt 
pathway. All these pathways are implicated in cell migration signaling. In cancer, 
VEGFs are secreted both by tumor and stromal cells including macrophages, 
endothelial cells and fibroblasts (Galdiero et al., 2013). VEGFs are able to interact with 
VEGF receptors on the surface of different cell types in order to activate several 
functions in the tumor microenvironment previously described. In addition, VEGFs 
stimulate the deposition of a temporary fibrin matrix that triggers the formation of 
desmoplastic stroma and increase the vascular permeability. VEGFs secreted by tumor 
cells can be seen as autocrine actors to allow their proliferation and dissemination 
(Bates et al., 2003). In tumor fibroblasts, VEGFs and Neuropilin1 (NRP1) are highly 
expressed contributing to tumor growth by nucleating fibronectin fibril formation 
(Yaqoob et al., 2012). 
VEGF can also function as a chemo-attractant to recruit regulatory T cells (TReg) that 
inhibit an antitumor immune response controlling self-tolerance and preventing 
autoimmunity through the secretion of anti-inflammatory cytokines such as TGFβ and 
IL-10 (Roland et al., 2009). 
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 MicroRNAs 1.3
1.3.1 MiRNAs and Melanoma 
MiRNAs are small single-stranded non coding transcripts of 20-23 nt length that are 
able to control several biological processes through post-transcriptional mechanisms. 
The first miRNA identified was lin-4 in C. elegans (Lee et al., 1993; Moss et al., 1997). 
This small transcript was found involved in the larval development through the 
repression of its target lin-14. Multiple conserved sites with a sequence 
complementarity with lin-4 were found within the lin-14 3’-UTR suggesting the type of 
interaction that miRNAs use to deregulate its mRNA target. 
Mature miRNAs derive from a multi-step process that occurs to the primary transcripts 
(pri-miRNAs) that contain one or more 70 nt hairpin miRNA precursors. These 
precursors are exported from the nucleus to the cytoplasm by Exportin5 activity. Here 
they are processed by the endonuclease Dicer obtaining an RNA duplex: the mature 
miRNA closer to 5’-end of miRNA precursor (miRNA-5p) and the mature miRNA 
closer to 3’-end of miRNA precursor (miRNA-3p). The RNA duplex is recruited by 
miRNA-containing ribonucleoprotein complex (miRNP) that is able to choose one of 
the mature miRNAs leading it to the right mRNA target. This complex is mainly 
composed by AGO family proteins (AGO1-4) which contain RNA-binding and RNAse 
H domains (Ender and Meister, 2010). MiRNA are leaded to mRNA targets that are 
recognized by pairing of the miRNA seed region (from 2nd to 8th nucleotide) to a 
complementary sequence positioned mainly in the 3’-UTR regions of the transcripts. 
MiRNAs are able to destabilize the mRNA target through several different mechanisms: 
CAP destabilization, de-adenylation, transcript degradation or translation inhibition (see 
Filipowicz et al., 2008; Bartel, 2009, for review). 
The ability of miRNAs to deregulate tens or hundreds different mRNA targets (Lim et 
al., 2005) make this non-coding transcripts as potential modulator of several biological 
processes involved in tumorigenesis, such as cell cycle regulation, differentiation, 
apoptosis and invasion. 
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It is well known that genomic instability plays a major role in the genesis and 
progression of tumors, and in the evolution of tumor heterogeneity. Interestingly, 
instable genomic regions contain miRNAs whose expressions are different comparing 
cancerous and normal samples. For instance the 52.5% of miRNA genes are located in 
amplified, translocated or deleted regions of different tumors, or nearby chromosomal 
breakpoints (Calin et al., 2004).  
MiRNAs involvement in cancer was first found by Lu and colleagues studying miRNA 
expression in different histotypes of cancer (Lu et al., 2005). The authors found that 
miRNA expression pattern was able to better discriminate different tumor types respect 
to mRNA expression signatures. Furthermore, they observed a general miRNAs down-
regulation in cancerous tissues compared with benign tissues, suggesting a role for 
miRNAs as tumor suppressors (Esquela-Kerscher and Slack, 2006; Volinia et al., 2006; 
W. Zhang et al., 2007). In particular, several authors found that a lot of miRNAs have as 
target mRNAs codifying for tumour-promoting proteins as RAS, c-MYC, BCL2, and 
cell dependent kinases. In this context we can understand how miRNA act as 
oncosuppressor and, thanks to their general downregulation in cancer, their proctective 
action is lost. In addition, miRNA expression down-regulation is also caused by 
mutation to the proteins involved in miRNA maturation and function (e.g. DICER1, 
AGO family, etc) that occurs in several cancerous diseases (Han et al., 2010; van 
Kouwenhove et al., 2011). 
Unfortunately, cancer progression is very complex and researchers found several 
miRNAs that also act as oncogenes, promoting cancer progression and metastases 
formation. For this reason these miRNAs are named onco-miRNAs. For instance, miR-
21, that is overexpressed in several cancers as breast cancer, oesophageal cancer, and 
glioblastomas, act as anti-apoptotic genes targeting pro-apoptotic genes (PTEN, 
PDCD4, TPM1, etc.) and inhibiting cell apoptosis (Becker Buscaglia and Li, 2011; P. 
Li et al., 2013). Another onco-miRNA is the miR-17-92 locus, which encodes for a 
cluster of miRNAs. The members of this miRNA cluster were first found overexpressed 
in B-Cell lymphoma where they inhibit tumor suppressor genes (He et al., 2005), and 
now they are well known as the most potent oncogenic miRNA cluster with a central 
role in cancer progression network (Olive et al., 2010). 
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Also in malignant Melanoma there are evidences about the involvement of miRNAs 
during Melanoma progression and metastases formation. These miRNAs are 
summarized in the table 1.1. 
Tab 1.1. miRNAs involved in Melanoma 
miRNA 
Direct 
target 
Indirect 
targeting 
Function in 
Melanoma 
References 
Upregulated miRNAs 
miR-148 MITF ↓ 
TYR, TYRP1, 
MLANA, 
SILV ↓ 
Proliferation, 
survival, cell 
cycle arrest 
(Haflidadóttir et al., 
2010) 
miR-149 cKit ↓  
Proliferation, 
invasion, 
migration, 
(Igoucheva and 
Alexeev, 2009) 
miR-181a PTEN ↓ 
PI3K/AKT 
pathway ↑ 
Invasion (Karreth et al., 2011) 
miR-182 
MITF↓, 
FOXO3↓ 
 
Cell 
transformation 
(Segura et al., 2009) 
miR-1908, miR-
199a-5p, miR-
199a-3p 
ApoE↓, 
DNAJA4 ↓ 
LRP1, LRP8 
Inducing 
Angiogenesis 
(Pencheva et al., 
2012) 
miR-195 WEE1↓  
stress-induced 
G2-M cell cycle 
arrest 
(Bhattacharya et al., 
2013a) 
miR-200b PTEN ↓ 
PI3K/AKT 
pathway ↑ 
Invasion (Karreth et al., 2011) 
miR-21 
PTEN, 
PDCD4, 
BTG2 ↓ 
 Proliferation 
(Satzger et al., 2012; 
Yang et al., 2011) 
miR-214 
TEAP2C ↓ 
ALCAM ↓ 
miR-148b 
Cell cycle 
progression, 
invasion, 
metastasis 
(Penna et al., 2013, 
2011) 
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miRNA 
Direct 
target 
Indirect 
targeting 
Function in 
Melanoma 
References 
miR-221 
p27Kip1 ↓, 
cKit↓ 
 
Evading growth 
suppressors 
(Felicetti et al., 2008; 
Igoucheva and 
Alexeev, 2009) 
miR-222 cKit ↓  
Evading growth 
suppressors 
(Felicetti et al., 2008; 
Igoucheva and 
Alexeev, 2009) 
miR-25 PTEN ↓ 
PI3K/AKT 
pathway ↑ 
Invasion (Karreth et al., 2011) 
miR-290/295 
cluster 
Atg7↓, 
ULK1↓ 
 
Resisting cell 
death 
 
miR-302a Notch4 ↓ Nodal ↓  (Costa et al., 2009) 
miR-338 cKit ↓  
Proliferation, 
invasion, 
migration, 
metastasis 
(Igoucheva and 
Alexeev, 2009) 
miR-532 RUNX3 ↓ 
 
 
Development (Kitago et al., 2009) 
miR-92a PTEN ↓ 
PI3K/AKT 
pathway ↑ 
Motility, 
migration 
(Karreth et al., 2011) 
Downregulated miRNAs 
miR-137 
MITF ↓, 
CtBP1↓ 
 Invasion 
(Bemis et al., 2008; 
Deng, 2011; Luo et 
al., 2013) 
miR-155 SKI ↑ 
TGFβ-signaling 
↓, Wnt/β-catenin 
MITF, Nr-Cam 
↑ 
Proliferation, 
apoptosis 
(Levati et al., 2011) 
miR-18b MDM2↑ p53 
Evading growth 
suppressors 
(Dar et al., 2013) 
miR-193b 
CycIinD1↑ 
Mcl-1  ↑ 
 
Proliferation, 
Resisting cell 
death 
(J. Chen et al., 2011; 
Chen et al., 2010) 
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miRNA 
Direct 
target 
Indirect 
targeting 
Function in 
Melanoma 
References 
miR-196a 
HoxB7, 
HoxC8 ↑ 
BMP4 ↑ 
Proliferation, 
invasion, 
migration 
(Braig et al., 2010; 
Mueller and 
Bosserhoff, 2011) 
miR199a* c-MET ↑  Invasion (Migliore et al., 2008) 
miR-203 E2F3 ↑ 
Cyclin A/E, c-
Myc, SIRT1, 
Rb ↓ 
Cell cycle 
regulation 
(Noguchi et al., 2012) 
miR-205 
pAkt ↑ E2F1, 
E2F5 ↑ 
 
Proliferation, 
Resistance to 
chemotherapy 
(Alla et al., 2012; Dar 
et al., 2011; Noguchi 
et al., 2013) 
miR-211 
TGFBR2 ↑, 
KCNMA1↑, 
BRN2↑ 
 
 Invasion 
(Boyle et al., 2011; 
Levy et al., 2010; 
Mazar et al., 2010) 
miR-26a SODD ↑  Apoptosis (Reuland et al., 2013) 
miR-29c 
DNMT3A, 
DNMT3B ↑ 
RASSF1A 
methylation ↑ 
Metastasis 
development 
(Nguyen et al., 2011) 
miR-34a/c ULBP2 ↑  
Proliferation, 
invasion, 
immune 
response 
(Heinemann et al., 
2012) 
miR-34b/c 
c-MET, 
pAkt, p-Rb, 
CDK4 ↓ 
 Invasion (Dong and Lou, 2012) 
miR-573 MCAM ↑  
Activating 
invasion 
(Bai, 2013) 
miR-9 NE-kB1 ↑ 
Snail ↑, E-
Cadherin ↓ 
Migration, 
Invasion 
 
(N. Liu et al., 2012; S. 
Liu et al., 2012) 
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miRNA 
Direct 
target 
Indirect 
targeting 
Function in 
Melanoma 
References 
miR-Iet-7a Integrin β3 ↑  Metastasis 
(Kumar, 2003; Müller 
and Bosserhoff, 2008) 
miR-Iet-7b 
Cyclins D1, 
D3, A, 
CDK4 ↑ 
 
Cell cycle 
progression, 
anchorage-
independent 
growth, 
proliferation 
(Schultz et al., 2008; 
D. Xu et al., 2012) 
miR-let-7 KRAS ↑  
Proliferation, 
differentiation 
(Kundu et al., 2012) 
 
In the table 1.1, we note that the most important miRNA target families in melanoma 
progression are: receptors and channel proteins, cell-cell signalling proteins, and 
transcription factors. 
The expression of receptors, channel proteins, and their correspondent ligands is often 
modulated in cancerous diseases (Casaletto and McClatchey, 2012). For instance, 
TGFBR2 is one of the receptors that bind Transforming growth factor TGFβ and it is 
able to phosphorylate downstream proteins involved in Melanoma cells invasion. 
Regulation of TGFBR2 mRNA stability through the downregulation of its interactor 
miR-211, is able to reduce the Melanoma cell invasion capability (Levy et al., 2010). 
Another example is v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
gene (c-Kit), the receptor tyrosine kinase for stem cell factor (SCF), that is 
downregulated by several miRNAs (miR-221, miR-222, miR-149, and miR-338) in 
cutaneous Melanoma cells respect to normal melanocytes (Felicetti et al., 2008; 
Igoucheva and Alexeev, 2009).  
Cell signalling allows connecting cell response to surrounding environment through cell 
surface receptors. After the interaction of ligands to their cell receptors, specific event 
cascades are activated allowing the activation or inhibition of different genes through 
the interaction of transcriptional regulators with gene promotors. For instance, Cyclin 
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D1 (CCND1) is a master gene involved in cell cycle progression through the activation 
of a signal cascade that leads to the cell cycle progression from G1 phase. CCND1 gene 
expression is regulated by external signals like estrogens (Ogba et al., 2008) but also by 
different miRNAs as miR-193b and miR-let-7b that regulate cell cycle of Melanoma 
cells (Chen et al., 2010; Schultz et al., 2008). 
As estrogen is important for CCND1 expression, also different miRNAs are important, 
in Melanoma cells, to regulate expression of transcription factors involved in Melanoma 
progression. In particular, microphtalmia-associated transcription factor (MITF) is a 
master gene in the melanocytic cell fate and it is an oncogene in malignant Melanoma 
development and progression (Garraway et al., 2005). High levels of MITF result in cell 
cycle arrest and reduced Melanoma cells proliferation through the targeting of several 
genes involved in melanogenesis (TYR, TYRP1, MLANA, and SILV). The MITF 
expression level seems to be regulated by miR-148, miR-182, miR-137 (Bemis et al., 
2008; Segura et al., 2009; Haflidadóttir et al., 2010). In addition, in Melanoma cells, it 
seems that MITF is able to up-regulate both the gene TRP1 and the miR-211 that is 
located in one of its introns. This miRNA is able to significantly increased cell invasion 
through the downregulation of several genes AP1S2, SOX11, IGFBP5, and SERINC3 
(Margue et al., 2013). These evidences sustain the possibility to use miRNAs as drugs 
to treat cancers. In fact, their short sequences are more stable than longer transfected 
genes and the action mechanism allows sufficient target specificity because based on 
the sequence pairing (Wu, 2010). On the other hand, it is demonstrated the complexity 
of the regulatory interaction based on miRNA networks. Due to the ability of miRNAs 
to regulate tens or hundreds different targets simultaneously, miRNA-based regulatory 
networks are very tangled due to the presence of target regulated by multiple miRNAs, 
single miRNA that regulate multiple mRNAs, negative loops and positive loops. 
An example of this complex interconnectivity is described in (Penna et al., 2013). Penna 
and colleagues identified a regulatory network associated with metastasis formation that 
involves two different miRNAs (miR-214 and miR148b), a transcription factor family 
(TFAP2A/C), and a transmembrane glycoprotein involved in cell adhesion (ALCAM). 
In the model proposed, ALCAM is overexpressed in metastatic Melanoma cell lines 
because miR-214 downregulates TFAP2A/C and miR-148b, both negative regulators of 
ALCAM (Figure 1.2).  
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1.3.2 MiRNAs and metastasis 
MiRNA ability to modulate several genes involved in cancer development and 
progression convinced researchers to find a correlation between miRNAs and 
metastases. First evidence about miRNA involvement in metastases formation were 
found in breast cancer cells by Ma and colleagues (Ma et al., 2007). They observed that 
miR-10b was able to enhance the migration and invasion capability of non-metastatic 
human breast cancer cells through targeting the Homebox D10 (HOXD10) mRNA and 
therefore indirectly inhibit the pro-metastatic Ras homolog gene family, RHOC. 
At the moment, it’s widely accepted that the cancer cells act on their intrinsic and 
extrinsic properties in order to improve their metastatic potential and the implication of 
miRNAs is well documented (see Joyce and Pollard, 2009 for review). Indeed, recent 
papers found that miRNAs involved in metastases formation could act in three different 
ways: a) cell-intrinsic regulation, b) cell-extrinsic regulation, or c) dual cell-
intrinsic/extrinsic regulation of metastasis (Pencheva and Tavazoie, 2013). 
a) According to cell-intrinsic regulation way, miRNAs are able to change the intrinsic 
phenotype of the cancer cell invasion. The signalling network described by Ma in breast 
cancer cells is an example of cell intrinsinc regulation, where miR-10b is able to 
activate a signaling cascade that promote reorganization of the actin cytoskeleton and 
regulate cell shape and motility, enhancing the metastatic power of the cells. 
Another example is the role of let-7 in breast cancer cells. The over-expression of let-7 
reduces the metastatic capability of breast cancer cells targeting the High Mobility 
Group AT-Hook 2 (HMGA2) and Basic Leucine Zipper Transcription Factor 1 
(BACH1) transcripts and leading to transcriptional inhibition of a set of pro-invasive 
genes (Dangi-Garimella et al., 2009; Yu et al., 2007; Yun et al., 2011). 
Figure 2.2 MiR-214 signaling circuit model proposed by Penna 
and colleagues. ALCAM is overexpressed in Melanoma because 
miR-214 downregulates both TFAP2A/C (ALCAM transcriptional 
repressors) and miR-148b (ALCAM-targeting miR). Furthermore, 
TFAP2A/C positively regulates miR-148b expression. Adapted from 
(Penna et al., 2013). 
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b) According to cell-extrinsic regulation model, miRNAs are able to regulate metastasis 
formation changing not the cell behavior but the metastatic microenvironment 
surrounding the cells. An example is miR-29b that seems to be responsible for the 
inhibition of breast, liver and prostate cancer metastasis. MiR-29b inhibits metastasis by 
targeting GATA3 transcription factor and a network of pro-metastatic regulators 
involved in cell-extrinsic processes such as angiogenesis, collagen remodelling and 
proteolysis (VEGFA, ANGPTL4, PDGF, LOX and MMP9). Moreover, it also affects 
differentiation and epithelial plasticity through the modulation of integrin transcripts 
ITGA6, ITGB1 and the transcript for TGFB (Chou et al., 2013; Fang et al., 2011; Ru et 
al., 2012). In addition, there are some miRNAs that are able to modulate the behaviour 
of neighbouring cells. For example, miR-9, which is secreted from cancer cells through 
microvesicles, is able to regulate endothelial cell migration activating their JAK-STAT 
signalling pathway (G. Zhuang et al., 2012). 
c) According to dual cell-intrinsic/extrinsic regulation miRNAs are able to modulate 
both the cell metastatic behaviour than the cell surrounding microenvironment. 
Recently, Pencheva and colleagues (Pencheva et al., 2012) identified a set of miRNAs 
(miR-199a-3p, miR-199a-5p, and miR-1908) that are able to  modulate the heat shock 
factor DNAJA4 and the metabolic protein apolipoprotein-E (APO-E) in Melanoma 
cells. Effects of this modulation are the APO-E upregulation and consequent 
suppression of metastasis process. APO-E, secreted from Melanoma cells, is able to 
block metastatic progression by both cell-autonomous and cell-non-autonomous 
mechanisms. It is able to inhibit Melanoma cell invasion by targeting the transcript for 
low density lipoprotein receptor-related protein 1 (LRP1) and, simultaneously, to inhibit 
endothelial cell migration by targeting the transcript for low density lipoprotein 
receptor-related protein 8 synthesized by neighbouring endothelial cells. 
MiRNAs seems to be involved in all steps that occur during metastases formation; from 
the initial intravastion process to the microenvironmental rearrangements in distant 
tissues (Y. Zhang et al., 2013). For instance, several miRNAs have been found involved 
in the extracellular matrix (ECM) degradation during cancer cell intravasation and 
extravasation. Indeed, they are able to affect the expression of matrix metalloproteinases 
(MMPs) that are the most important effectors in ECM remodelling (Deryugina and 
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Quigley, 2006). In breast cancer cells, for example, miR-29b upregulation alters 
collagen remodelling, angiogenesis and proteolysis through the inhibition of MMP2 and 
MMP9 (Chou et al., 2013). On the contrary, miR-21 is able to affect metastasis 
formation through the upregulation of several MMPs including MMP2 and MMP9. 
MiR-21 is able to control MMPs expression through the regulation of different MMP 
inhibitors as PTEN in hepatocellular carcinoma cells (Meng et al., 2007) and RECK and 
TIMP3 in glioblastoma cells (Gabriely et al., 2008). 
Also EMT transition is regulated by different miRNA. MiR-200 family (miR-200a, 
miR-200b, miR-200c, miR-141, and miR-429) and miR-205 are involved in EMT 
regulation. Downregulation of these miRNAs leads to the induction of ZEB family 
transcription factors, which control the regulation of E-cadherin during EMT transition 
in different cancer cells (Gregory et al., 2008; Korpal et al., 2008). In addition, several 
miRNAs were found involved in the regulation of EMT-related transcription factors: 
miR-214 regulates Twist1 in cholangiocarcinoma (B. Li et al., 2012), miR-9 regulates 
Snail1 in Melanoma (S. Liu et al., 2012), miR-124 and miR-203 regulate Snail2 in 
breast cancer (Liang et al., 2013; Zhang et al., 2011). 
During distant tissue colonization, it is also important the contribution of the 
mesenchymal-epithelial transition (MET). Regulation of MET is enhanced by blocking 
the actions of factors and signaling pathways that activate EMT. Thus, the same 
miRNAs that are able to regulate EMT transition are also able to regulate MET 
transition. The reversibility of EMT and MET programs act through an imbalance of 
miRNAs and EMT transcription factors expression. For example, the feedback loop that 
has been observed between Snail2 and miR-203 in human breast cancer cells, where 
Snail2 expression reduces miR-203 expression and ectopic miR-203 expression directly 
represses Snail2 (Zhang et al., 2011), could change this equilibrium. This feedback loop 
could activate EMT programs during tissue invasion but activating MET signalling 
during colonization of the organ once EMT is completed. 
MiRNAs also regulate biological processes that control oxygen and nutrients supply to 
metastasis mass mediated by hypoxia-inducible factors (HIFs). MiR-210 is an example 
of dual cell-intrinsic/extrinsic regulator of oxygen homeostasis inside tumors. Indeed, 
miR-210 is upregulated by HIF transcription factors induced by hypoxic environment 
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and acts intrinsically and extrinsically. MiR-210 acts intrinsically targeting the MYC 
antagonist MNY allowing cancer cells to bypass the hypoxia-induced cell cycle arrest 
(Z. Zhang et al., 2009) and extrinsically through microvescicles based transport 
allowing its expression increasing in neighbouring cells. Communication between 
cancer and epithelial cells by microvescicles transport of miR-210 leads to a down-
regulation of Ephrin-A3 gene (EFNA3) that stimulates the formation of new vessel 
structures and enhance the cell migration (Fasanaro et al., 2008). 
Unfortunately, it’s difficult to fully understand the interaction network of miRNAs in 
microenvironmental regulation of metastasis due to the intricate tumor-stroma 
connections and the context-dependent function of miRNAs. Indeed, there are single 
miRNA that regulates more than one step in metastasis signalling cascade (e.g miR-21 
(Zhu et al., 2008)). Moreover, the ability of a miRNAs to regulate different target seems 
to be based on a specific cellular context. For instance, the role of miR-126 in 
metastasis formation results different in two breast cancer cell lines: MDA-MB-231 
cells and 4T1 cells. MiR-126 may suppress the metastatic process inhibiting different 
metastatic genes in different subsets of breast cancer patients (Png et al., 2012; Zhang et 
al., 2013). Finally, the complexity of interaction network of miRNAs in metastatic 
processes is highlighted by the role of miR-200 on a specific metastasis step context. At 
the primary tumor site, miR-200 acts as breast cancer suppressor inhibiting the action of 
the EMT-regulatory transcription factor ZEB1 and ZEB2 while, in the colonization step, 
miR-200-ZEB1/2 interaction promotes metastases formation enhancing the MET 
transition in a mouse xenograft model (Bracken et al., 2008; Dykxhoorn et al., 2009). 
 
 Target prediction 1.4
1.4.1 In-silico approaches 
When researchers understood the enormous regulatory potential for miRNAs in all the 
biological processes, they started to develop in-silico approaches in order to identify 
both all miRNAs transcribed by a genome and their possible mRNA targets.  
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Studying molecular structures during miRNA biogenesis, researchers discovered some 
features that permit to identify putative miRNAs in the genome: a) presence of stable 
hairpin precursors; b) relative symmetry of the internal loops of stem-loop precursor 
structures; c) free-energy estimations of the miRNA precursors d) conservation of the 
miRNA sequence across the species. 
Although the majority of the miRNA sequences are conserved across different species, 
researchers have identified several miRNA species-specific estimating that they 
represent the 7% of human and the 11% of mouse miRNome (Berezikov et al., 2006). 
In 2002, when Lai (Lai, 2002) demonstrated that the first eight nucleotides of 11 
miRNAs were perfect complementary to the K box and Brd box motifs known in 
Drosophila as post-transcriptional regulator, he talked for the first time about the “seed 
region”. Now, we know that miRNA targets are recognized by pairing of the sequence 
from 2nd to 8th nucleotide of the miRNAs (seed region) to regions positioned mainly in 
the 3’-UTR of targeted transcripts. Unfortunately, following researches showed that 
miRNA targeting was based more than the seed region, indeed miRNA:mRNA duplex 
allows mismatches, gaps and G:U pairs increasing excessively the number of possible 
targets based uniquely on the alignment and  leading to the conclusion that miRNA 
regulation was very complex. 
In this context, there were developed new algorithms in order to integrate the seed 
region identification along the transcripts and knowledge about allowed mismatches. 
The first approach used is based on sequence conservation of the target sites among 
different species. The algorithm that take advantage of this method is TargetScan 
(Lewis et al., 2005) that, starting from the assumption that the major part of miRNA 
sequences are conserved in different species, searches for highly conserved seed pairing 
regions on transcript 3’UTRs. Research is then refined using a score based on the 
number of possible base pairing and the surrounding sequence composition. 
Another approach used is based on the thermodynamic stability of miRNA:mRNA 
duplex. C:G, A:U, and G:U pairs contribute differently to the calculation of 
hybridization stability and the algorithm, combining these information with the position 
of base pairing in the miRNA sequence, is able to score duplexes. Most common used 
algorithm based on this approach are miRanda (John et al., 2004; Betel et al., 2008), 
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RNAhybrid (Rehmsmeier et al., 2004; Krüger and Rehmsmeier, 2006), and PITA 
alghorithm (Kertesz et al., 2007). 
Last approach, here mentioned, is based on the observations that multiple miRNAs 
target only one mRNA and a single miRNA could have multiple binding sites on the 
same mRNA target. In this way, multiple miRNAs binding sites on the same 3’UTR 
enhance the regulatory strength of these small non–coding transcripts. Algorithms that 
search for multiple sites for the same miRNA are mimiRNA (Ritchie et al., 2010) and 
PicTar (Krek et al., 2005). They have the disadvantage of eliminating several true target 
sites but, on the other hand, they produce a list of high confidence gene targets. 
Several works was done to compare all prediction algorithms in order to understand 
which is the prediction approach better correlate with biological condition (Rajewsky, 
2006; Doran and Strauss, 2007; Zhang and Verbeek, 2010). Unfortunately, comparing 
in-silico target predictions with experimentally validated targets, the false positive rate 
is around 20-30%. Using a proteomic approach (Selbach et al., 2008), Selbach affirmed 
that TargetScan and Pictar algorithms seem to give best correlation between in-silico 
prediction and experimental validation, but every target prediction approaches have 
advantages and disadvantages. To combine different algorithms could be useful for the 
identification of all the possible targets but not for the decrease of false positive 
predictions number. In this context, we understand that is essential combine in-silico 
prediction with experimental approaches in order to reduce the number of possible 
targets.  
One approach is to combine miRNA and mRNA expression profiles produced from the 
same samples. This approach is based on the fact that miRNAs mainly inhibit mRNA 
targets through their degradation (Hu and Coller, 2012). MAGIA2 algorithm (Bisognin 
et al., 2012) is able to compare miRNA and mRNA profiles calculating their correlation 
in order to filter miRNA target predictions from several algorithms (TargetScan, PITA, 
PicTar, miRanda, etc). The disadvantage of this approach is that, as said before, target 
prediction algorithms have high false positives and that not all the miRNAs change the 
concentration of their mRNA target, but some miRNAs act on protein level. It is 
important to notice that in a lot of cases mRNA concentration change also in this last 
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case (Hu and Coller, 2012). If there are miRNAs that do not change mRNA 
concentration the correlation approach used in MAGIA2 algorithm does not work.   
In this context, are glaring the drawbacks of in-silico target prediction and because it is 
important to develop new approaches, based on experimental techniques, that are able 
to identify a large number of true miRNA:mRNA interactions. 
 
1.4.2 Biochemical approaches 
Scientific works that have tried to understand the efficiency of algorithms used for 
miRNA target prediction (Rajewsky, 2006; Doran and Strauss, 2007; Zhang and 
Verbeek, 2010) showed a false positive rate around 20-30%. Bioinformaticians have 
tried different approaches (sequence conservation, thermodynamic stability, multiple 
miRNAs target) in order to reduce the number of false positives, but results were not 
satisfactory. Thus, in the last years, several biochemical approaches have been 
developed in order to identify true miRNA:mRNA interactions. 
These experimental approaches take advantage of the physical interaction between 
miRNA and mRNA through the miRNA-loaded RNA-induced silencing complex 
(miRISC) that is essentially composed by AGO family proteins. 
Mourelatos and colleagues (Mourelatos et al., 2002), for the first time, identified 40 
human miRNAs that co-immunoprecipitated with AGO2 protein complex in HeLa cells. 
Several other papers, using this approach, identified other miRNA-mRNA physical 
interactions in different species (Beitzinger et al., 2007; Easow et al., 2007; 
Hendrickson et al., 2008; Karginov et al., 2007; L. Zhang et al., 2007; Landthaler et al., 
2008). In recent years the combination between AGO-RNA co-immunoprecipitation 
and next generation sequencing have improved the sensitivity and the throughput of this 
biochemical technique leading to the develop by Darnell’s group of HITS-CLIP method 
(High-Throughput Sequencing by Cross-Linking and ImmunoPrecipitation) (Licatalosi 
et al., 2008; Chi et al., 2009). This method uses ultraviolet irradiation to covalently 
crosslink RNA–protein complexes that are in direct contact (approximately over single 
ängstrom distances) within cells and allows the subsequent purification of interacting 
molecules that co-precipitate with AGO proteins. After purification, a partial RNA 
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digestion reduces bound RNA to fragments that can be sequenced by high-throughput 
sequencing methods. Recently, HITS-CLIP method has been improved by Hafner and 
colleagues that enhanced crosslinking efficiency developing the PAR-CLIP method 
(Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation) 
(Hafner et al., 2010a, 2010b). Hafner introduced the incorporation of the photoactivable 
nucleoside analog 4-thiouridine into transcripts of cultured cells. In this method, after 
the UV-irradiation at 365 nm, thymidines placed in the crosslinking sites are converted 
in cytidines. The resulting method uses the same protocol of HITS-CLIP method but 
with the advantage that the thymidine-cytidine conversion makes more precise the 
identification of RNA-protein binding sites. Combining PAR-CLIP method with deep 
sequencing Hafner and colleagues identified binding sites of AGO and TNRC6 family 
proteins in RNAs (Hafner et al., 2010a). Due to the necessity to use photoactivable 
nucleoside analog 4-thiouridine this method is not useful for an in-vivo experiment but 
only for in-vitro ones.  
Another biochemical approach useful for miRNA:mRNA interactions has been 
developed by Vatolin and colleagues (Vatolin et al., 2006; Vatolin and Weil, 2008). 
This method takes advantage from the hypothesis that miRNAs form a temporary stable 
duplex with their target. It is possible to use miRNAs as primers for cDNA synthesis by 
reverse transcriptase. Using cytoplasm cell extract, Vatolin and colleagues performed a 
retro-transcription in order to elongate miRNA sequences. Elongated miRNAs were 
used as secondary primers in a second retro-transcription in order to increase reaction 
specifity. Through specific primers and PCR amplification miRNA targets were 
identified in the hTERT-immortalized retinal epithelial cell line. 
These new biochemical approaches have revolutionized the knowledge about the 
interactions between miRNAs and mRNAs. Indeed, researchers have always thought 
that miRNAs bind only the 3’-UTR region of their targets, but new experiments have 
identified several interactions on coding sequences (CDSs) of the genes. Target sites on 
the CDS seems to be not effective in protein regulation like 3’UTR interactions 
(Schnall-Levin et al., 2011), but their role in gene expression fine-tuning is not been 
elucidated. Moreover, recent studies identified alternative pairing sequences to the seed 
region. For instance, Bartel’s group find a class of miRNAs that lack perfect seed 
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pairing but have 11–12 contiguous Watson-Crick pairs to the center of the miRNA that 
impart Argonaute-catalyzed mRNA cleavage in elevated Mg2+ concentration (Shin et 
al., 2010). These evidences show again the importance of efficient miRNA target 
prediction algorithms and for this reason, recently, Marin and colleagues (Marin et al., 
2013) developed a new algorithm to identify miRNA targets also considering the coding 
region. 
Good target prediction algorithms and valid experimental approaches are essential to 
shed light on miRNA:mRNA interaction networks. 
 
 Interaction network importance 1.5
In the last ten years, modern high-throughput methods in molecular biology (e.g. 
microarrays, next generation sequencing) have been produced an enormous amount of 
data concerning gene expression, protein expression, non-coding RNA expression, and 
all molecular factors that interact each other towards the development of cancer 
diseases. 
Before these advances in genomics technologies, tumoral processes were studied by 
single gene approach losing complete vision of molecular interconnection in a cell. 
They perturbed cancerous system through gene expression knock-down or protein 
mutagenesis in order to understand the function of single genes or proteins. Without 
considering the entire network of genes or proteins influenced by the mutated one we 
can have partial information. 
Therefore, we are interested in approaching tumoral diseases from a different point of 
view to identify regulatory interaction networks altered by disease. Microarray and next 
generation sequencing (NGS) have improved, identifying thousands of biological 
elements a time, our knowledge in the complex signalling networks. We understood that 
a perturbation in the system leads to several changes in the molecular processes 
undertaken by the cell. Therefore, we need to integrate information at different 
biological levels, from receptor-ligand interactions to gene-regulatory networks in order 
to understand every significant interaction perturbed. At the moment, there are 
algorithms that can help us to identify these perturbations. Clipper algorithm (Martini et 
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al., 2013) is one of these algorithms. It is freely available on Graphiteweb web tool 
(http://graphiteweb.bio.unipd.it/). Thanks to this web tool, we are able to dissect the 
complexity of a gene perturbation recognizing the portions of the biological pathways 
involved in the studied problems. 
Considering miRNAs interaction networks become more complicated. For example, Wu 
and colleagues (Wu et al., 2010) validated 28 different miRNAs that were able to 
interact with p21 transcript. This work pointed out the ability of interaction of different 
miRNAs with the same transcript. At the same time, it is emerged that every miRNA is 
able to regulate tens or hundreds of different target simultaneously making these small 
non-coding transcripts fundamental regulators of cellular processes but very difficult to 
study (Peter, 2010). At the moment, we know that miRNAs affect different pathways 
that contribute to tumour progression as migration, invasion, apoptosis, cell 
proliferation, epithelial-to-mesenchymal transition, and angiogenesis (Jiang et al., 
2013). Recently, Volinia and colleagues (Volinia et al., 2010) studied miRNA networks 
in a collection of 4000 cancerous samples. They identified some common miRNAs 
behaviour in different cancer histotypes and some specific cancer type interactions 
understanding the complex networking that exist in cancerous processes. In this study, 
analyzing the correlation between targets deregulation and biological pathways from 
Kyoto Encyclopedia of Genes and Genomes (KEGG) database, they found that the most 
common pathways identified are WNT signalling, Phosphatidylinositol, Focal 
Adhesion, and Vascular Endhotelial Growth Factor (VEGF) pathways. 
Considering results obtained by Volina and colleagues and the recent publications from 
ENCODE consortium (https://genome.ucsc.edu/ENCODE/ or 
http://www.genome.gov/10005107 and http://www.nature.com/encode/#/threads) we 
understood the needing of genome wide data to identify every single interaction and 
modification that occurs in cancer cells. From the transcriptional point of view human 
genome is 80% transcribed (Pennisi, 2007) allowing also the synthesis of long non-
coding RNA that have important implication in miRNA regulation (Tay et al., 2014).  
At the moment, microarrays and NGS are the technologies most used to identify 
thousands of elements in a single experiment. In the table 1.3 the different commercial 
product available for miRNA profiling are summarized. 
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Advantages Disadvantages Assay or 
platform 
Company RNA 
in 
input 
Costs 
per 
sample 
MicroRNA microarray 
Established 
method.  
Fairly low-cost 
and high-
throughput  
Lower specificity 
than RNA 
sequencing.  
Difficult to use for 
absolute 
quantification.  
Cannot identify 
novel miRNAs 
Geniom 
Biochip 
miRNA 
CBC (febit) ng–
μg 
$ 
GeneChip 
miRNA array 
Affymetrix 
GenoExplorer Genosensor 
MicroRNA 
microarray 
Agilent 
miRCURY 
LNA miRNA 
array 
Exiqon 
NCode 
miRNA array 
Invitrogen 
OneArray Phalanx 
Biotech 
Sentrix array 
matrix and 
BeadChips 
Illumina 
μParaFlo 
biochip array 
LC 
Biosciences 
RNA sequencing: high-throughput next-generation sequencing platforms 
High accuracy in 
distinguishing 
miRNAs with 
similar 
sequences (e.g. 
isomiRs) 
Can detect novel 
miRNAs 
Substantial 
computational 
support needed for 
data analysis.  
Cannot be used for 
absolute 
quantification 
HiSeq 2000 / 
MiSeq 
Illumina ng–
μg or 
>μg 
$$$ 
SMRT Pacific 
Biosciences 
SOLiD Life 
Technologies 
GS FLX+ / 
GS junior (454 
sequencing) 
Roche   
 
 Ion Proton / 
Ion Torrent 
 
Life 
Technologies 
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TABLE 1.3.  (on page 28) Different commercial product available for miRNA profiling. The 
table explain the comparison between product for miRNA profiling based on microarray 
technology or based on NGS technology. In the first two columns are indicated advantagesand 
disadvantages. In the last two columns are indicated the amount of material that every product 
need and the costs per sample. 
 
1.5.1 Microarray techniques 
Microarrays are glass or plastic slides (sometimes plastic beads) onto thousand probes 
were linked. Probes are able to recognize and to bond biological materials like DNA, 
RNA, proteins, peptides, antibodies, and chemical compounds. These biological 
elements are usually labelled with fluorophores and a CCD camera is able to quantify 
the amount of material bound to the microarray. Platforms and assays developed for 
transcriptome protocols, usually differ each other for the methods of RNA labelling 
(e.g. types of enzyme, 3’-end or 5’-end labelling) and for the probe spotting technology 
(e.g. probe deposition, probe synthesis through coupling of photolithography and 
phosphoramidite chemistry). 
Microarrays have the advantage that they are generally less expensive than sequencing 
methods. In addition, this technique has well established data analysis methods for the 
comparison of RNA abundance. This technique has also some disadvantages, in 
particular it is useful for relative quantitation but have some problems in absolute 
quantitation. Moreover, microarrays are not able to distinguish miRNAs/mRNAs with 
similar sequences (e.g. isomiR, mRNA with point mutation).  
MRNA and miRNA microarrays are the most used microarrays to discover network 
regulation. In particular, common experiments are based on the induction of a system 
perturbation, through gene silencing or enhancing approaches, in order to identify, in a 
single experiment, changes induced in cell transcriptome.  
 
1.5.2 Next Generation Sequencing (NGS) techniques 
Sequencing technology has come a long way since Sanger first introduced a method for 
DNA sequencing. It was based on the balancing between synthesis of a complementary 
30 
 
DNA template using natural 2′-deoxynucleotides (dNTPs) and termination of that 
synthesis using 2′,3′-dideoxynucleotides (ddNTPs). This approach allows obtaining a 
set of nested fragments that differ in terminal nucleoside monophosphate units (Sanger 
et al., 1977). Now, after 35 years, next generation sequencing (NGS) technologies are 
based on the same principle or on completely different technologies. The unique 
combination of specific protocols distinguishes one technology from another 
(summarized in (Metzker, 2010)). The major template preparation protocol used is the 
clonal amplification starting from single DNA molecules (e.g. emulsion PCR or solid-
phase amplification) in order to amplify every single DNA fragment. In addition, there 
are platforms like the SMRT of Pacific Biosciences that use a single DNA-molecule 
template method and do not need material amplification. Different sequencing machines 
use different approaches to perform the sequencing run: a) Single nucleotide addition 
(SNA) that uses limiting amounts of individual natural dNTPs to cause DNA synthesis 
pause in order to understand the bases added by polymerase after injection of given 
dNTPs; b) Cyclic reversible termination (CRT) that uses reversible terminators 
containing a protecting group (e.g. 3′-O-azidomethyl-dNTPs) attached to the nucleotide 
that terminates the synthesis of cDNA and where cycles of coupling and deprotection 
permits the identification of bases added by polymerase reaction; c) Sequencing by 
ligation (SBL), an approach in which DNA polymerase is replaced by DNA ligase that 
joins the probe to the template and a fluorescence imaging determine the identity of the 
ligated dye-labelled probe; d) real-time sequencing that, unlike reversible terminators, 
do not halt the process of DNA synthesis but involves imaging that identify the 
continuous incorporation of dye-labelled nucleotides during DNA synthesis. In all these 
methods, bases added are conjugate with fluorophors or dyes useful for the detection 
through a camera. On the other hand, Ion Proton and Ion Torrent sequencers (Life 
Technologies) are able to identify the bases added by polymerase without the usage of 
an expensive high-resolution camera. Indeed, they do not use fluorescence dNTPs but 
they use the H+ emission that occurs during polymerase reaction. pH changes are used 
to identify the incorporation of a single nucleotide in the polymerizing DNA. However, 
in spite of the technology used, the amount of data produced is enormous that demands 
on information technology high performances in terms of data storage, tracking and 
quality control. 
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NGS technologies allow the production of millions of reads from 50 to 400 bp long. In 
contrast to traditional sequencing methods, NGS has a lot of advantages. It is high 
throughput, precise, accurate, and repeatable. Sequencing based methods allow the 
identification and quantification of rare transcript variants without prior knowledge 
providing also information about alternative splicing sites. Moreover, sequencing 
approach allows miRNA discovery taking in account also isomiR sequences and the 
identification of miRNA targets. Sequencing already is more expensive than microarray 
analysis, but it is in continue decrease. Bigger limitation for sequencing data is data 
analysis. Do not exist a consolidated workflow to analyse sequencing data as, instead, 
for microarray data. 
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2 Project aim and organization of the 
thesis 
 
 
The aim of this thesis is the identification of functional miRNA:mRNA interactions 
involved in Melanoma metastasis through a combination of in silico and experimental 
approaches, in order to understand the real involvement of miRNAs in this serious 
cancer disease and to identify all the elements that contribute to its development. 
Indeed, the identification of true miRNA targets is fundamental to understand miRNA 
functions. Moreover, the higher stability of miRNAs than mRNAs allows their future 
use as drugs in pathologies treatment instead gene therapy.  
To reach proposed aims I have set up a meta-analysis approach first and a genome wide 
biochemical approach later. The combination between the two approaches has been 
allowed the experimental validation of results obtained by meta-analysis and the 
identification of new miRNA interactors. 
Results and discussions section of this thesis is divided in three parts. The first, where 
the meta-analysis results are described, the second where are illustrated the results 
obtained through biochemical approach and the last where the two results are integrated.  
In the last part of results I have also discussed the involvement of a new class of 
effectors (long non-coding RNAs – lncRNAs) in the interaction network that can 
interfere/regulate miRNA:mRNA interactions in Melanoma.  
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3 Materials and methods 
 
 
 Primers list 3.1
oligo d(T) – Ion  
3′-CCTCTCTATGGGCAGTCGGTGATCCTCAGCTTTTTTTTTTTTTTTTTTTTVN-5′ 
 
Smart primer 
5′-CACACACAATTAACCCTCACTAAAGGG-3′ 
 
A-BC3 (in blue the barcode sequence) 
5′-CCATCTCATCCCTGCGTGTCTCCGACTCAGAAGAGCACACACAATTAACCCTCACTAAA-3′ 
 
A-BC4 (in blue the barcode sequence) 
5′-CCATCTCATCCCTGCGTGTCTCCGACTCAGTACCACACACACAATTAACCCTCACTAAA-3′ 
 
A-BC5 (in blue the barcode sequence) 
5′-CCATCTCATCCCTGCGTGTCTCCGACTCAGCAGAACACACACAATTAACCCTCACTAAA-3′ 
 
Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GADH)   
forward 5′-TCCTCTGACTTCAACAGCGA-3′  
reverse 5′-GGGTCTTACTCCTTGGAGGC-3′ 
 
Homo sapiens forkhead box N3 (FOXN3) 
forward 5′-GCGATCAGCCGAACTCTAGG-3′ 
reverse 5′-TTGGCAATATGATTACATACGAAGA-3′ 
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Homo sapiens fibronectin type III domain containing 3B (FNDC3B) 
forward 5′-TGCCATCACACACGAACAAT-3′ 
reverse 5′-GCCACTCATTCACTCCTCACA-3′ 
 
Homo sapiens CAP, adenylate cyclase-associated protein 1 (CAP1) 
forward 5′-TATGGAACGGGCAGAAGTTG-3′ 
reverse 5′-GTGAAGGGAGGGCAAAGAAC-3′ 
 
 Buffers and solutions 3.2
1X PXL (wash Buffer) 
• 1X  PBS (tissue culture grade; no Mg2+, no Ca2+) 
• 0.10%  SDS       
• 0.50%  NP-40 (Nonidet P-40 detergent)  
 
1X PXL + protease Inhibitor (store -20°C x 12weeks or 2-4°C 2 weeks) 
• 1X  PBS (tissue culture grade; no Mg2+, no Ca2+)  
• 0.10%  SDS        
• 0.50%  NP-40 (in PBS 1X)      
• 1 tablet  EDTA-free Protease Inhibitor Cocktail 25X   
 
2.5X PXL (High-salt Wash Buffer) 
• 2.5X  PBS (tissue culture grade; no Mg2+, no Ca2+)  
• 0.10%  SDS        
• 0.50%  NP-40      
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1X PNK Buffer         
• 50 mM Tris-HCl, pH 7.4       
• 10 mM MgCl2        
• 0.50%  NP-40      
          
1X PNK+EGTA Buffer 
H2O Gibco           
• 50 mM Tris-HCl, pH 7.4      
• 20mM  EGTA        
• 0.50%  NP-40         
 
 
 Sample preparation and RNA extraction 3.3
A375P cell line and derived variants (MA1, MA2, MC1, MC2) were provided by RO 
Hynes (Xu et al., 2008a) and maintained in Dulbecco’s Modified Eagle’s Medium 
containing 10mM Glutamax and 4.5 g/ml glucose (DMEM GlutamaxTM, GIBCO 
Invitrogen Life Technologies, Carlsbad, CA), supplemented with 10% heat-inactivated 
FCS, 1mM sodium pyruvate, 25mM HEPES pH 7.4, 1X MEM vitamin solution, 1X 
MEM non-essential amino acids and 100 mg/ml gentamicin (all from GIBCO 
Invitrogen Life Technologies) at 37° C in 5% CO2 in a humidified incubator. 
Total RNA from lung metastases or cells in culture was isolated with TRIzol reagent 
(Life Technologies) according to manufacturer protocol. 
RNA quantitation was performed using the NanoDrop 1000 spectrophotometer 
(Nanodrop). Total RNA integrity and the percentage content of miRNAs in each sample 
were assessed by capillary electrophoresis using the Agilent Bioanalyzer 2100 with the 
RNA 6000 Nano and the Small RNA Nano LabChips, respectively (Agilent 
Technologies). Only total RNA samples with an RNA integrity number (RIN) >6 and 
<30% of small RNAs were used for miRNA microarray analysis.7 
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 MiRNA and mRNA expression profiles 3.4
MiRNA microarray experiments were performed using the Agilent Human miRNA 
Microarray (V2) 8 x 15K platform (Agilent technologies) containing probes for 723 
mature miRNAs. 200 ng of total RNA were labelled using miRNA Complete Labeling 
and Hyb Kit (Agilent Technologies) according to manufacturer protocol. Labelled RNA 
was hybridized onto microarray slides in the rotation hoven at 55°C for 22 hours. After 
hybridization, microarray slides were scanned with an Agilent microarray scanner. 
MiRNA microarray expression data were extracted using Feature Extraction Software 
(Agilent Technologies) according to manufacturer protocol. 
In addition mRNA expression profiles performed by Xu (Xu et al., 2008) were obtained 
from GEO database under accession number GSE7929. 
 
 Meta-analysis procedures 3.5
3.5.1 STEP 1: Microarray data processing 
Figure 2.1 shows the data processing workflow used in this work. In order to remove 
inter- and intra- arrays technical biases and noise artifacts, miRNA microarray 
expression data were normalized using a modified Loess normalization (LoessM) in R 
Package (www.r-project.org) (Risso et al., 2009) while mRNA expression data 
normalization was performed by quantile normalization (Bolstad et al., 2003).  
The unsupervised cluster analysis was performed using Pearson Correlation (Eisen et 
al., 1998), through the Multi Experiment Viewer 4.9 (TMev) of the TM4 Microarray 
Software Suite (Saeed et al., 2006). 
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Figure 3.1 Meta-Analysis data processing workflow. 
 
3.5.2 STEP 2: miRNA-mRNA anti-correlation identification 
In order to identify possible miRNA-target pairs, MAGIA2 (Bisognin et al., 2012) was 
used to combine miRNA and mRNA expression data. 
This web tool is useful for the reconstruction of post-transcriptional regulatory networks 
starting from miRNA and mRNA expression data. The algorithm is able to discern 
miRNA-target pairs (identified with several target predictions algorithms) that show 
negative correlated expression profiles. According to the capability of miRNA to 
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degrade their targets expression correlation could be a useful method to identify miRNA 
targets.  
After data upload you can select the best association measures in relation to the number 
of replicates in the starting matrices. For matched design you can use Spearman 
correlation for non-normally distributed data or small sample size (e.g. 3–5), Pearson 
correlation for normally distributed data and medium-large sample size (>5), and 
Mutual information for large sample size (> 20). I used a meta-analysis approach since 
the availability of mRNA and miRNA expression from different samples. This 
algorithm first calculate miRNA and mRNA differential expression patterns using the 
empirical Bayes test LIMMA and subsequently it identifies oppositely variable 
miRNA–target pairs using an inverse chi square distribution. I used Targetscan 
(Friedman et al., 2009) predictions algorithms with a stringency value of 0.4 in order to 
use top 75% trustable predictions. The correlated interactions are associated to an 
adjusted p-value (q-value) and I decide to analyze only the pairs with q-value lower 
than 0.1. 
 
3.5.3 STEP 3: Signal Paths identification using CliPPER 
MRNA expression data were analyzed using CliPPER algorithm (Martini et al., 2013). 
CliPPER is based on Gaussian graphical models that perform gene set analysis 
exploiting the topology of the pathways. With this method, we are able to dissect the 
complexity of a pathway recognizing the portions (called Signal Paths) mostly 
associated to the phenotype under study. Basically it performs two different tests. In the 
first step, the algorithm perform the analysis on the whole pathways: it integrates 
pathway and expression data testing both concentration matrix and mean vectors. In the 
second step, the algorithm breaks down the pathway into small portions of connected 
genes (called cliques) and performs the tests on covariance matrices in order to identify 
a continuous chain of cliques that mutually influence their expression.  
CliPPER results consist in a list of significant pathways for the mean (the alphaMean 
adjusted p-value) or for the concentration matrices (the alphaVAR adjusted p-value). 
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For each of the significant pathways, we can access all the associated signal paths. A 
signal path represents a connected portion of a pathway and an intra-pathway score 
reflects the strength of its association with the phenotype under study. 
 
3.5.4 STEP 4: Selection relevant pathways 
In order to identify only the significant pathways strongly regulated by miRNAs I 
decided to perform CliPPER based analysis using only the expression profiles of 
mRNA identified as miRNA targets (see paragraph 3.5.2). For this analysis I used only 
mRNA predicted interacting with miRNAs with a p-value < 0.1. I used Venny web tool 
(Oliveros, 2007) to identify common pathways (called Relevant Pathways) between the 
two CliPPER analyses. 
The list of relevant pathways was trimmed according to their relevance in the 
Melanoma basing on literature searching algorithm (Le and Kwon, 2012). The pathway 
lists of each analysis are available on appendix. (Tables A1 and A2)  
 
3.5.5 STEP 5: Data mining and visualization 
Microarray data analysis: for identification of differential expressed miRNAs or mRNA, 
2-class significance analysis of microarray (SAM) algorithm (Tusher et al., 2001) was 
used. SAM uses a permutation-based multiple testing algorithm and associates a 
variable false discovery rate (FDR) to the significant genes. FDR refers to the 
percentage of error that can occur in the identification of the statistically significant 
differentially expressed genes in multiple comparisons; in all the analyses I used FDR < 
0.001. Unsupervised cluster analysis was performed using Pearson Correlation. All 
these analyses were performed with Multi Experiment Viewer 4.9 (TMev) of the TM4 
Microarray Software Suite (Saeed et al., 2006).  
Signal Path Visualization: Lists of mRNAs for each signal path identified by CliPPER 
algorithm were mapped on KEGG Search&Color Pathway mapping tool. Red boxes 
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represent mRNAs with an expression level upregulated in lung metastases respect to 
A375P cells while green boxes show mRNAs upregulated in A375P cell lines respect to 
metastases. 
miRNAs identified with MAGIA2 analysis were manually added to their targets with 
the same colour decodification of mRNA. Starred miRNAs are also identified like 
differntialy expressed with 2-class SAM analysis (FDR<0.001). In the schemas, boxes 
could correspond to protein complexes. In order to know which mRNA of the complex 
is connected with miRNAs I constructed tables with all the miRNA-mRNA interaction 
for every signal paths. 
Every schema is combined with lines graph that show miRNA expression levels in low 
and high metastatic cell lines and lung metastases. Data are presented as means ± 
Standard Deviation. 
 
 HITS-CLIP Modified protocol 3.6
Hits-CLIP is a biochemical method for the identification of miRNA-target developed by 
Chi and colleagues (Chi et al., 2009) that take advantage of the physical interaction 
between miRNAs and mRNAs through the miRNA-loaded RNA-induced silencing 
complex (miRISC). MiRISC is essentially composed by AGO family proteins. This 
method uses ultraviolet irradiation to covalently crosslink RNA–protein complexes that 
are in direct contact (approximately over single ängstrom distances) within cells 
allowing the subsequent interactors purification through the immunoprecipitation (IP). 
After purification, a partial RNA digestion reduces bound RNA to fragments that can be 
sequenced by high-throughput sequencing methods 
I modified the original protocol in order to avoid the use of ligase and radioactive stuff. 
Indeed, T4 RNA ligase used for the adapters 3’-ligation has got low efficiency (F. 
Zhuang et al., 2012). To overcome this problem, I decided to label RNA obtained by IP 
using a SMART (switching mechanism at the 5'-end of RNA templates of reverse 
43 
 
transcriptase) PCR approach (Zhu et al., 2001) optimized for smallRNAs labeling 
(Biscontin et al., 2010). The detailed protocol is below described. 
 
3.6.1 UV Cross-linking of cell lines 
Melanoma cells are irradiated with UV rays in order to create covalent bonds between 
RNAs (both miRNA and mRNA) and proteins that are close to them (AGO proteins). 
UV irradiation does not induce protein-protein crosslinks like formaldehyde 
crosslinking. Crosslinks between proteins and RNA occurs on only 1–5% of contact 
sites (Fecko et al., 2007; Darnell, 2010). 
 
- Seed 3 x 106 cells in 6-8 plates (diameter 15 cm). 
- Expand cells to 80% confluence. 
- Wash cells once with 10 ml ice-cold PBS per plate and remove PBS completely. 
- Maintain plates on ice. 
- Place plates on a tray with ice and irradiate one time uncovered with 200mJ/cm2 
of 254 nm UV light in a Stratalinker 2400 (Stratagene). 
- Scrape cells off with a rubber policeman in 1 ml PBS per plate, transfer to a 50 
ml centrifugation tube.   
- Pellet cells by centrifugation at 500 x g for 5 min. at 4° C and discard the 
supernatant. 
- Re-suspend pellet in 3 ml of PBS and distribute 1ml of suspension to ~ 4 
different eppendorf. 
- Quick spin at 4° C, remove supernatant and freeze pellet in liquid nitrogen and 
store at -80° C until use (each tube is about 200 μl of cells). Cell pellets can be stored 
for at least 12 months. 
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3.6.2 Preparation of magnetic beads  
Dynabeads Protein G magnetic beads are covered with anti-Ago2 antibody (Millipore) 
because showed better specifity respect Anti-Ago2 antibodies from Sigma and Santa 
Cruz (see Results and Discussion chapter). 
 
- Transfer 150 μl of Dynabeads Protein G magnetic particles (Life Technologies) 
per each Eppendorf of crosslinked lysate.  
- Wash beads three times with 500 ul of 0.1 M Na-phosphate pH 8.0 buffer. 
- Resuspend beads in 200 µl of 0.1 M Na-phosphate pH 8.0 buffer. 
- Add 3,5 ug of Millipore anti-AGO2 antibody for sample.  
- Incubate on a rotating wheel overnight (O.N.) at  4° C. 
- Wash beads two times with 1X PXL to remove unbound antibody. If you are not 
yet ready to add crosslinked lysate, leave beads in last wash step. 
 
3.6.3 Lysis 
In this step crosslinked cells are lysed and the length of mRNA is reduced by RNAse A 
digestion. High salt concentration in this step causes the digestion of only ssRNA by 
RNAse A (Chi et al., 2009). 
- Resuspend each tube of crosslinked lysate using ~550 μl of 1X PXL (with 
protease inhibitors) and 12 μl RNAsin; ~1 ml total.   2 for each samples 
- Disgregate the cell pellet pipetting through a 5 ml syringe, maintaining the tube 
on ice. 
- Add 30 μl of RQ1 DNAse (RQ1 RNase-Free DNase, Promega) to each tube. 
- Incubate at 37° C for 5 min. in agitation (1.000 rpm) in a Thermomixer R 
(Eppendorf). 
- Make a dilution of RNAse A at 1:5,000 in 1X PXL (medium-RNAse). 
- Add 10 μl of each RNAse dilution to each tube. 
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- Incubate at 37° C for 5 min. in agitation (1.000 rpm) in a Thermomixer R 
(Eppendorf). 
- Spin lysates in pre-chilled ultra-microcentrifuge 16.000 x g for 30 min. at 4° C. 
- Carefully remove the supernatant and pool the same samples saving 10 μl for 
immunoblot analysis. 
 
3.6.4 Immunoprecipitation 
Thanks to the beads prepared before, miRNAs linked mRNAs are immunoprecipitated 
together with Ago2 protein. 
- Add the supernatant prepared in the previous step to one prepared tube of beads. 
- Incubate in 2 ml centrifugation tubes on a rotating wheel O.N. at 4°C. 
- Remove the supernatant and save all for immunoblot analysis (in order to test 
the relative depletion of the antigen). 
- Wash beads twice with ice-cold buffer: 
1. 1X PXL (Wash Buffer). 
2. 2,5X PXL (High-salt Wash Buffer). 
3. 1X PNK Buffer. 
 
3.6.5 Phosphatase treatment (on bead) 
The 3’ phosphate group of the digested RNA is removed by alkaline phosphatase, 
enabling the future ligation of specific oligonucleotides to the 3’ end of RNA. 
- Remove the surnatant and add Phosphatase Mix 
Phosphatase mix 1X 
CIP Buffer 10X 8 ul 
CIP [1U/ul] 3 ul 
RNAsin 2 ul 
H2O 
 
67 ul 
 
Tot 100 ul 
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- Incubate at 37° C for 20 min. (agitation at 1.000 rpm 2 min. every 15 sec.) 
- Wash beads twice with ice-cold buffer: 
1. Wash 1X with 1X PNK Buffer. 
2. Wash 1X with 1X PNK+EGTA Buffer. 
3. Wash 2X with 1X PNK Buffer. 
 
 
3.6.6 Polynucleotide kinase (PNK) treatment (on bead) 
5’-OH must be phosphorylated in order to have better results in the following 
polyadenylation reaction. 
- Remove the supernatant 
- Add PNK mix 
PNK mix 1X 
PNK Buffer 10X 8 ul 
T4 PNK [1U/ul] 4 ul 
ATP [10mM] 1 ul 
RNAsin 2 ul 
H2O 
 
65 ul 
 
Tot 100 ul 
 
- Incubate at 37° C for 20 min. (agitation at 1.000 rpm 2 min. every 15 sec.) 
- Wash beads twice with ice-cold buffer: 
1. Wash 1x with 1X PXL buffer. 
2. Wash 1x with 2,5X PXL buffer. 
3. Wash 3x with 1X PNK buffer. 
 
47 
 
3.6.7 Proteinase K treatment 
In this step the ternary complex miRNA-mRNA-Ago2 is destroyed and the RNA is 
collected thanks to Phenol-Acid – Chloroform extraction. 
- Remove the surnatant. 
- Add 200 ul of Proteinase K Buffer. 
- Add 10 ul of Proteinase K [0,2 U/ul]. 
- Incubate 45 min. at 50° C (30 min. 600 rpm; 750 rpm 50 sec. and 20 sec. pause). 
- Add 1 ml Trizol (Life Technologies) and 200 ul of Chloroform. 
- Incubate 10 min. on ice. 
- Centrifuge for 25 min. at 12.000 x g at 4° C. 
- Take the aqueous phase. 
- Add 1/10 volumes of NaAC and 4 volumes of EtOH Absolute for the 
precipitation. 
- Incubate at -20° C O.N. 
- Centrifuge for 30 min. at 15.000 x g at 4° C. 
- Remove the supernatant. 
- Wash the pellet with EtOH 80% and centrifuge for 20 min. at 15.000 x g at 4° C. 
- Remove the supernatant. 
- Resuspend in 5 ul of GIBCO water. 
 
3.6.8 RNA Polyadenylation 
In this step RNA (both miRNA and digested mRNA) is polyadenylated at the 3’-end. 
This reaction is essential for the following retrotranscription reaction and SMART PCR 
reaction. 
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Reaction Mix  
Polyadenylation mix 1X  
RNA 5 ul 
5X Pap Buffer 5 ul 
MnCl2 [25mM] 2.5 ul 
ATP [10 mM] 2.5 ul 
Pap Enzyme 1 ul 
H2O Gibco 
 
9 ul 
 
Tot 25 ul 
- Incubate in Thermomixer 1 h and 30 min. at 37° C (lid 38° C). 
- Precipitate RNA with 1/10 NaAc and 4 volumes of EtOH abs. 
- Put at - 20° C O.N. 
- Centrifuge at 16.000 x g for 30 min. at 4° C. 
- Remove the supernatant. 
- Wash the pellet with EtOH 80% and centrifuge for 20 min. at 15.000 x g at 4° C. 
- Dry the pellet on air. 
- Resuspend in 3,2 ul of GIBCO water. 
 
3.6.9 SMART Reaction 
Using the method described by Biscontin (Biscontin et al., 2010) for the smallRNA 
labeling, I performed a retrotranscrpition reaction followed by 2 PCR cycles. The 
SMART primer bind to the three cytosines added by SuperScriptII at the 5’-end. On the 
other side it was used the overhang sequence of the oligo-d(T)–Ion primer for first 
strand synthesis. 
Reaction mix: 
Retrotranscription mix 1 X 
RNA  3,2 ul 
SMART primer [60 uM] 0,8 ul 
Oligo dT + primer P1 [10uM] 
 
1 ul 
 
Tot 5 ul 
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- Incubate at 72° C for 2 min. 
- Maintain on ice. 
- Add the following reaction mix: 
 1X  
5X First strand Buffer 2 ul 
DTT [0,1 M] 1 ul 
dNTPs [10 mM] 0,5 ul 
Superscript II 200 U/ul 0,5 ul 
H2O Gibco 
 
1 
 
Tot 5 ul 
 
- Incubate 42° C 1h and 20 min.  
- Store a -20° C. 
 
3.6.10 Amplification through PCR 
PCR 1 
In this step only ssDNA having a SMART anchor sequence at the 5'-end are used as 
template and exponentially amplified. In this step, in order to label DNA fragments with 
a precise barcode, different primers are used for cDNAs from different samples. The 
P1-rev primer was used in all the reaction, while for DNA derived from A375 and MA2 
cells it was used A-BC3 and A-BC5 primers, respectively.  
PCR was performed preparing followed reaction mix. 
PCR reaction mix 1X  
10X High Fidelity PCR 
Buffer 
2.5 ul 
10 mM dNTP mixture 0.5 ul 
50 mM MgSO4 1 ul 
Primer A-BC (10 μM) 0.2 ul 
Primer P1 rev (10 μM) 0.2 ul 
RT 4 ul 
PlatinumR Taq High 
Fidelity 
0.2 ul 
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H2O 16.4 ul 
Tot 25 ul 
94°C  2 min 
94°C   25 sec 
53°C  30 sec     20 cycles 
68°C  1 min 30 sec 
68°C  3 min 
4°C  ∞ 
 
- PCR products were purified twice through GenElute PCR Clean-Up Kit 
(SIGMA-Aldrich) according to manifacturer protocol and then used in a second round 
of PCR. This should avoid to have primer dimers from longer primers used in the first 
PCR round. 
PCR 2 
Second round of PCR was performed using follow mix. 
 
PCR2 reaction mix 1X  
10X High Fidelity PCR Buffer 2.5 ul 
10 mM dNTP mixture 0.5 ul 
50 mM MgSO4 1 ul 
Primer A for (10 μM) 0.2 ul 
Primer P1 rev(10 μM) 0.2 ul 
RT 20.4 ul 
PlatinumR Taq High Fidelity 0.2 ul 
H2O --- 
Tot 25 ul 
 
 
Cycle 
 
94°C  2 min 
94°C   25 sec 
55°C  30 sec     22 cycles 
68°C  1 min 30 sec 
68°C  3 min 
4°C  ∞ 
 
- PCR products were purified twice through GenElute PCR Clean-Up Kit 
(SIGMA-Aldrich) according to manifacturer protocol. 
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3.6.11 Gel purification 
To have DNA framents useful for sequencing with Ion Torrent sequencer (Life 
Technologies) I performed a gel sizing followed by a purification.  
- Library size selections was performed through E-Gel SizeSelect Gels (Life 
Technologies) according to manufacturer protocol. 
- Fragments from 120 nt to 300 nt were size selected. 
- Purified DNA is compatible with library construction protocols of major 
generation sequencing platforms, such as ION Torrent PGM sequencer (Life 
Technologies). 
- Samples were stored at -20° C until use. 
 
  Next Generation Sequencing 3.7
3.7.1 Library amplification through Emulsion PCR (emPCR) 
DNA library obtained through previous described steps were clonally amplified by 
emPCR. By this step sequencing beads, covered by probes that link to P1 primer, are 
covered by the same DNA fragment to be sequenced. Briefly, beads and DNA 
fragments are put in an oil-buffer emulsion to allow the production of small water 
bubbles where every drop should contain PCR components, a single bead and a single 
DNA fragment. Every drops become a micro-reactor where occur PCR-based 
amplification. Later, using beads that recognize the Ion Torrent sequencing primer A 
placed at the other extremity of the DNA fragments, the reaction mix is enriched for full 
length DNA fragments. The Ion Touch System (Life Technolgies) was used to perform 
emPCR. It integrates 4 steps into a single system: 1) drop-based micro-reactor 
generation for massively parallel clonal amplification, 2) template amplification using 
an in-line PCR technology, 3) magnetic beads recovery using an integrated mini-
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centrifugation system, and 4) full length template-positive beads enrichment by 
magnetic separation. 
Purified beads was used to load the Ion Torrent sequencing chip. Every chip contains 
millions of wells where beads can fell and where the sequencing reaction occurs. The 
template loading and the following chip lading in the sequencing machine was done 
according to the Ion Torrent manual. 
 
 
3.7.2 Sequencing data processing 
Ion Torrent PGM returns a BAM file containing all the sequences identified associated 
with a Quality Control (QC) report. The QC report gives information about: beads 
loading density in the sequencer chip, beads quality (total number, polyclonal beads, 
empty beads, beads with low quality reads), read lengths and internal sequences quality 
controls. In particular, it is important the Test Fragment Accuracy in order to evaluate 
the sequencing quality for a particular run. Test Fragments are known sequences spiked 
into the experimental sample before loading the sequencing chip. The sequencer 
software calculates the percentage of 50AQ17 that corresponds to the number of test 
fragments with at least one error in the first 50 bases. In addition, software calculates 
Phred quality score (Q score), the most common metrics used to assess the accuracy of 
a sequencing platform. The software shows the number of read that have an accuracy of 
99% (Q20) that correspond of 1/100 chance to find an incorrect base call. 
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Figure 3.2 Workflow describing analysis of sequencing reads. Hits-CLIP reads are aligned first 
to miRNA database (miRBASE) and later, the not aligned reads are aligned against transcript 
database (Ensemble). For each alignment I took only sequences supported by at least 4 reads. 
Reads mapped closer on the same transcript sequence are joined and, adding 50 bp upstream 
and downstream them, are  identified the regions where miRNAs bind (in orange in the figure). 
For the miRNA seed region analysis are taken only miRNAs found also on miRNA microarray 
experiments. If the seed region of miRNAs identified is recognized within the binding region, the 
miRNA:transcript interaction is called validated (in dark green in the figure). 
 
Raw reads that pass quality controls were used for searching barcode according to Ion 
plug-in installed in the Torrent server. After barcode sequences removing, reads were 
filtered for length (≥ 10). Reads were mapped on pre-miRNA sequences from miRBase 
database ver. 19.0 (Kozomara and Griffiths-Jones, 2011, 2014) using Bowtie2, in order 
to identify miRNA sequences. I decided to use only miRNAs identified at least by 3 
reads. Remaining reads were than mapped on transcripts from Ensembl database release 
73 (Flicek et al., 2012) using Bowtie2 (Langmead et al., 2009; Langmead and Salzberg, 
2012). In the analysis were studied only reads that align uniquely in the reference. If a 
read mapped on two or more transcripts, it was discarded. Only transcripts presenting at 
least 4 reads were considered for further enrichment analyses. Pathways enriched were 
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detected using DAVID (Huang et al., 2009a, 2009b), and Graphite web tool (Sales et 
al., 2013).  
 
 Western Blot 3.8
Cells cultured under desired conditions were first irradiated with 200 mJ/cm2 of 254 nm 
UV light on plate, then they were collected in eppendorf and lysed in 1X PXL 
containing EDTA-free Protease Inhibitor Cocktail (Roche). Lysates were incubated on 
ice and centrifuged for 30 minutes at 13.000 × g, and supernatants were removed and 
stored at 20° C until use. Whole-lysate proteins was splitted in three tubes where 
occurred IP reaction as described in Hits-Clip modified protocol section using 3,5 ug of 
different anti AGO2 antibodies: Anti-Ago2 Antibody clone 9E8.2 (Millipore), eIF2C 
(H-300): sc-32877 (Santa Cruz Biotechnology) , and Anti-AGO2 Clone 11A9 (Sigma-
Aldrich).  Beads were re-suspended in 30 μl of 1X PNK buffer + 30 μl of Novex 
loading buffer (without reducing agent) (Life Technologies). Samples were separated by 
4% to 12% SDS-PAGE (Invitrogen Life Technologies) using rainbow marker (GE 
Healthcare), and transferred to nitrocellulose membranes (Amersham Biosciences). 
Membranes were blocked for 1 hour at room temperature with 3% nonfat milk in PBS 
and then incubated with Anti-Ago2 Antibody clone 9E8.2 (1:1000, Millipore), Each 
antibody was diluted in PBS containing 0.1% (v/v) Tween 20 and then used for staining 
overnight at 4° C. After washing three times for 5 minutes each with PBS containing 
0.1% (v/v) Tween 20 at room temperature, membranes were incubated at room 
temperature for 1 hour with a diluted peroxidase-labeled secondary antibody. The 
membranes were then washed three times for 5 minutes with PBS containing 0.1% (v/v) 
Tween 20 at room temperature, and immunopositive signals were visualized using an 
enhanced chemiluminescence detection kit (Cyanagen).  
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 Transient transfections of anti-miRs 3.9
In order to obtain transient hsa-let-7c down-expression, A375P cells were plated in 6-
well plates at 30–50% confluence and transfected using siPORT™ NeoFX™ 
Transfection Agent (Life Technologies), according to the manufacturer’s instructions, 
with 100 nM Anti-let-7c (Life Technologies). I performed preliminary experiments to 
achieve the highest efficiency and reproducibility. Cells were collected 48 h later and 
the efficacy of gene knockdown was evaluated at the mRNA level by using RT-PCR 
analysis. 
 
 Real-Time PCR (RT-qPCR) 3.10
Total RNA was isolated using the TRIzol reagent (Life Technologies) and reverse 
transcribed using SuperScriptII (Life Technologies), according to the manufacturer's 
instructions. Each sample was analyzed for quality control by capillary electrophoresis 
using the RNA 6000 Nano LabChip and the Agilent Bioanalyzer 2100 (Agilent 
Technologies). An aliquot of first-strand cDNA was PCR amplified using SYBR Green 
chemistry (Applied Biosystems, Life Technologies). Quantitative RT-PCR (RT-qPCR) 
was performed in the Applied Biosystems SDS-7500 thermal cycler (Applied 
Biosystems, Life Technologies). Gene-specific primers were designed using 
Primer3web software version 4.0 (http://primer3.ut.ee/) or Application Design Tools 
(Roche Applied Science). By using SYBR Green chemistry, I performed the 
dissociation curve to confirm the specificity of the amplicons. Cycling parameters 
consisted of an initial denaturation step at 95° C for 10 minutes; followed by 40 cycles 
of denaturation at 95° C for 25 seconds, annealing, and elongation steps at 59° C for 1 
minute; and a final elongation step at 72° C for 3 minutes. To evaluate differences in 
gene expression, I chose a relative quantification method in which the expression of 
target gene is standardized by a reference genes (GADPH). The mathematical method 
presented by Pfaffl (Pfaffl, 2001), which calculates the efficiency of each PCR using a 
standard curve, was applied. To calculate the relative expression ratio, I used the ΔΔCT 
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method implemented in the software of the Applied Biosystems thermal cycler (Livak 
and Schmittgen, 2001). 
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4 Results and discussion 
 
 
In the first part of this thesis dissertation, I integrated miRNA and mRNA microarray 
data from the Melanoma cell line A375P and the lung metastases arisen after injection 
of A375P cell lines and derivative variants into the tail vein of 7-week-old female 
CB.17 SCID mice. MRNA data set generated by Xu et al. (Xu et al., 2008) was 
combined with a miRNA data set I produced. miRNA data contains A375P cell line, 
A375P derivative variants cell lines (MA1, MA2, MC1, MC2), and lung metastases 
expression profiles. Conversely, mRNA data contains A375P cell line and lung 
metastases expression profiles. 
In this context, I decided to perform the data integration considering A375P cell line 
and lung metastases samples. This cellular system should mimic the path of a tumoral 
cell into the circulatory system to reach distant organs where it metastatizes. This 
approach could help to understand processes involved in metastasis processes that, 
recently, was discovered as “cancer stem cell” dependent (Shiozawa et al., 2013). 
This experimental design is comparable with the approach followed by Pencheva and 
colleagues that have permitted to discover the interplay between different miRNAs 
(miR-1908, miR-199a-5p, and 199a-3p) and their target genes ApoE and DNAJA4 in 
metastatizing processes (Pencheva et al., 2012). 
In the second part of the study, I set up the AGO-HITS-CLIP method (Chi et al., 2009) 
and used it on A375P and MA2 cell lines in order to experimentally identify 
miRNA:transcripts involved in the metastasis processes. The aim of experimental 
approach is to validate in-silico predicted interactions and to found new interactions 
between miRNAs and transcripts that could shed light on Melanoma metastatic 
processes regulated by miRNAs. 
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 Bioinformatic microarray expression data integration 4.1
4.1.1 miRNA expression Data Analysis 
Unsupervised cluster analysis showed the ability of miRNA expression profiles to 
discriminate between low and high metastatic conditions (Figure 4.1). Same conditions 
are homogeneously grouped together allowing the identification of 3 different groups: 
low metastatic cells A375P, high metastatic cells (MA1, MA2, MC1, MC2), and lung 
metastases. Low metastatic cells (LMC) and high metastatic cells (HMC) have got 
closer expression pattern respect to lung metastases (Mets). This result confirms the 
strength of our Melanoma metastatic model. 
 
 
Figure 4.1 Unsupervised cluster analysis (Pearson Correlation) of miRNA expression data. 3 
sample groups are identified: Low Metastatic Cells (LMC; green bar), High Metastatic Cells 
(HMC; blue bar), and lung metastases (Mets; red bar).The 3 classes have uniform miRNA 
expression profiles. LMC and HMC have got closer expression pattern respect to Mets. 
 
Several miRNAs differentially expressed I identified through microarray analysis 
(Table 4.1.) were identified as important oncomiRs in Melanoma (Kunz, 2013; 
Pencheva and Tavazoie, 2013).  
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miRNAs over-expressed in Mets miRNAs over-expressed in LMC 
hsa-let-7b hsa-let-7e hsa-miR-27b 
hsa-let-7i hsa-miR-100* hsa-miR-28-5p 
hsa-miR-1234 hsa-miR-105 hsa-miR-296-5p 
hsa-miR-125a-3p hsa-miR-1228 hsa-miR-29b-1* 
hsa-miR-140-3p hsa-miR-1238 hsa-miR-301b 
hsa-miR-146a hsa-miR-125a-5p hsa-miR-30a* 
hsa-miR-146b-5p hsa-miR-130a hsa-miR-30b 
hsa-miR-148b hsa-miR-130b hsa-miR-30b* 
hsa-miR-187* hsa-miR-132 hsa-miR-30d* 
hsa-miR-193a-3p hsa-miR-135b hsa-miR-30e* 
hsa-miR-199b-3p hsa-miR-151-3p hsa-miR-32 
hsa-miR-204 hsa-miR-151-5p hsa-miR-331-3p 
hsa-miR-21 hsa-miR-15b hsa-miR-33a 
hsa-miR-21* hsa-miR-15b* hsa-miR-33b* 
hsa-miR-214 hsa-miR-16-2* hsa-miR-361-3p 
hsa-miR-218 hsa-miR-17 hsa-miR-370 
hsa-miR-26a hsa-miR-17* hsa-miR-374a 
hsa-miR-27a hsa-miR-181a* hsa-miR-374b 
hsa-miR-29a hsa-miR-181b hsa-miR-425 
hsa-miR-29c hsa-miR-181c hsa-miR-454 
hsa-miR-340* hsa-miR-18a hsa-miR-595 
hsa-miR-378 hsa-miR-18b hsa-miR-598 
hsa-miR-424 hsa-miR-191 hsa-miR-623 
hsa-miR-494 hsa-miR-193b hsa-miR-625 
hsa-miR-542-3p hsa-miR-196b hsa-miR-630 
hsa-miR-542-5p hsa-miR-19a hsa-miR-652 
hsa-miR-551b hsa-miR-19b hsa-miR-7 
hsa-miR-564 hsa-miR-19b-1* hsa-miR-744 
hsa-miR-602 hsa-miR-20a hsa-miR-768-5p 
hsa-miR-622 hsa-miR-20a* hsa-miR-769-3p 
hsa-miR-629* hsa-miR-20b hsa-miR-770-5p 
hsa-miR-874 hsa-miR-221* hsa-miR-876-3p 
hsa-miR-887 hsa-miR-23b hsa-miR-9* 
hsa-miR-923 hsa-miR-25 hsa-miR-92a 
hsa-miR-940 hsa-miR-26b hsa-miR-96 
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Table 4.1 miRNAs differentialy expressed between lung metastases (Mets) and low metstatic 
cell lines (LMC). SAM analysis; FDR<0.001. 
Several miRNAs, which in Melanoma act as tumour suppressor, show a decreasing 
expression profile from LMC to Mets (Figure 4.2. A). This result could be in 
accordance with the progressive loss of their ability to function as tumour suppressors 
with the progression of metastatic capacity. For instance, downregulation of miR-193b 
expression is associated with cell death resistance, mediated by c-myc, in Melanoma 
cells (J. Chen et al., 2011). Another miRNA involved in cell proliferation that acts as 
tumoral repressor is miR-18b. Overexpression experiments showed that miR-18b 
regulates growth suppression capacity and regulate indirectly p53 expression (Dar et al., 
2013). Melanoma tumor growth and metastasis is also inhibited by miR-9 through the 
regulation of NF-kB1-Snail1 pathway (S. Liu et al., 2012). Another example of 
Melanoma metastasis inhibitor is miR-196a that is able to reduce Melanoma cell 
invasion capability targeting HOX-C8 and related adhesion proteins (Mueller and 
Bosserhoff, 2011).    
 
Figure 4.2 miRNA expression level tendency obtained by microarray data. miRNAs in the 
graph are also identified as Melanoma inhibitor (A) or as pro-oncogenic miRNA (B) in (Kunz, 
2013) review. 
 
If miRNAs acting as tumor suppressors show a decreasing expression associated with 
the increasing metastatic capacity, those acting as oncogenes show an opposite 
expression profile (Figure 4.2. B) 
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Kunz’s laboratory identified the upregulation of miR-195 in high aggressive Melanoma 
cell line compared to less aggressive ones in association with reduced stress-related cell 
cycle arrest (Bhattacharya et al., 2013b). This result is in accordance with microarray 
expression analysis that shows its expression increase from low metastatic cell line to 
lung metastases (in blue in figure 4.2 B) 
In addition, miR-199a-5p, that I find upregulated in metastatic conditions (in red in 
figure 4.2 A), seems to drive Melanoma metastasis promoting angiogenesis (Pencheva 
et al., 2012). Pencheva and colleagues identified miR-199a-5p as a part of miRNA set 
which are able to increase lung metastatic colonization after their overexpression in a 
metastatic mouse model similar to one used in this thesis work.    
Moreover, I identified the increasing of expression level during the metastasis process 
of miR-214 (in green in figure 4.2 A). Results were confirmed through qRT-PCR and 
associated to increase migration, invasion, and extravasation capacity of Melanoma cell 
lines (Penna et al., 2011, 2013).  
In addition to miRNAs already demonstrated to be involved in Melanoma metastatic 
processes, microarray analysis allowed the identification of several miRNAs associated 
to metastasis progression of other tumors. This result is useful to parallelize metastatic 
processes of different tumors for a better comprehension of such complicate event. For 
instance, miR-31 upregulation was found to reduce metastatic capability of breast 
cancer cells inhibiting anoikis resistance and cell invasion (Valastyan et al., 2009, 
2010). I observed its downregulation in metastases in comparison with poor metastatic 
cells (in blue in figure 4.3). This confirms its involvement in tumor metastasis.  
62 
 
 
Figure 4.3 Metastatic miRNAs expression level tendency obtained by microarray data. miRNAs 
in the graph are also identified as or pro-metastatic miRNAd in (Pencheva and Tavazoie, 2013) 
review. 
Also two miRNAs that act as pro-metastatic genes (miR-10b and miR-223) I found 
activated in Melanoma derived metastases (in red and in green respectively in Figure 
4.3). MiR-10b is part of a regulatory network that involve HOXD10 and later RhoC to 
regulate breast cancer metastatic progression (Ma et al., 2007), While miR-223 promote 
invasion and metastasis in two different cancer types (gastric cancer and glioblastoma) 
by targeting two oncosuppressor gene:  EPB41L3 (Li et al., 2011) and PAX3 (Huang et 
al., 2013).  
 
4.1.2 Identification of miRNA-mRNA interaction through anti-
correlation analysis 
Correlation analysis between miRNA and mRNA expression identified 16,029 possible 
miRNA-mRNA interactions (positive and negative correlation) statistically significative 
(q-value > 0.1).  
Negative correlations between miRNA and mRNA expression profiles were ~7,000 
with 70 miRNAs that can regulate around 3,500 different genes. 
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Several miRNA-target interactions I identified through this approach are important in 
Melanoma progression and in metastasis formation and were discussed in different 
scientific pubblications. 
For instance, I correlated miR-96 expression with micropthamia associated transcription 
factor (MITF), the master regulator of melanogenesis (Xu et al., 2007). Goodness of the 
approach is sustained by the identification of several miRNA-mRNA interactions that 
were validated through luciferase assay by other authors or by the fact that miRNA 
targets are strictly related with Melanoma cell proliferation. For example, miR-193b 
directly interacts with cyclin D1 which promotes proliferative processes downregulating 
the tumor suppressor function of retinoblastoma mRNA RB1 (Chen et al., 2010). 
Another example is miR-26a that induces cell death interacting with SMAD family 
member SMAD1 (Reuland et al., 2013). Melanoma progression is also regulated by 
miR-145 and miR-221/222 that interact with actin-bundling protein FSCN1 (Dynoodt et 
al., 2013) and proto-oncogene cKIT (Felicetti et al., 2008) genes, respectively. Both 
interactors were identified by correlation analysis. 
As previously described for single miRNAs gene expression pattern, I identified a 
remarkable number of miRNA-mRNA interactions that were validated through 
luciferase assays and their partecipation in metastasis processes of different tumors is 
well known. An example is miR-200b-ZEB1 and miR-200b-ZEB2 interactions. These 
interactions allow the regulation of epithelial to mesenchymal transition in breast cancer 
cells (Gregory et al., 2008). 
 
4.1.3 Signal Path identification  
Signal path identification was performed using CliPPER algorithm as described in 
Material and Methods section. Whole mRNAs, without selecting only for differentially 
expressed genes according a false discovery or fold change cut off, were used in a 
pathway context. This approach allows the identification of congruent changes along 
the pathway cascade also if changes are too small to be considered changes in 
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expression according fold changes. I identified 137 pathways and relative signal paths 
(see appendix Table A1) significantly involved in metastasis process.  
KEGG database, the one used to perform CliPPER based analysis, divide pathways in 
functional categories: human diseases, organismal systems, metabolism, environmental 
information processing, cellular proccesses, and genetic information processing. 
Pathways I found as responsive to metastasis process prevalently are associated to the 
KEGG category “human diseases” including the category “cancer diseases”. Moreover, 
several pathways describing metabolism processes were identified. This result is in 
accordance with big changes in cell metabolism that occur during invasion (e.g. 
Warburg effect, (see T. Han et al., 2013 for review)). Signal transduction pathways 
involved in the communication between ambient and cell responses and other signals 
that regulate cell growth and death are enriched in the analysis Any pathways associated 
with genetic information processing were involved in the metastasis process. 
 
4.1.4 Data integration: the effect of miRNAs in pathway regulation 
Pathway identified as responsive to metastasis process appeared to be numerous (137) 
and if miRNAs are able to discriminate between different metastatic capacities (Figure 
4.1.) they should regulate these pathways. In order to test this hypothesis I verified if 
miRNA targets, identified through MAGIA2 analysis, identified alterations in same 
pathways identified as important in the metastasis process. This approach allowed the 
identification of 63 pathways and relative signal paths as important in metastasis 
process and regulated by different miRNAs (see appendix for pathway complete list 
TABLE A2). 
Through a literature based search pathways were organized for their consistency with 
the pathology analyzed: Melanoma formation or progression. 12 pathways and relative 
path were identified after this last association (Table 4.2). Interestingly, path with the 
highest score is one involving the Gap junction function. This is in accordance with cell 
ability to pass the endothelial barrier to move through blood vessels (Ito et al., 2000). 
Most invasive cells have the ability to easily extravasate or intravasate in comparison 
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with the ability of normal cells (Ito et al., 2000). Thus, impaired intercellular 
communication via gap junctions may facilitate the release of a potentially neoplastic 
cell from the controlling regime of the surrounding tissue, leading to tumor promotion 
(Czyz, 2008). 
 
Pathway + path Score 
Number of 
pathway 
mRNAs 
Number of 
path mRNAs 
miRNAs 
negative 
correlated to 
path mRNA 
Number of 
miRNA 
targeted 
mRNAs 
Adherens junctions path 1 3.91 70 12 7 3 
Adherens junctions path 1 3.45 70 5 23 3 
Adherens junctions path 1 0.81 70 6 0 0 
Gap junction path-1 121.84 89 34 12 8 
Gap junction path-2 44.77 89 35 22 11 
Gap junction path-3 22.53 89 29 27 12 
Jak-STAT path-1 35.03 99 72 35 24 
mTOR signalling pathway 
path 1 
36.88 61 17 15 6 
mTOR signalling pathway 
path 2 
21.93 61 26 37 15 
mTOR signalling pathway 
path 3 
9.21 61 11 17 6 
p53 signalling pathway path 
1 
4.98 68 7 8 4 
p53 signalling pathway pat 2 2.81 68 12 11 6 
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Pathway + path Score 
Number of 
pathway 
mRNAs 
Number of 
path mRNAs 
miRNAs 
negative 
correlated to 
path mRNA 
Number of 
miRNA 
targeted 
mRNAs 
p53 signalling pathway path 
3 
1.65 68 4 2 2 
p53 signalling pathway path 
4 
1.35 68 4 1 1 
P53 signalling pathway path 
5 
1.07 68 6 14 5 
TGFβ signalling pathway 
path 1 
25.33 83 13 15 6 
TGFβ signalling pathway 
path 2 
9.52 83 18 25 9 
TGFβ signalling pathway 
path 3 
4.48 83 10 5 3 
ErbB signalling pathway 
path 1 
26.69 88 21 31 11 
ErbB signalling pathway 
path 2 
22.10 88 16 21 10 
ErbB signalling pathway 3 8.04 88 15 20 8 
ErbB signalling pathway 
path 4 
0.70 88 2 1 1 
WNT signalling pathway 
path 1 
73.29 144 46 26 26 
WNT signalling pathway 
path 2 
45.36 144 32 23 16 
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Pathway + path Score 
Number of 
pathway 
mRNAs 
Number of 
path mRNAs 
miRNAs 
negative 
correlated to 
path mRNA 
Number of 
miRNA 
targeted 
mRNAs 
WNT signalling pathway 
path 3 
4.28 144 21 13 5 
WNT signaling pathway 4 1.73 144 15 9 2 
Melanoma pathway path 1 13.30 69 25 31 15 
N-glycan biosynthesis path1 2.88 48 22 6 5 
N-glycan biosynthesis path2 2.30 48 3 1 1 
Melanogenesis path 1 6.26 101 17 20 9 
Melanogenesis path 2 5.76 101 14 16 7 
Melanogenesis path 3 3.24 101 26 19 11 
Melanogenesis path 4 0.77 101 2 0 0 
VEGF signaling pathway 
path1 
36.66 67 24 20 10 
VEGF signaling pathway 
path 2 
8.67 67 23 17 8 
VEGF signaling pathway 
path 3 
3.71 67 30 21 12 
Table 4.2. Pathways identified after data integration and filtering according to 
miRNA regulation and their involvement in Melanoma. The first column shows the 
name of the path identified by CliPPER analysis with the correspondent intra-pathway 
score calculated by the algorithm. Higher score indicates more statistically significance 
of the different paths in the pathway. In the following columns are indicated the number 
of mRNAs for each pathway, the numbers of mRNAs for each path identified by 
CliPPER, the number of miRNA that interact with the path mRNAs identified by 
MAGIA2 analysis, and the number of different mRNAs targeted by miRNAs in the path.  
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4.1.5 Relevant pathways 
As evidenced in the previous paragraph the path with the highest score is involved in 
the Gap junction function. This is in accordance with cell ability to pass the endothelial 
barrier to move through blood vessels (Ito et al., 2000). Indeed, metastatic model I used 
in this thesis work, mimics the cancer cell colonization of distant organs and 
extravasation is one of the most important step during this phase. Several processes are 
involved in cancer cells extravasation as the increase of membrane permeability, the gap 
junctions disassembly, the actin organization remodelling, the microenvironment 
modification to allow invasion, secretion of factors for cell-cell communication, and the 
formation of protruding structures like invadopodia and lamellipodia (Hanahan and 
Weinberg, 2011). 
Here, I’m going to discuss the gene expression regulation that occur in most important 
pathways involved in the extravasation processes as discussed in (Reymond et al., 2013) 
and find associated to metastasis through CliPPER analysis for the identification of 
significant path regulated by miRNAs. Considered path are part of WNT, adherens 
junction, and VEGF signaling pathways. 
 
4.1.5.1 WNT Signaling Pathway 
WNT signal paths are those most enriched after Gap Junction paths. This indicates that 
it is particularly important in the processes under study and that it is strongly regulated 
by different miRNAs. This pathway is a critical regulator of stem cells (Reya and 
Clevers, 2005) and in cancers, in particular in adenocarcinoma cells metastasis 
processes (Nguyen et al., 2009). It is probable that specific regulation in cell renewal is 
lost during cancer development to allow malignant proliferation.  
WNT Signalling Pathway is divided in three signal pathways: the principal (the 
canonical pathway) and two non-canonical pathways (Planar Cell Polarity pathway and 
WNT/Ca2+ pathway). Gene transcription is regulated through the canonical Wnt 
pathway while the non-canonical planar cell polarity pathway regulates the 
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cytoskeleton, responsible for the shape of the cells, and the non-canonical Wnt/calcium 
pathway regulates calcium inside the cell. 
My analysis identified four different perturbed signal paths involved in metastasis for 
the entire WNT signalling pathway (Table 4.2). The two top ranked according to the 
CliPPER score were discussed. 
The ability to discriminate between different paths in the same pathway is fundamental 
to understand the contribution of different signal cascades grouped in one pathway. In 
this case it is important to discriminate the contribution of the three signal pathways that 
constitute WNT pathway.  
Most significant path (path1 in table 4.2 and Figure 4.4), is 46 genes long and it is 
regulated by 26 miRNAs which insist on 26 genes. The list complete is in appendix in 
TABLE A3 A. 
 
Figure 4.4 A) Schematic view of WNT path1. miRNAs and mRNAs upregulated in lung 
metastases are coloured in red while miRNAs and mRNAs upregulated in LMCs are coloured in 
green B) β-catenin is regulated through TBL1 and GSK-3β that are regulated by different 
miRNAs, including miR-199a-5p, miR-199b-5p and miR-214. MiR-199a-5p, miR-199b-5p and 
miR-214 were demonstrated involved in Melanoma (Pencheva et al., 2012; Penna et al., 2011, 
2013) and their increasing expression from low metastatic to high metastatic condition evidence 
their pro-metastatic behaviour. C) Members of miR-148/152 cluster, identified as important 
cluster in our  Melanoma model, targets PSN1 and show an increasing expression from low 
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metastatic to high metastatic conditions. This supports their pro-metastatic behaviour. When the 
expression is not indicated miRNA is completely absent in the sample. Bars indicate SEM 
calculated for 4 independent experiments. LMC= low metastatic cell lines; HMC= High 
metastatic cell lines; Mets= lung metastases. 
We can see the behaviour of the canonical pathway during metastasis. Aberrant 
signalling of WNT canonical pathway promotes oncogenesis by increasing the nuclear 
accumulation of β-catenin and the activation of downstream target genes (Li and Wang, 
2008)  
Without Wnt proteins signaling, the β-catenin would not accumulate in the cytoplasm 
since a degradation complex would normally degrade it. Glycogen synthase kinase 3 
(GSK-3beta) and casein kinase 1α (CK1α) allow phosphorylation of β-catenin (Minde 
et al., 2011) that is then targeted for ubiquitination and subsequent degradation 
(MacDonald et al., 2009). 
In addition, under genotoxic conditions the activation of p53 occurs, starting an 
additional pathway for β-catenin degradation mediated by the SCF(TBL1) E3 ligase 
complex (Dimitrova et al., 2010) TBL1 and its related gene TBL1R function as E3 
ubiquitin ligase adaptors for the recruitment of specific ubiquitin/proteasome machinery 
in order to degrade β-catenin (Li and Wang, 2008). 
Analysing altered pathways in Melanoma and transcripts regulated by important 
miRNAs involved in metastasis process I observed that the β-catenin degradation 
complex (GSK-3β, TBL1, TBL1R, and β-TrCP) is upregulated in low metastatic cell 
line (Figure 4.4 A), where they act to decrease cytoplasmic β-catenin level, while during 
metastasis several upregulated miRNAs (Figure 4.4. B) targeting GSK-3β, TBL1, 
TBL1R, and β-TrCP prevent their activity. MiRNA activity has the effect to allow the 
hoard of β-catenin that translocate in the nucleus activating downstream oncogenic 
signals also in Melanoma (Goodall et al., 2004).  
Several miRNAs are common regulators of transcripts that codify for proteins of the β-
catenin degradation complex. For instance three miRNAs regulate the expression level 
of both GSK-3β and TBL1R: miR-199b-5p, miR-199a-5p, and miR-214. While the first 
one was found deregulated in more aggressive osteosarcoma cell line (Lauvrak et al., 
2013), the other two miRNAs was found strictly related in Melanoma metastasis 
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progression (Pencheva et al., 2012; Penna et al., 2011, 2013). In addition, another 
metastatic-miRNA (miR-200b) could regulate at the same time TBL1R and β-TrCP. 
This could be interesting as possible therapeutic usage of miRNAs because targeting a 
single miRNA it is possible to block different targets in WNT canonical pathways. On 
the other hand, due to their ability to interact with different transcripts, it is important to 
avoid undesired effects.  
It is also interesting that in lung metastases I detected the downregulation of Presenilin 
1 (PSEN1), a master gene in Alzheimer Disease initiation and also an important 
negative regulator of β-catenin (Serban et al., 2005). According to gene expression, it 
seems that two members of miR-148/152 cluster (miR-148a and miR 152) 
downregulates PSEN1 in order to stabilize the β-catenin accumulation in the cell and 
the subsequent oncogenic transcriptional signals.  
In order to understand how WNT signal cascade initiate during metastasis, I analysed 
the expression profiles of WNT receptors: the Frizzled (FZD) proteins. I detected the 
uprgulation of Fzd receptors (FZD1, FZD4, and FZD7) in lung metastases (SAM 
analysis; FDR < 0.001%).  
Ueno and colleagues (Ueno et al., 2013) discussed the involvement of miRNAs in FZD 
transcripts regulation and subsequent WNT pathway suppression/activation. They 
conclude that miRNAs are promising therapeutic targets in relation on the success of the 
delivery system and on their stability in the injected tissue. According to the analyses I 
performed, FZD4 and FZD7 seems to be regulated by two members of miR-106a/363 
cluster (miR-106a and miR-20b). Analysing miRNA and mRNA expression levels 
(Figure 4.5. B) we can see that miR-106a and miR-20b, that are down-regulated in lung 
metastases, have got a negative correlation respect to FZD4 and FZD7. This sustains the 
regulative hypothesis and suggests the activation of WNT pathway occurred during 
metastasis progression due to miR-106a/363 cluster downregulation. 
All Fzd proteins are able to activate canonical pathway but only FZD7 is able to activate 
the non-canonical pathway called planar cell polarity pathway (PCP) (Ueno et al., 
2009). This pathway is known as regulator in multiple embryonic processes (Wang and 
Steinbeisser, 2009) but due to the many similarities shared between cancer development 
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and embryonic development, cell polarity associated pathways seem to be involved also 
in cell adhesion and cell migration processes during tumor invasion and metastasis 
(Christofori, 2006). 
CliPPER analysis decomposed WNT pathways in three significant paths (Table 4.2). 
The second most significant (WNT path2) contain PCP pathway (Figure 4.5). We can 
see that the entire molecular cascade of this non-canonical pathway is deregulated; 
starting from receptors to the final kinases effectors (ROCK and JNK). Pathway 
deregulation that start from its first receptor was considered stronger than a deregulation 
that start in a different point of the pathway (Draghici et al., 2007). (The list of complete 
interactions is in appendix in TABLE A3 B). 
In addition, we can see the tightly interconnection between the canonical pathway and 
the PCP pathway, indeed several genes are recognized by CliPPER analysis as effectors 
of both pathways. 
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Figure 4.5 A) Schematic view of WNT path2. miRNAs and mRNAs upregulated in lung 
metastases are in red while miRNAs and mRNAs upregulated in LMCs are in green. * indicates 
miRNAs found statistically differentially expressed (SAM analysis; FDR<0.001). B) Trend of 
expression of three members of miR-106a/363 cluster (miR-106a, miR20b, and miR18b) in the 
different samples. The negative trend indicates their anti-metastatic behaviour. They can 
regulate the expression of FZD7 and FZD4. C) Trend of expression of two members of miR-
17/92 cluster (miR-18a and miR19a). The negative trend indicates their anti-metastatic 
behaviour. They can regulate the expression of dishevelled-associated activator of 
morphogenesis DAAM1 and DAAM2 D) Trend of expression of members of miR-148/152 
cluster. The positive trend of both cluster members indicates their pro-metastatic behaviour. 
MiR-148/152 cluster can regulate Melanoma metastasis mediated by ROCK1. MiRNA 
expression is shown as means ± SEM of four independent experiments. LMC= low metastatic 
cell lines; HMC= High metastatic cell lines; Mets= lung metastases. 
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I found that all the genes upregulated in lung metastases (Figure 4.5) and regulated by 
miRNAs were found also in other works as pro-metastatic regulators. For instance the 
dishevelled-associated activator of morphogenesis DAAM1 is upregulated in a signal 
cascade, that includes Dvl2 and RhoA, involved in cells migration of breast cancer (Zhu 
et al., 2012). The Rho-associated coiled-coil containing protein kinase ROCK1 is a 
central regulator in EMT transition, cell migration, and cell invasion in several cancer 
types where it usually is highly expressed (Cimino et al., 2013; Jipeng Li et al., 2013; 
Yong Wang et al., 2013). I identified ROCK1 downregulated in metastases. This result 
is in accordance with the findings of Wilhelm and colleagues (Wilhelm et al., 2013) that 
discovered a correlation between the number of Melanoma cells migrating through the 
brain endothelial monolayer and the inhibition of ROCK. Also the function in cancers 
of c-Jun NH2-terminal kinases (JNK1 and JNK2) is not fully understood because they 
can act as either tumor promoter or as tumor suppressor kinases in different types of 
cancer (reviewed in (Bubici and Papa, 2013)). 
Several miRNA clusters or miRNA families are involved in the regulation of this path. 
Moreover, they act on a reduced number of transcripts. For instance the signal path is 
activated by the receptor FZD7. FZD7 overexpression during metastasis process can be 
a consequence of a downregulation of all its miRNA regulators: two members of miR-
106a-363 and miR-17/92 clusters (miR-106a, miR-20b and miR-18a and miR-19a 
respectively). Another member of miR-17/92 cluster (miR-18b) seems to regulate 
DAAM1 and DAAM2. In addition ROCK1 seems to be regulated by miR-148/152 
family while miR130b/301b regulate ROCK2.  
 
4.1.5.2 Adherens junction 
If Gap junction resulted pathway most significant, another type of cell-cell junction is 
adherens junction. Epithelial cells are held together by strong anchoring (zonula 
adherens) junctions and for this reason their destabilization allow the movement of the 
cells through endothelium. This is an important mechanism in the metastasis process. It 
is interesting that the analysis of pathways involved in metastasis and regulated through 
miRNAs identified adherens junction as relevant pathway. Longest relevant path was 
75 
 
composed by 12 genes and regulated by 7 miRNAs which insist on only 3 genes. The 
list complete of interactions  is in appendix in TABLE A3 C. 
During the cell travel through the vascular system, Melanoma cells need to physical 
interact with neighboring cells in order to regulate cell-cell contacts, morphogenesis and 
tissues architecture remodelling (Reymond et al., 2013). In addition, cells movement 
and proliferation can be limited by adherens junction (Meng and Takeichi, 2009). 
Physical cell-cell links is mediated by the extracellular domains of transmembrane 
proteins which are essentially cadherin family proteins and nectins (Rikitake et al., 
2012). Downstream proteins like actin and myosin are positioned to support tightly the 
cell architecture and to produce tissue morphogenesis and cell migration through their 
contraction activity (Baum and Georgiou, 2011; Kardash et al., 2010). 
β-catenin, previously described as central switch for the activation of WNT pathway, 
also is the main partner of one of the cadherin proteins (E-cadherin) in adherens 
junctions. This evidence the strong interplay existing between adherens junctions and 
WNT Signalling pathway. (Heuberger and Birchmeier, 2010) 
CliPPER analysis allowed the identification of a particular path in the adherens junction 
components that could be very important in the migration and cell communication 
mediated by adherens junctions in Melanoma cell metastasis (Figure 4.6). 
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Figure 4.6 A) Schematic view of Adherens junction path1. miRNAs and mRNAs upregulated in 
lung metastases are in red while miRNAs and mRNAs upregulated in LMCs are in green. All the 
mRNAs involved in actin polymerization are upregulated in Mets respect to LMCs. * indicate 
miRNAs differentialy expressed (SAM analysis; FDR<0.001). B) MiRNA expression trend. Two 
members of miR-106a/363 cluster (miR-106a and miR20b) present decreasing expression from 
low to high metastatic condition. This is related to their anti-metastatic behaviour since their 
ability to regulate WAVE3. C) Two members of miR-130b/301b cluster (miR-130b and miR-
301b) have similar expression of miR-106/363 members cluster and have the ability to regulate 
NWASP involved in the invadopodium formation. Expression is expressed as means ± SEM 
derived from four independent experiments. LMC= low metastatic cell lines; HMC= High 
metastatic cell lines; Mets= lung metastases. 
 
We can appreciate that mRNAs regulated by miRNAs codify for proteins associated to 
actin filaments (Figure 4.6 A). A lot of these components are involved in actin 
polymerization in order allow the formation of new adherens junctions and to produce 
invadopodia and lamellipodia that are cell protrusions that enable motility and invasion 
of the cancer cell (Sibony-Benyamini and Gil-Henn, 2012). MiRNA expression profiles 
analysis evidenced that these effectors are upregulated in lung metastases where cells 
have to increase the protrusions production to allow a higher metastatic capacity. These 
genes could be good target to modulate metastatic capacity, but it is hard to work on 
genes approaching the problem through genetic engineering due to viruses used as 
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vectors and their health related problems. It is easy a miRNA based approach since they 
are smaller than a gene, more stable and they can be injected in the tissue or in 
circulatory torrent to function (Shibata et al., 2013). 
I observed that miRNAs act on this path only on three transcript: v-src avian sarcoma 
viral oncogene homolog (SRC), the WAS protein family member 3 (WAVE3), and the 
Wiskott-Aldrich syndrome-like gene (N-WASP). All of these transcripts codify for 
protein related to metastases formation and, in particular, in the invadopodia and 
lamellipodia formation (Figure 4.7). 
 
Figure 4.7 Typical protrusive structures in invasive cancer cells. Cancer cell invasive 
phenotypes involve the formation of typical protrusive structures, such as invadopodia or 
pseudopodia. Invadopodia are actin-rich cellular protrusions that are tailored for the 
degradation of the extracellular matrix. The formation of invadopodia relies on N-WASP–
Arp2/3-driven actin assembly and requires cortactin for invadopodia initiation and 
stabilization. Pseudopodia of cancer cells are lamellipodia-like structures and depend on the 
polymerization and assembly of actin by the WAVE–Arp2/3 nucleation machinery.Adapted from 
(Nürnberg et al., 2011) 
 
For instance, it is well known that various physiologic stimuli have been shown to 
upregulate SRC kinase activity becoming a critical step in invadopodia formation in 
cancerous cells (Yeatman, 2004). In addition SRC signalling is activated in Melanoma 
metastasis progression and in Melanoma cells invadopodia formation (Hanna et al., 
2013; Ruifei Wang et al., 2013). According to results I obtained, miR-9 seems to act as 
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oncosuppressor in ovarian serous carcinoma and in uveal Melanoma blocking cell 
migration and invasion (N. Liu et al., 2012; S. Liu et al., 2012; H. Tang et al., 2013). 
Furthermore, WAVE3, that codify for a protein that forms a multi-protein complex able 
to link receptor kinases and actin, was identified as a master regulator involved in 
epithelial to mesenchimal transition (EMT), cancer invasion and metastasis progression 
in several cancer types (reviewed in Sossey-Alaoui, 2013).  
I observed a possible regulation of WAVE3 through miR-106a and miR-20b (Figure 4.6 
B). Sossey-Alaoui and colleagues identified different miRNAs (mir-200 family and 
miR-31) that influence WAVE3 expression producing an increasing of breast cancer 
cells invasion capability (Sossey-Alaoui et al., 2009, 2011). In addition Teng and 
colleagues, in a recent scientific work, identified a double feedback loop among 
ZEB1/2, miR-200 family and WAVE3 which is associated with epithelial-to-
mesenchyme transition (Teng et al., 2013). This loop was associated to the acquisition 
of invasion potential of breast cancer cells. My in silico results add knowledge in 
WAVE3 regulation and allow a better elucidation of this complicate network and its 
effects on metastasis in Melanoma.  
The last transcript I evidenced regulated by miRNAs in this path is Wiskott-Aldrich 
syndrome-like (WASL or N-WASP) mRNA. N-WASP is a member of WASP family 
proteins and it is involved in reorganization of the actin cytoskeleton as well as it is an 
essential component of invadopodia (Gligorijevic et al., 2012). I observed that N-WASP 
is up-regulated in lung metastases, accordingly with its pro-metastatic behaviour, and 
that it could be regulated by miR-98, miR-301b, miR130b, and miR-32. 
Recently, it was discussed miR-98 as an inhibitor of cell migration and invasion in 
human esophageal squamous carcinoma (Huang et al., 2012) while miR-32, targeting 
PTEN, is able to influence cell migration, and invasion in colorectal carcinoma (W. Wu 
et al., 2013). 
MiR-301b and miR-130b belong to miR-130b/301b cluster and together, they regulate 
N-WASP. MiR-301b and miR-130b are both located on chromosome 17 and have the 
same seed region therefore, they could cooperate to deregulate the same targets. They 
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were not been studied together like a cluster. MiR-130b individually acts as 
oncosuppressor inhibiting cell proliferation and invasion in Pancreatic Cancer (Zhao et 
al., 2013) while miR-301b is involved in malignant progression from Barrett's 
esophagus to esophageal adenocarcinoma (X. Wu et al., 2013). I evidenced a decreasing 
expression from low to high metastatic cells (Figure 4.6 C) and the concurrent 
increasing of N-WASP expression. This tendency is in accordance with the capacity of 
cells to invade tissues and therefore with the capacity to form invadopodia. 
 
4.1.5.3 VEGF Signaling Pathway 
One of the most important steps in metastasis is the tissue vascularisation. In order to 
supply the new tumor mass with nutrients and oxygen it is fundamental to produce new 
vessels activating the neovascularization program. The development of new blood 
vessels is mainly regulated by Vascular Endhotelial Growth Factor (VEGF) and the 
pathway downstream. 
CliPPER analysis allowed the identification of VEGF Signaling Pathway as significant 
in the metastasis process. 24 genes compose the top ranked signal path in the VEGF 
Signaling Pathway and it is regulated by 20 miRNAs. MiRNAs are associated to only 
10 genes (Figure 4.8 A). The list complete of interactions is in appendix in TABLE A3 
D. 
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Figure 4.8 A) Schematic view of VEGF path1. miRNAs and mRNAs upregulated in lung 
metastases are in red while miRNAs and mRNAs upregulated in LMCs are in green. Both 
VEGFA and its receptor VEGFR2 are upregulated in Mets respect to LMC. This expression is 
indicative of the activation of tissue vascularization process. * indicate miRNAs differentialy 
expressed (SAM analysis; FDR<0.001). B) Trend of expression of miR-221/222 cluster (miR-
221 and miR-222). The negative trend from low to high metastatic conditions indicates their 
pro-vascularization behaviour. C) Trend of expression of miR-106a/363 cluster (miR-106a and 
miR20b). The negative trend from low to high metastatic conditions indicates their pro-
vascularization behaviour. Through the upregulation of VEGFA allowed by downregulation of 
miR-106a and miR20b the pro-metastatic VEGFA-VEGFR2 feed-forward signaling loop can be 
activated. Expression is expressed as mean ± SEM from four independent experiments. LMC= 
low metastatic cell lines; HMC= High metastatic cell lines; Mets= lung metastases. 
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The upregulation of the pro-angiogenic factor VEGF and of its receptor VEGFR2 in 
lung metastases generates a very remarkable destabilization in the signal cascade 
downstream (Figure 4.8 A). 
VEGF and VEGFR2 seem to be regulated by two different miRNA clusters. MiR-
221/222 cluster seems to regulate VEGFR2 while miR-106a/363 cluster seems to 
regulate VEGF (Figure 4.8 A). 
In hypoxic environment, Chatterjee and collegues identified a VEGF-VEGFR2 feed-
forward loop that generate a signal cascade mediated by mTOR (Chatterjee et al., 
2013). This signal cascade allows the amplification of VEGF secretion by tumor cells in 
order to develop angiogenesis (Chatterjee et al., 2013). In addition, Darrington and 
colleagues identified another VEGF-VEGFR2 autocrine loop in prostate cancer that is 
mediated by TGF-beta (Darrington et al., 2012). Darrington and colleagues evidenced 
that TGF-beta mediated loop improves the migration of cancer cells. The miRNA 
clusters I identified could be the triggering elements or modulators for these loops. 
Indeed, miR-20b-VEGF and miR-106a-VEGF interactions were confirmed in other 
scientific works (Lei et al., 2009; Ling et al., 2013), while miR-221-VEGFR2 
interaction was not confirmed in literature even though miR-221 is known as a regulator 
in lung airways and vascular development showing an inverse correlation in expression 
level with VEGFR2 mRNA (Mujahid et al., 2013). 
In Figure 4.8B e 4.8C we can appreciate the decreasing trend of miR-221/222 and miR-
106a/363 expression associated to the increasing of cell metastatic capacity. These 
miRNA clusters seems to act as switch in order to trigger the pro-metastatic VEGF-
VEGFR2 autocrine loop.  
The activated signals seem to induce phospholipases (PLA2 and PLCγ1) and endothelial 
nitric oxide synthase (eNOS) in order to increase membrane permeability (Linkous et 
al., 2010; Mocellin et al., 2004; Szymanski et al., 2012). On the other hand the signals 
involved in migrations (Paxillin and the protein phosphatase 3, CALN) are not 
perturbed by VEGF-VEGFR pathway activation in metastases samples but seem to be 
upregulated in LMCs (in green in figure) where they can enhance the migration 
capability of these cells. 
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 Validation of miRNA-target interactions: AGO 4.2
HiTS-CliP approach  
 
Bioinformatic analyses performed on microarray data give several information about 
miRNA-mRNA interaction networks. Specifically, I evidencing that a lot of pathways 
involved in metastasis are potentially regulated by miRNAs and therefore those 
miRNAs are involved in malignant Melanoma metastatic processes. 
On the other hand, there is a lot of scientific debates about the efficiency of miRNA 
target prediction algorithms. Algorithms as Targetscan (Hafner et al., 2010a), miRanda 
(John et al., 2004; Betel et al., 2008), PicTar (Krek et al., 2005), evidenced a false 
positive rate around 20% (Rajewsky, 2006; Doran and Strauss, 2007; Zhang and 
Verbeek, 2010). 
In this context, I decided to use a genome wide biochemical approach to validate 
miRNA-mRNA interactions.  
Thus, I cultured A375P low-metastatic Melanoma cell line and its high-metastatic 
derivative cell line (MA2) and I performed a modified Ago-HITS-CLIP experiment (see 
Material and Methods). 
 
4.2.1 AGO-Hits-CLIP set up 
Ago-HITS-CLIP is a biochemical approach that allows the identification, through 
AGO2 immunoprecipitation, of RNA bound to AGO2 proteins and reduced in length by 
RNAse digestion. Digested RNA molecules obtained are identified through next-
generation RNA sequencing (Chi et al., 2009).  
The selection of the best anti-AGO2 antibody for the immuno-precipitation reaction is 
an important step in the Ago HITS-CLIP procedure. I tested different antibodies in 
order to understand which of these give lesser aspecific products and better throughput. 
I tested three different antibodies used in different scientific works to immunoprecipiate 
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AGO proteins (Rüdel et al., 2008; Farazi et al., 2014): Anti-Ago2 Antibody clone 9E8.2 
(Millipore), eIF2C (H-300): sc-32877 (Santa Cruz Biotechnology), and Anti-AGO2 
Clone 11A9 (Sigma-Aldrich). Testing was performed through Western Blot analysis 
(Figure 4.9).  
 
Figure 4.9 A) Western blot using different Ago antibodies for the IP. Anti-Ago2 Antibody clone 
9E8.2-Millipore (well 2) allowed best results. Sigma-Aldrich one (well 1) presented different 
aspecific products, while the Santa Cruz one (well 3) presented low throughput. L = ladder B) 
Electrophoresis gel of cDNA samples. L = ladder. C. and D. Capillary electrophoresis of 
amplified cDNA (sample analyzed by gel electrophoresis) and of a size selected sample.   
 
After the identification of better antibody to perform Ago immunoprecipitation I set 
conditions to obtain a cDNA library suitable for sequencing experiments. I checked the 
length of DNA fragments obtained after two rounds of PCR of RNA fragments co-
immunoprecipitated with AGO2 protein and labeled through the SMART approach 
described in Matherial and Method. In figure 4.9 B we can appreciate that for both 
samples (A375P and MA2) I amplified cDNA compatible in dimension with mRNA 
fragments and miRNAs. We can also see a brighter band above 100 bp that correspond 
to the length of miRNAs and small pieces of transcripts (digested by RNAse) plus the 
sequencing adaptors. 
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An equal amount of DNA from both samples were pooled together and read through 
High Sensitivity DNA chip in an Agilent 2100 Bioanalyzer (Agilent Technologies) 
(Figure 4.9 C). Using this technique we can appreciate better results obtained by PCR 
amplification than agarose gel results (Figure 4.9 B). I evidenced that PCR 
amplification of cDNA library produced material of high variable dimensions (from 100 
bp to 800-1000 bp) with a peak around 150 bp that correspond to the length of miRNAs 
with adaptors. 
Ion Torrent PGM sequencer is able to read reads long up to 200-300 bp. Since this 
constrain I decided to select only the fragment population up to 300 bp (Figure 4.9 D) 
through E-Gel purification (Life Technologies). 
The library obtained was used to perform 3 different sequencing runs with the Ion 
Torrent PGM sequencer. 
We obtained 3,064,855 reads for A375P sample and 1,866,027 reads for MA2 sample. 
After barcode sequences removing, reads were filtered for length (≥ 10) obtaining 
525,981 reads for MA2 cell line and 714,195 reads for A375 cell line. Reads obtained 
were aligned against pre-miRNA sequences recovered from miRBase database V.19 
and reads that did not align with pre-miRNAs, were aligned against Ensembl transcript 
database V.73 identifying 2,492 mRNAs and 156 lncRNAs for A375P cell line 1,124 
mRNAs and 78 lncRNAs for MA2 cell line, each transcript is supported by at least 4 
reads. 
4.2.2 miRNA reads analysis 
I obtained 887 human mature miRNA sequences aligned by CLIP reads in A375P 
sample and 754 human mature miRNA sequences in MA2 sample. In order to reduce 
the background noise and to simplify the interaction networking, I decided to consider 
for further analyses only miRNAs that are recognized by at least 5 different reads. 205 
mature miRNAs in A375P sample and 282 mature miRNAs in MA2 sample are covered 
at least by five reads. I checked how many miRNAs identified in microrarray 
experiments, performed on the same samples and described before, were found also in 
the CLIP libraries. 80 miRNAs were identified by both techniques and represent good 
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target to better understand metastasis (Figure 4.10). I used only these miRNAs in the 
following miRNA:mRNA interaction analysis..  
 
Figure 4.10  Comparison between miRNA identified through AGO immunoprecipitation and 
subsequent RNA sequencing (miRNA A375P and miRNA MA2) and microarray experiments 
(miRNA µarray). 
 
4.2.3 MiRNA clusters 
MiRNAs identified both in microarray and CLIP experiments show the presence of 
several miRNA clusters or miRNA families. I discussed before their importance in the 
pathway modulation. Analyzing an enormous dataset (4,419 human samples of 50 
normal and 51 cancer tissues), Volinia and colleagues identified several miRNA 
clusters common to different cancer types that collaborate each other in cancer 
progression and regulation (Volinia et al., 2010). MiRNAs I found in common between 
microarray and CLIP data present an oncogenic potential. For instance, I identified 4 
out of 5 of mir-17~92 cluster members (miR-106a, miR-19b, and miR-92a) and 3 out of 
6 members of mir-106a~363 cluster (miR-106a, miR-19a, miR-19b, and miR-92a), that 
are well known  oncogenic miRNA clusters (Olive et al., 2010; Landais et al., 2007). 
Furthermore, we can also note the presence of 2 out of 3 miR-23b cluster members 
(miR-23b and miR-24) that are known as pro-oncogenic factors in breast cancer cells 
(Jin et al., 2013) and 4 out of 5 of mir-30 family members (miR-30a, miR-30c, miR-
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30d, miR-30e) that are able to regulate growth of breast cancer cells (Ouzounova et al., 
2013). 
Searching for specificities for the two cell lines I observed that miR-26 family (miR-
26a, miR-26b), that act as tumor suppressor (Chang et al., 2008), is only present in the 
HITS-CLIP library derived from less metastatic cell line (A375P). On the other side, in 
the library derived from the more metastatic cell line MA2 I evidenced the presence of 
oncogenic clusters. For instance, 3 out of 4 members of mir-181 family, found 
overexpressed in breast, pancreas, and prostate cancer (Spizzo et al., 2009) were present 
only in MA2 cells. This miRNA family is able to inhibit Wnt/beta-catenin signaling in 
Hepatic Cancer Cells (HCC) (Ji et al., 2009). I also identified mir-27 family (miR-27a, 
miR-27b) as specific form MA2 derived library. Targeting semaphorin 6A (SEMA6A), 
miR-27 family seems involved in repulsion regulation of neighboring endothelial cells 
and consequent angiogenic processes (Urbich et al., 2012). Finally, the presence of both 
miR-196 family members (miR-196a, miR-196b) in high metastatic cell line library, is 
controversial because, even if it is well known the oncogenic potential of this miRNA 
family in several cancerous diseases, for example in breast cancer, leukemia, colorectal 
cancer, pancreatic cancer and oesophageal adenocarcinoma (C. Chen et al., 2011; 
Mueller and Bosserhoff, 2011), some data suggest its tumour suppressive role. For 
example, in Melanoma cells (Braig et al., 2010) and in breast cancer cells (Li et al., 
2010),  the enforcement of miR-196a or miR-196b expression reduced in vitro invasion 
and in vivo spontaneous metastasis of cells.  
 
4.2.4 Cell line specific miRNAs 
It is important to define miRNAs expressed in a specific cell line or prevalently 
expressed in a cell line to understand their effect on metastasis process. Through 
microarray experiments I evidenced that miR-26b is significantly over-expressed in 
A375P cell line. This result is also confirmed by HITS-CLIP experiments. Reads that 
align against miR-26b are found only in A375P library. This result is in accord with the 
tumor suppressor potential of miR-26b in several cancerous diseases. Indeed, miR-26b 
may act as a tumor suppressor in breast cancer (Jia Li et al., 2013; Verghese et al., 
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2013), glioma (Wu et al., 2011) and colorectal cancer cells (Ma et al., 2011). In 
Melanoma, a recent study on miRNome found the reduction of miR-26b expression 
level in primary cutaneous Melanoma respect to common nevus (Kozubek et al., 2013). 
The action mechanism described in these scientific works showed the involvement of 
miR-26b in several biological processes. Indeed, this miRNA lead to the significant 
suppression of cell growth and to the induction of apoptosis targeting the prostaglandin-
endoperoxide synthase 2 (PTGS2) (Jia Li et al., 2013). However, it is also able to 
enhance migration and invasion capability of breast cancer cells targeting proteins 
involved in glycolysis/TCA cycle and cytoskeletal regulation (Verghese et al., 2013). 
Furthermore, miR-26b seems to be involved in colorectal cancer cells invasiveness and 
metastasis development targeting four genes (TAF12, PTP4A1, CHFR and ALS2CR2) 
(Ma et al., 2011). It is interesting that in the analysis I identified four miR-26b targets 
(PTGS2, COL12A1, TNKS1BP1, and CHFR) strength the tumor suppressor ability of 
miR-26b. 
Another example of correlation between microarrays and sequencing data is miR-27a. 
In microarray data, this miRNA is significantly up-regulated in MA2 cell line. 
Sequencing data confirmed miR-27a upregulation in MA2 cells (8 fold). Oncogenic 
potential of miR-27a is well documented in several scientific works. Indeed, miR-27a is 
significantly up-regulated in solid tumor like breast (Guttilla and White, 2009; W. Tang 
et al., 2013), cervical cancer (Wang et al., 2008), gastric carcinoma (Liu et al., 2009). It 
acts as promoter of cell cycle progression and tumor growth. It was observed that 
inhibition of miR-27a increased the percentage of cells in G2-M phase through the 
induction of myelin transcription factor 1 (Myt-1) which, phosphorylating cyclin-
dependent kinase 1 (CDK1), leads to the inhibition of CDK1/cyclin B dependent 
initiation of mitosis (Mertens-Talcott et al., 2007). In HIST-CLIP analysis I identified 
the interaction between miR-27a and Runt Domain Transcription Factor1 (RUNX1) 
also discovered by Ben-Ami and colleagues (Ben-Ami et al., 2009). 
The comparison of microarray and sequencing data allowed the identification of an 
important miRNA in Melanoma: miR-214 (Penna et al., 2011, 2013). MiR-214 is 
recognized by 26 reads in MA2 sample and by only 2 reads in A375P sample and, at the 
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same time, microarray data showed its specific expression in MA2 cell line. Microarray 
results was confirmed by qRT-PCR (Figure 4.11 A) where we can note the 40 times up-
regulation of miR-214 in MA2 cells respect to A375P cells. MiR-214 presents an 
increasing expression from low to high metastatic cells (Figure 4.11 B) that can be 
associated to its oncogenic role. MiR-214 is involved in several cancerous diseases, 
acting both as onco-suppressor and pro-oncogenic entity. Different scientific reports 
identified miR-214 as tumor suppressor, for example in cervical cancer (Qiang et al., 
2011; Peng et al., 2012), breast cancer (Derfoul et al., 2011), and hepatocellular 
carcinoma (Xia et al., 2012; Jian Wang et al., 2013). 
 
Figure 4.11 A) qRT-PCR of different miRNAs. MiR-214 is the one most upregulated in MA2 
cells. B) Expression of miR-214 in different metastatic conditions. *P<0.05; **P<0.01; 
***P<0.001. Adapted from (Penna et al., 2011). 
 
On the other hand, other scientific reports identified miR-214 as oncogenic promoter, 
for example in ovarian cancer (C.-X. Xu et al., 2012), gastric cancer (Yang et al., 2013), 
nasopharyngeal carcinoma (Deng et al., 2013), and pediatric osteosarcoma (Wang et al., 
2014). My results suggest a pro-oncogenic/metastatic role for miR-214 in accord with 
Penna’s work that analyzed Melanoma cancer (Penna et al., 2011, 2013).  
 
4.2.5 Transcripts identified by HITS-CLIP  
Reads not aligned against miRNAs, were aligned against Ensembl transcript database 
V.73. Transcripts identified at least 4 reads were considered. 2,648 transcripts were 
identified in A375P cell line and 1,202 in MA2 cell line. Interestingly, 46 pathways 
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identified in CliPPER analysis as responsible for metastasis (see paragraph 4.1.3) 
resulted enriched also by the analysis of transcripts identified by HITS-CLIP (Figure 
4.12). 
Interestingly, all pathways identified as involved in Melanoma through a literature 
based filtering and regulated by miRNA (Table 4.2) were identified through HITS-CLIP 
method. This result sustains the importance of miRNAs in the regulation of Melanoma 
metastasis.  
 
Figure 4.12  Over-imposition between results obtained by CliPPER analysis and HITS-CLIP 
results. 46 pathways identified as responsive for metastasis were identified both by microarray 
CLIP analyses.   
 
4.2.6 Interaction between miRNA and transcripts 
Data generated by sequencing of immunoprecipitated RNA (miRNA and transcripts) 
were combined to identify the pairs miRNA:transcript that physically interact through 
AGO proteins.  
As previously discussed I identified interaction pairs validated in other scientific works 
and new ones. For example miR-26b interactions, identified in Melanoma cell lines, 
with prostaglandin-endoperoxide synthase 2 (PTGS2), collagen, type XII (COL12A1), 
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tankyrase 1 binding protein (TNKS1BP1), and the checkpoint with forkhead and ring 
finger domains (CHFR) (Ma et al., 2011; Verghese et al., 2013; Jia Li et al., 2013) were 
confirmed.  
My analyses evidenced a potential role of oncosuppressor for miR-26b. It is able to 
interact with genes involved in cell growth as CHFR that has been implicated in mitosis 
checkpoint (Sanbhnani and Yeong, 2012) and to induce apoptosis targeting PTGS2 
gene (Huang et al., 2014). Moreover, it interacts with COL12A1 and TNKS1BP1 
controlling cytoskeleton  (Verghese et al., 2013). 
Pathways influenced by miR-26b are focal adhesion, ECM-receptor interaction, 
Arrhythmogenic right ventricular cardiomyopathy (ARVC), Dilated cardiomyopathy 
(DCM), Regulation of actin cytoskeleton and Adherens junction. This result confirms 
the potential role in metastasis development for miR-26b since its ability to influence 
cell-cell communication and regulation of cytoskeleton. ARVC and DCM are included 
in the list because they are caused by several mutations in cytoskeleton related genes 
and they are defined as cytoskeletalopathies (McNally et al., 2013; Sheppard, 2014) 
Another interesting miRNA is miR-27a that is activated in the metastatic cell lines. It 
was discussed by Ben-Ami and colleagues (Ben-Ami et al., 2009) as a negative 
regulator of the transcription factor RUNX1. In this paper, authors identified conserved 
RUNX binding sites upstream of miR-27a locus, indicating that RUNX1 acts positively 
in the regulation of miR-27a. I confirmed the interaction between miR-27a and RUNX1 
that recently was described as tumor suppressor in gastric cancer (Zhuang et al., 2014). 
Focal adhesion, ECM-receptor interaction, Pathways in cancer, and Small cell lung 
cancer pathways are pathways enriched by pathway analysis of miR-27a targets. These 
pathways confirm the pro-oncogenic potential of this miRNA that could influence cell 
adhesion. 
Finally, the integration of microarray and HITS-CLIP data strongly evidenced the 
involvement of miR-214 in metastasis formation and specifically in the regulation of 
cytoskeleton organization. In fact, gene ontology analysis of all transcripts that could 
physically interact with miR-214 evidenced the enrichment for the term cytoskeletal 
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organization, microtubule-based process, and motor activity. This is in accordance with 
results obtained by our collaborator Dr. Taverna of University of Torino that showed 
the metastatic potential of miR-214 in Melanoma through modulation of cell movement, 
cell adhesion and cell invasion capability (Penna et al., 2011, 2013). 
 
The analysis of pathway regulation through miRNA action described a lot of miRNAs 
involved (see paragraph 4.1.4). Even if the bioinformatic analysis was based on 
strengthen of miRNA and mRNA expression correlation it presents a percentage of 
false positive around 20% (Rajewsky, 2006; Doran and Strauss, 2007; Zhang and 
Verbeek, 2010). In order to validate described miRNA-mRNA interactions and to 
confirm data obtained by bioinformatic meta-analysis approach, I combined data from 
the two different approaches: microarray pathway analysis and Ago-Hits-CLIP data.  
In the Adherens junction path 1 the interaction between miR-106a and WASF3 was 
confirmed. I evidenced that in both cell lines (A375P and MA2) the interaction occurs 
at the same transcript region. This means that in both cell lines, miR-106a regulate 
WASF3 expression binding the transcript always in the same position (Figure 4.13 A). 
In WNT path 2, that affects non-canonical Polar Cell Planar pathway, I validated the 
interaction between let-7c and MAP kinase MAPK9 (or JNK2) (Figure 4.13 B). 
In VEGF signaling path 1, I validated three interactions: miR-106a and VEGFA, miR-
199a-5p and PXN and miR-98 and AKT2 (Figure 4.13 C). The first was just identified 
by luciferase assay by (Ling et al., 2013) while the last two interactions are specific for 
A375P cells. This result is interesting since abnormal expression of paxillin correlates 
with tumor progression and poor survival in patients with gastric cancer (Chen et al., 
2013) Its expression inhibition in low metastatic cell line could be a mechanism through 
which cells maintain low metastatic capacity. 
A portion of WNT canonical path is described in the figure 4.13 D). I validated the 
interaction between of miR-199a-5p and the serine threonine glycogen kinase GSK-3β 
and with the E3 ubiquitin ligase adaptors TBL1. Both proteins are involved in β-catenin 
degradation. Interactions were confirmed only in A375P cells and this is in accordance 
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with their low metastatic capacity. In fact, the absence of β-catenin prevents the 
activation of specific genes involved in cell cycle progression and cell proliferation. 
 
 
Figure 4.13 Confirmed interaction between miRNA and mRNA in specific pathways. A) 
Enlargement of adherens junction pathway. B) e D) WNT pathway. C) VEGF signal pathway. 
Red is for upregulated in metastases while green for downregulated. * indicates significant 
differentially expressed. In blu are indicated confirmed interactions with HITS-CLIP approach. 
 
 Let-7c activity 4.3
Let-7c is a good candidate, together with miR-214, to modulate metastatic capacity. It is 
upregulated in Melanoma metastases (Figure 4.14 A) and it is involved in the regulation 
of focal adhesion and adherens junction pathways and many other pathways I evidenced 
as important in metastasis process (see appendix table TAB A5). Since these evidences, 
I checked effects of let-7c downregulation on its predicted (bioinformatic approach) and 
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validated (HITS-CLIP approach) targets. Using single stranded chemically modified let-
7c inhibitors (anti-let-7c) transfected in A375P cell line, I performed qRT-PCR 
experiments to analyze the expression of different let-7c targets.  
Results are showed in figure 4.14 B. Two targets of let-7c were upregulated after 48h of 
anti-let7c transfection. Both targets were identified by HITS-CLIP and are important in 
cancer progression: the factor forkhead box N1 (FOXN1) and the fibronectin type III 
domain containing 3B (FNDC3B). 
 
Figure 4.14  Let-7c activity A) Expression profile of let-7c miRNA. Its expression increases in 
metastases indicating a possible metastatic role. Expression is expressed as mean ± SEM of 
four independent experiments. B) Effect of down-regulation of let-7c on their identified targets 
in A375P cell line through qRT-PCR. Results are shown as fold changes (mean±s.e.m.) relative 
to A375P cells, normalized on GADH level.* P<0.05; NS = Not Significative. LMC= low 
metastatic cell lines; HMC= High metastatic cell lines; Mets= lung metastases 
 
FOXN1 is a transcription factor that has been implicated in a variety of biochemical and 
cellular processes, such as development, metabolism, aging and cancer. In particular, it 
is expressed in skin epithelial cells where it acts regulating the balance between cell 
growth and cell differentiation (Palamaro et al., 2014). On the other hand, FNDC3B is 
known as an activator of multiple cancer pathways in hepatocellular carcinoma and it is 
capable of malignantly transforming mammary and kidney epithelial cells (Cai et al., 
2012). Furthermore, the up-regulation of a miRNA (miR-143) represses FNDC3B 
expression promoting prostate cancer metastasis (Fan et al., 2013). The metastatic 
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mechanism explained in the Fan’s work could be similar of the one in Melanoma where, 
in place of miR-143, let-7c modulates FNDC3B expression promoting Melanoma 
cancer metastasis. 
 
 Long non-coding RNAs: special miRNA targets 4.4
Long non-coding RNAs (lncRNAs) are non-coding transcripts with length more than 
200 nucleotides, that have been implicated in a lot of biological processes and in several 
steps of the metastatic progression (see Crea et al., 2013 for a review). In particular, it 
has become increasingly clear that numerous miRNA-binding sites exist on a wide 
variety of RNA transcripts (lncRNAs included), leading to the hypothesis that all RNA 
transcripts that contain miRNA-binding sites can communicate and regulate each other 
by competing specifically for shared miRNAs. In this way, lncRNAs could act as 
miRNA sponges (Ebert and Sharp, 2010) in order to reduce the amount of available 
miRNAs, reducing their action to target transcripts and acting as competing endogenous 
RNAs (ceRNAs) (see Tay et al., 2014 for a review). The interaction mechanism 
between miRNAs and lncRNAs is based on the recruitment by miRNA-containing 
ribonucleoprotein complex (miRNP) like for mRNAs regulation. Therefore, using 
AGO-Hits-CLIP it is possible to identify also lncRNA-miRNA interactions. 
Reads produced by sequencing RNA precipitated in association with AGO proteins 
allowed the identification of 87 lncRNAs supported by at least 5 reads in A375 sample 
and 28 lncRNAs in MA2 sample. 
There are different subclasses in the lncRNAs family. I identified mainly antisense 
RNAs that overlap coding sequence for a specific gene and locate in the opposite strand 
respect to the gene. They can act as regulation for the coding gene (Nishizawa et al., 
2012). Other lncRNA I identified are the long intergenic non-coding RNAs (lincRNAs) 
that are located between coding genes and apparently are not conserved between species 
(Ulitsky and Bartel, 2013). Moreover, I identified a small number of sense intronic 
RNAs that are placed in introns of a coding gene.  
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LincRNAs are emerging as a new regulators for cancer progression. LincRNAs were 
found misexpressed in several solid tumors and leukemias (Calin et al., 2007) where 
they can act as tumor suppressor like lincRNA-p21 (Huarte et al., 2010) or as oncogene 
like lincRNA-HOTAIR (Gupta et al., 2010). 
In my analysis, one of the most represented lincRNAs is the metastasis-associated lung 
adenocarcinoma transcript 1 (MALAT1) also known as nuclear-enriched transcript 2 
(NEAT2). It was first discovered as a prognostic marker for lung cancer metastasis but 
it has also been linked to several other human tumors (Gutschner et al., 2013). 
HITS-CLIP data allowed the identification of about 50 different interactions between 
MALAT1 and miRNAs, suggesting a sponge role for it. In addition, analyzing functions 
of targets of miRNAs seized by MALAT1, I evidenced that they are mainly involved in 
several pathway important for cancer progression (e.g. Wnt signaling pathway, Focal 
adhesion, Regulation of actin cytoskeleton, MAPK signaling pathway and PI3K-Akt 
signaling pathway)  
The interaction between miRNAs and MALAT1 was confirmed also in bladder cancer 
where Han and colleagues validated the down-regulation of MALAT1 after the 
transfection of an artificial miRNA-125b (Y. Han et al., 2013). This interaction allows 
the oncogenic potential reduction. miR-MiR125b/MALAT1 interaction was also 
identified by AGO-Hits-Clip data I produced confirming its importance in metastasis 
process. 
Even though the nuclear localization of MALAT1 could reject our experimental 
evidences for its miRNA-sponge function, it has been shown that thousands of lncRNAs 
possess cell type-, tissue type-, developmental stage- and disease-specific expression 
patterns and localization (Tay et al., 2014). For instance, Nakagawa and colleagues, 
after the generation of MALAT1-KO mice, noted that the MALAT1-KO mice were 
viable and fertile with no apparent phenotypes. Furthermore, also the nuclear bodies 
where MALAT1 usually interacts with a set of pre-mRNA processing factors, were 
correctly localized in cells that lacked MALAT1, suggesting that this lincRNA is not 
essential in living mice and that its function becomes apparent only in specific cell types 
and under particular conditions (Nakagawa et al., 2012). 
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Most represented lincRNA was the long intergenic non-protein coding RNA 324 
(LINC00324), a transcript of 2,082 nt whose function has not been identified. As 
MALAT1 also LINC00324 is able to interact with different miRNAs. In the two 
libraries, I found around 25 putative miRNA interactors that are summarized in table 
4.3.  
Tab 4.3. LINC00324 putative miRNA interactors. On the left there is the name of 
miRNAs and on the right the positions of binding site in the transcript starting from its 
5’-end 
miRNA found in 
A375P library 
Position of seed 
region (distance 
from 5’end in bp) 
miRNA found in 
MA2 library 
Position of seed 
region (distance 
from 5’end in bp) 
hsa-miR-100 6   
hsa-miR-99a 6   
hsa-miR-99b 6   
hsa-miR-31 519   
hsa-miR-574-3p 638 hsa-miR-574-3p 638 
hsa-miR-423 667 hsa-miR-423 667 
 
 hsa-miR-27b 698 
hsa-miR-23a 1148 hsa-miR-23a 1148 
hsa-miR-23b 1148 hsa-miR-23b 1148 
hsa-miR-30a 1153 hsa-miR-30a 1153 
hsa-miR-30d 1153 hsa-miR-30d 1153 
hsa-miR-30e 1153 hsa-miR-30e 1153 
hsa-miR-28 1197 hsa-miR-28 1197 
hsa-miR-191 1609   
hsa-miR-663a 1734 hsa-miR-663a 1734 
hsa-miR-29a 1787 hsa-miR-29a 1787 
hsa-miR-29b 1787 hsa-miR-29b 1787 
hsa-miR-29c 1787 hsa-miR-29c 1787 
hsa-miR-130a 1841 hsa-miR-130a 1841 
hsa-miR-130b 1841 hsa-miR-130b 1841 
hsa-miR-301a 1841 hsa-miR-301a 1841 
hsa-miR-301b 1841 hsa-miR-301b 1841 
 
In this list, we can recognize several miRNAs associated to cancer progression such as 2 
out of 3 members of pro-oncogenic cluster miR-23b/miR-27b/miR-24 (Jin et al., 2013), 
the miR-30 family involved in cell growth in breast cancer (Ouzounova et al., 2013), 
and the miR-29 family that is involved in complex regulatory process by targeting 
multiple factors associated with several common cancerous pathways (Yang Wang et 
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al., 2013). Analyzing pathway regulated by targets of miRNAs that interact with 
LINC00324, I evidenced that they are involved in cell-matrix adhesions (Focal adhesion 
and ECM-receptor interaction pathway) and in several amoebic proteins such as lectins, 
and cysteine proteineases that are associated with the ameboid movement typical of the 
invasion process. This result suggests a potential role for LINC00234 in the regulation 
of processes that allow cell invasivity. In a competitive endogenous RNA context, 
LINC00234 could sequester these miRNA in order to increase the expression level of 
their mRNAs target involved in cell-cell communications and invasion. 
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5 Conclusions 
 
 
In the last decade, accumulating evidence indicates that miRNAs are involved in 
multiple processes of cancer development and progression. It is becoming increasingly 
clear that miRNAs are important regulators of proliferation, apoptosis, invasion, and 
metastasis in cancer cells. They can regulate tens or hundreds mRNA targets at a time 
by post-transcriptionally mechanisms. Their multiple targeting ability is at the same 
time pleasure and pain, because these non-coding transcripts has got a great potential 
regulatory power, but on the other side, they produce an enormous amount of possible 
interactions that are very difficult to understand and to relate to biological pathways. 
In this thesis dissertation, I have tried to shed light in the intricate interaction network 
that occurs during Melanoma progression processes. Using different approaches, I 
identified Melanoma-specific miRNAs and transcripts, the relationships between them 
and finally I associated this information to known biological metastatic pathways. 
In order to understand the effective involvement of miRNAs in Melanoma metastases 
development, I performed miRNA microarray experiments using a Malignant 
Melanoma metastasis model developed by Xu (Xu et al., 2008b). In this work, Xu and 
colleagues injected a poorly metastatic Melanoma cell line (A375P) into the circulation 
of immunodeficient mice and the few deriving lung metastases were isolated and in-
vitro amplified as cell lines (MA1 and MC1). These cells were reinjected into mice for a 
second round of selection to generate MA-2 and MC-2 cell lines. For all the lung 
metastases produced total RNA were collected and used for the experiments. This 
Melanoma model mimic the travel of the metastasis-initiating cells (Malanchi, 2013; 
Giancotti, 2013) through the vascular system up to lungs where they invade the tissue 
and form the metastasis masses. I evidenced that miRNA expression pattern is able to 
distinguish the low metastatic cell lines (LMC) from the high-metastatic cell lines 
(HMC) and the lung metastases (Mets). This result suggested the existence of different 
miRNA-mediated gene regulation programs that can be responsible for the increased 
sample metastatic potential. Results identified several miRNAs, also confirmed in 
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literature, that increase their expression level with the increasing of metastatic potential. 
These miRNAs act as pro-metastatic miRNAs (e.g. miR-195, miR-199a-5p, miR-214, 
miR-10b, and miR-223). However, the analysis of miRNA expression also evidenced 
miRNAs presenting a decreasing expression from low to high metastatic samples. 
Considering the used experimental model they could have a tumor suppressor role (e.g. 
miR-193b, miR-18b, miR-9, miR-196a, and miR-31). 
MiRNA microarray results confirmed the central role of miRNAs in the regulation of 
metastasis, but the biggest problem in miRNA research is identify their targets to 
understand their function. I used a meta-analysis approach to dissect this problem. 
MiRNA microarray data were integrated with gene expression data produced by Hynes’ 
laboratory (Xu et al., 2008b). MRNA experiments were performed on same samples I 
used to perform miRNA experiments. 
All genes, without filtering according differentially expression, were used in the 
CliPPER analysis (Martini et al., 2013) recognizing the portion of pathways involved in 
metastasis formation. This approach is very useful to study the behaviour of cancer cell 
lines during metastasis because, due to the high number of pathways involved, it is 
better to identify a synergistic gene deregulation than to identify single genes strongly 
deregulated losing their interplay. To avoid to lose the focus of this work, I performed 
the identification of miRNAs influence in metastasis process, integrating mRNA and 
miRNA expression (Bisognin et al., 2012). The association of miRNA and mRNA 
expression allows the identification of putative mRNA-miRNA interactions. Using this 
approach not only it was identified miRNA-mRNA interactions, but also pathways 
important in Melanoma that are influenced by miRNAs.  
Meta-analysis allowed the identification of 12 relevant pathways that are strongly 
regulated by miRNAs and between them three are relevant for the metastatic processes: 
WNT signalling pathway, Adherens junction, and VEGF signalling pathway. These 
pathways are involved in cell extravasation process, cell protrusion development, cell-
cell signaling, and tissue vascularization.  
The presence of several miRNA clusters or families (miR-148/152 in WNT signalling 
pathway, miR130b/301b in Adherens junction pathway and miR-221/222 in VEGF 
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signalling pathway) that could regulate all these pathways was evidenced. Furthermore, 
two members of miR-106a/363 cluster (miR-106a and miR-18a) were found as potential 
regulators of all the three relevant pathways. This could sustain the strong interplay of 
considered pathways and the presence of a synergic regulation. MiR-106a/363 have an 
oncogenic function in leukemias (Landais et al., 2007). In addition, analysing Ewing 
sarcoma, Dylla and Jedlicka (Dylla and Jedlicka, 2013) evidenced that blocking selected 
individual miRNA of the miR-106a/363 cluster has little or no effect on their oncogenic 
power respect to a combinatorial inhibition strategy. This result highlights the redundant 
effect of cluster components and is in accordance with evidences of Guo and 
colleagues. Analysing human miRNA clusters and families, they affirmed that clustered 
miRNAs have evolved from common ancestral miRNA genes not randomly but due to 
functional and evolutionary pressures in order to co-regulate biological processes (Guo 
et al., 2013). 
Meta-analysis performed on microarray data gave us several informations about 
miRNA-mRNA interaction network involved in malignant Melanoma metastatic 
processes, but the high false-positive rate of miRNA target prediction algorithms 
(Rajewsky, 2006; Doran and Strauss, 2007; Zhang and Verbeek, 2010) remain a pitfall. 
To overcome this constrain I set up a new method to identify all miRNA-target 
interaction: the High-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation (HITS-CLIP) (Chi et al., 2009). This method uses ultraviolet 
irradiation to covalently crosslink RNA–AGO complex that are in direct contact 
(approximately over single ängstrom distances) within cells. Crosslinking allows the 
subsequent complex purification and then the identification of precipitated RNA 
through high-throughput sequencing methods. This new approach allowed the 
identification of several members of miRNA clusters and families that are involved in 
the regulation of metastatic capacity of cell lines analyzed. For example,  miR-23b and 
mir-17~92 clusters, and mir-30 family are all well-known pro-oncogenic entities (Olive 
et al., 2010; Jin et al., 2013; Ouzounova et al., 2013). The HITS-CLIP approach was 
useful for meta-analysis data validation. Members of the pro-oncogenic cluster miR-
106a~363 (Landais et al., 2007) were confirmed involved in metastasis. 
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The comparison between miRNA expression microarray data and miRNA sequencing 
data identified some cell-specific miRNAs such as miR-26b in A375P cells, miR-27a 
and miR-214 in MA2 cells. Some of the interactions identified by AGO-HiTS-CLIP 
approach were already known (Ma et al., 2011; Verghese et al., 2013; Jia Li et al., 2013; 
Ben-Ami et al., 2009). Known miRNA:mRNA interactions are mainly involved in cell 
proliferation and cytoskeletal regulation. HITS-CLIP permitted to confirm the 
importance of miR-214 to regulate metastatic processes in Melanoma. This miRNA 
regulates cell movement, cell adhesion and cell invasion capability (Penna et al., 2011, 
2013). 
Thanks to the AGO-Hits-CLIP approach, I have also validated some miRNA:mRNA 
interactions identified by meta-analysis. In particular, it is very interesting the validation 
of two miR-106a targets: WASF3 that is involved in cell protrusion development in 
adherens junction pathway and VEGFA, the main effector of the angiogenesis. In 
particular miR-106a-VEGFA interaction was just identified by luciferase assay by (Ling 
et al., 2013). Mir-106a is a member of the oncogenic cluster miR-106a~363. Moreover, 
recent scientific works indicate its role in the metastasis promotion of different tumors 
(Feng et al., 2012; Li et al., 2014; Zhu et al., 2014). In particular, it was proposed an 
oncogenic function for miR-106a (Li et al., 2014; Zhu et al., 2014) through interaction 
with the metallopeptidase inhibitor  (TIMP2). Interestingly, I confirmed this interaction. 
Many other interactions were confirmed through HITS-CLIP approach demonstrating 
the validity of both experimental designs I applied in this thesis work. In particular, 
another interesting miRNA identified through HITS-CLIP approach was has-let-7c. It is 
upregulated in metastases and could have a role in the colonization of different tissues 
form the starting tumor location. In order to understand the role of let-7c and confirm 
identified miRNA-mRNA interactions evidenced by HITS-CLIP I performed the let-7c 
inhibition and quantitative Real Time PCR (qRT-PCR) on identified targets. I was 
expecting that if an mRNA is targeted by let-7c inhibiting it the target would increase its 
concentration. Using A375P cells, after 48h of transfection I evidenced a significant 
increase of 2 out of 3 let-7c targets: the factor forkhead box N1 (FOXN1) and the 
fibronectin type III domain containing 3B (FNDC3B). These targets are important in 
cancer progression. FOXN1 is a transcription factor that has been implicated in a 
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variety of biochemical and cellular processes (Palamaro et al., 2014), while FNDC3B 
has got a primary role in promoting prostate cancer metastasis (Fan et al., 2013). Results 
suggest that let-7c could act as a tumor suppressor gene.  
Recently, it was emerged the importance of lncRNAs in cell regulation mechanisms. 
LncRNAs have been demonstrated implicated in a large number of post-transcriptional 
events. They can control stability and translation of mRNAs (Gong and Maquat, 2011; 
Yoon et al., 2012; Jiashi Wang et al., 2013), or the activity of miRNAs acting as 
sponges (Poliseno et al., 2010; Cesana et al., 2011; Kallen et al., 2013). In particular, 
miRNA-sponge function, suggests that coding and non-coding RNAs may compete for 
miRNA binding, influencing the expression of other transcripts with the same miRNA 
binding sites. (see (Tay et al., 2014) for a review). Ago-Hits-CLIP based approach also 
allows the identification of these new relationships highlighting the complex molecular 
network present in a cell. Moreover, the comprehension of lncRNA function in tumor 
progression appears fundamental to have new opportunities to treat the pathology. 
LncRNAs can be utilized for cancer diagnosis, prognosis, and serve as potential 
therapeutic targets (Tsai et al., 2011).  
The mechanism involved in miRNA-lncRNA interaction is the same for miRNA-
mRNA interactions. Therefore, Ago-HITS-CLIP allows the identification of miRNA-
mRNA and miRNA-lncRNA interactions. I identified several well-characterized 
lncRNAs as miRNA partners. Much of these have several miRNA binding sites 
strengthening their miRNA-sponge function, but it is necessary to perform further 
experiments in order to validate functionally this metastasis-associated lncRNAs. 
To conclude, combinatorial approaches associated to genome wide techniques, as 
microarray mRNA and miRNA expression analysis and AGO-Hits-CLIP, allowed the 
identification of important effectors in Melanoma metastasis. Considering that this 
pathology is untreatable and that after metastasis 90% of patients die (Parkin et al., 
2005) the identification of pharmacological targets could have high impact in patients’ 
life.  
MiRNAs represent a promising molecule and for this reason it is important understand 
their role in Melanoma metastasis. In fact, they are more stable than longer transcripts 
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and are currently tested in clinical trials. MiR-122 inhibitor drug (Miravirsen or 
SPC3649) is used to treat hepatitis C virus (HCV) infection. Miravirsen efficiently 
suppress infections derived from HCV type 1a and 1b when administered to 
chimpanzees (Lanford et al., 2010). Moreover, its activity was tested on 36 patients 
demonstrating good results with no apparent side effects (Janssen et al., 2013). This is a 
promising result because sustains the ability of using miRNA regulators as drug to treat 
many other diseases. 
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7 Appendix 
 
Table A1 
Clipper results with all mRNA 
index pathway alphaMean alphaVar 
1 Alanine, aspartate and glutamate metabolism 0 0 
2 Amino sugar and nucleotide sugar metabolism 0 0 
3 Amyotrophic lateral sclerosis (ALS) 0 0 
4 Antigen processing and presentation 0 0 
5 Apoptosis 0 0 
6 Arachidonic acid metabolism 0 0 
7 Axon guidance 0 0 
8 B cell receptor signaling pathway 0 0 
9 Cell adhesion molecules (CAMs) 0 0 
10 Circadian rhythm 0 0 
11 Cocaine addiction 0 0 
12 Cytosolic DNA-sensing pathway 0 0 
13 Dilated cardiomyopathy 0 0 
14 Drug metabolism - other enzymes 0 0 
15 ECM-receptor interaction 0 0 
16 Epithelial cell signaling in Helicobacter pylori infection 0 0 
17 Epstein-Barr virus infection 0 0 
18 Fc epsilon RI signaling pathway 0 0 
19 Gap junction 0 0 
20 Glioma 0 0 
21 Glyoxylate and dicarboxylate metabolism 0 0 
22 GnRH signaling pathway 0 0 
23 Hepatitis B 0 0 
24 Hepatitis C 0 0 
25 Herpes simplex infection 0 0 
26 HIF-1 signaling pathway 0 0 
27 Influenza A 0 0 
28 Insulin signaling pathway 0 0 
29 Jak-STAT signaling pathway 0 0 
30 Legionellosis 0 0 
31 Leishmaniasis 0 0 
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32 Leukocyte transendothelial migration 0 0 
33 Long-term depression 0 0 
index pathway alphaMean alphaVar 
34 Measles 0 0 
35 mTOR signaling pathway 0 0 
36 Mucin type O-Glycan biosynthesis 0 0 
37 Natural killer cell mediated cytotoxicity 0 0 
38 NF-kappa B signaling pathway 0 0 
39 NOD-like receptor signaling pathway 0 0 
40 Osteoclast differentiation 0 0 
41 p53 signaling pathway 0 0 
42 Pertussis 0 0 
43 PPAR signaling pathway 0 0 
44 Propanoate metabolism 0 0 
45 Rheumatoid arthritis 0 0 
46 RIG-I-like receptor signaling pathway 0 0 
47 Small cell lung cancer 0 0 
48 Synaptic vesicle cycle 0 0 
49 Toxoplasmosis 0 0 
50 Valine, leucine and isoleucine degradation 0 0 
51 Vibrio cholerae infection 0 0 
52 Bile secretion 0 0.01 
53 Folate biosynthesis 0 0.01 
54 Galactose metabolism 0 0.01 
55 Glycine, serine and threonine metabolism 0 0.01 
56 Hypertrophic cardiomyopathy (HCM) 0 0.01 
57 Pancreatic cancer 0 0.01 
58 Pathogenic Escherichia coli infection 0 0.01 
59 Prion diseases 0 0.01 
60 Progesterone-mediated oocyte maturation 0 0.01 
61 Shigellosis 0 0.01 
62 T cell receptor signaling pathway 0 0.01 
63 TGF-beta signaling pathway 0 0.01 
64 Toll-like receptor signaling pathway 0 0.01 
65 Viral myocarditis 0 0.01 
66 Arginine and proline metabolism 0 0.02 
67 Cell cycle 0 0.02 
68 Colorectal cancer 0 0.02 
69 Cysteine and methionine metabolism 0 0.02 
70 ErbB signaling pathway 0 0.02 
71 Fructose and mannose metabolism 0 0.02 
72 Oxidative phosphorylation 0 0.02 
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73 Pentose phosphate pathway 0 0.02 
74 Pyruvate metabolism 0 0.02 
index pathway alphaMean alphaVar 
75 Serotonergic synapse 0 0.02 
76 Steroid biosynthesis 0 0.02 
77 Wnt signaling pathway 0 0.02 
78 Citrate cycle (TCA cycle) 0 0.03 
79 Endometrial cancer 0 0.03 
80 Hedgehog signaling pathway 0 0.03 
81 Intestinal immune network for IgA production 0 0.03 
82 Pancreatic secretion 0 0.03 
83 Prostate cancer 0 0.03 
84 Salivary secretion 0 0.03 
85 Acute myeloid leukemia 0 0.04 
86 Bladder cancer 0 0.04 
87 Cardiac muscle contraction 0 0.04 
88 Chagas disease (American trypanosomiasis) 0 0.04 
89 Sphingolipid metabolism 0 0.04 
90 Adherens junction 0 0.05 
91 Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 
0 0.05 
92 Glycosphingolipid biosynthesis - lacto and neolacto 
series 
0 0.05 
93 Melanoma 0 0.05 
94 N-Glycan biosynthesis 0 0.05 
95 Parkinson's disease 0 0.05 
96 Pentose and glucuronate interconversions 0 0.05 
97 Vascular smooth muscle contraction 0 0.05 
98 Chronic myeloid leukemia 0 0.06 
99 Fc gamma R-mediated phagocytosis 0 0.06 
100 Melanogenesis 0 0.06 
101 Salmonella infection 0 0.06 
102 Terpenoid backbone biosynthesis 0 0.06 
103 Type II diabetes mellitus 0 0.06 
104 Fatty acid metabolism 0 0.07 
105 Maturity onset diabetes of the young 0 0.07 
106 Notch signaling pathway 0 0.07 
107 Pyrimidine metabolism 0 0.07 
108 Dopaminergic synapse 0 0.08 
109 Huntington's disease 0 0.08 
110 VEGF signaling pathway 0 0.08 
111 Neuroactive ligand-receptor interaction 0 0.09 
112 Renal cell carcinoma 0 0.1 
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113 Selenocompound metabolism 0 0.11 
114 Taste transduction 0 0.11 
index pathway alphaMean alphaVar 
115 Non-small cell lung cancer 0 0.12 
116 Phosphatidylinositol signaling system 0 0.12 
117 Gastric acid secretion 0 0.15 
118 beta-Alanine metabolism 0 0.16 
119 Cholinergic synapse 0 0.16 
120 Graft-versus-host disease 0 0.16 
121 Neurotrophin signaling pathway 0 0.17 
122 Porphyrin and chlorophyll metabolism 0 0.17 
123 Primary bile acid biosynthesis 0 0.17 
124 Phototransduction 0 0.18 
125 Bacterial invasion of epithelial cells 0 0.19 
126 Drug metabolism - cytochrome P450 0 0.21 
127 Glycosaminoglycan degradation 0 0.21 
128 Oocyte meiosis 0 0.22 
129 Alzheimer's disease 0 0.23 
130 Circadian entrainment 0 0.23 
131 Tight junction 0 0.27 
132 Tryptophan metabolism 0 0.3 
133 Retrograde endocannabinoid signaling 0 0.36 
134 Amphetamine addiction 0 0.4 
135 Glutamatergic synapse 0 0.54 
136 Glycolysis / Gluconeogenesis 0 0.63 
137 GABAergic synapse 0 0.65 
 
Table A2 
Clipper results with only mRNA identified by MAGIA2 analysis 
index pathway alphaMean alphaVar 
1 Acute myeloid leukemia 0 0 
2 Amyotrophic lateral sclerosis (ALS) 0 0 
3 Axon guidance 0 0 
4 B cell receptor signaling pathway 0 0 
5 Chronic myeloid leukemia 0 0 
6 Dopaminergic synapse 0 0 
7 ECM-receptor interaction 0 0 
8 Endometrial cancer 0 0 
9 Epithelial cell signaling in Helicobacter pylori infection 0 0 
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10 Epstein-Barr virus infection 0 0 
11 ErbB signaling pathway 0 0 
index pathway alphaMean alphaVar 
12 Fc gamma R-mediated phagocytosis 0 0 
13 Gap junction 0 0 
14 Glioma 0 0 
15 GnRH signaling pathway 0 0 
16 Hepatitis B 0 0 
17 Hepatitis C 0 0 
18 Herpes simplex infection 0 0 
19 Influenza A 0 0 
20 Insulin signaling pathway 0 0 
21 Jak-STAT signaling pathway 0 0 
22 Leukocyte transendothelial migration 0 0 
23 Long-term potentiation 0 0 
24 mTOR signaling pathway 0 0 
25 Natural killer cell mediated cytotoxicity 0 0 
26 NF-kappa B signaling pathway 0 0 
27 Oocyte meiosis 0 0 
28 Osteoclast differentiation 0 0 
29 p53 signaling pathway 0 0 
30 Pancreatic cancer 0 0 
31 Progesterone-mediated oocyte maturation 0 0 
32 Prostate cancer 0 0 
33 Renal cell carcinoma 0 0 
34 RIG-I-like receptor signaling pathway 0 0 
35 Serotonergic synapse 0 0 
36 T cell receptor signaling pathway 0 0 
37 Toll-like receptor signaling pathway 0 0 
38 Toxoplasmosis 0 0 
39 VEGF signaling pathway 0 0 
40 Bacterial invasion of epithelial cells 0 0.01 
41 Chagas disease (American trypanosomiasis) 0 0.01 
42 Colorectal cancer 0 0.01 
43 Gastric acid secretion 0 0.01 
44 HIF-1 signaling pathway 0 0.01 
45 Sphingolipid metabolism 0 0.01 
46 Vascular smooth muscle contraction 0 0.01 
47 Bladder cancer 0 0.02 
48 Cell cycle 0 0.02 
49 N-Glycan biosynthesis 0 0.02 
50 Pyrimidine metabolism 0 0.02 
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51 Salivary secretion 0 0.02 
52 Wnt signaling pathway 0 0.02 
index pathway alphaMean alphaVar 
53 Circadian rhythm 0 0.03 
54 Cocaine addiction 0 0.03 
55 Adipocytokine signaling pathway 0 0.04 
56 Circadian entrainment 0 0.04 
57 Non-small cell lung cancer 0 0.04 
58 Aldosterone-regulated sodium reabsorption 0 0.05 
59 Adherens junction 0 0.06 
60 Long-term depression 0 0.08 
61 Melanogenesis 0 0.08 
62 Cholinergic synapse 0 0.11 
63 Neurotrophin signaling pathway 0 0.12 
64 Tight junction 0 0.13 
65 Amphetamine addiction 0 0.18 
66 TGF-beta signaling pathway 0 0.65 
 
Table A3 
A) WNT signaling path1 miRNA-mRNA interactions negatively correlated 
miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
dst mRNA Protein 
complex 
Differential 
expressed 
SAM FDR<0.01 
Upregulated 
in Mets 
Correlaztion 
hsa-
mir-
128 
1 0 8312 AXIN1 Axin 1 1 Negative 
hsa-
mir-30c 
1 1 1452 CSNK1A1 CK1a 1 0 Negative 
hsa-
mir-
218 
0 1 1454 CSNK1E CK1e 1 0 Negative 
hsa-
mir-32 
1 0 56998 CTNNBIP1 ICAT 1 1 Negative 
hsa-
mir-19a 
1 0 23002 DAAM1 Daam1 1 1 Negative 
hsa-
mir-18a 
1 0 23500 DAAM2 Daam1 1 1 Negative 
hsa-
mir-
18b 
1 0 23500 DAAM2 Daam1 1 1 Negative 
hsa-
mir-
200b 
2 1 23291 FBXW11 b-TrCP 1 0 Negative 
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miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
dst mRNA Protein 
complex 
Differential 
expressed 
SAM FDR<0.01 
Upregulated 
in Mets 
Correlaztion 
hsa-
mir-26a 
1 1 10023 FRAT1 GBP 1 0 Negative 
hsa-
mir-
26b 
1 1 10023 FRAT1 GBP 1 0 Negative 
hsa-
mir-26° 
1 1 23401 FRAT2 GBP 1 0 Negative 
hsa-
mir-
26b 
1 1 23401 FRAT2 GBP 1 0 Negative 
hsa-
mir-
135b 
1 0 8321 FZD1 Frizzled 1 1 Negative 
hsa-
mir-30c 
1 1 2535 FZD2 Frizzled 1 0 Negative 
hsa-
mir-30c 
1 1 7976 FZD3 Frizzled 0 0 Negative 
hsa-
mir-
20b 
1 0 8322 FZD4 Frizzled 1 1 Negative 
hsa-
mir-98 
1 0 8322 FZD4 Frizzled 1 1 Negative 
hsa-
mir-
106a 
1 0 8322 FZD4 Frizzled 1 1 Negative 
hsa-
mir-
199b-
5p 
1 1 8323 FZD6 Frizzled 1 0 Negative 
hsa-
mir-
424 
1 1 8323 FZD6 Frizzled 1 0 Negative 
hsa-
mir-
497 
1 1 8323 FZD6 Frizzled 1 0 Negative 
hsa-
mir-
199a-
5p 
2 1 8323 FZD6 Frizzled 1 0 Negative 
hsa-
mir-
195 
 
 
1 1 8323 FZD6 Frizzled 1 0 Negative 
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miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
dst mRNA Protein 
complex 
Differential 
expressed 
SAM FDR<0.01 
Upregulated 
in Mets 
Correlaztion 
hsa-
mir-
128 
1 0 8324 FZD7 Frizzled 1 1 Negative 
hsa-
mir-
20b 
1 0 8324 FZD7 Frizzled 1 1 Negative 
hsa-
mir-
106a 
1 0 8324 FZD7 Frizzled 1 1 Negative 
hsa-
mir-26a 
1 1 2932 GSK3B GSK-3b 1 0 Negative 
hsa-
mir-
199b-
5p 
1 1 2932 GSK3B GSK-3b 1 0 Negative 
hsa-
mir-
26b 
1 1 2932 GSK3B GSK-3b 1 0 Negative 
hsa-
mir-
199a-
5p 
2 1 2932 GSK3B GSK-3b 1 0 Negative 
hsa-
mir-
214 
2 1 2932 GSK3B GSK-3b 1 0 Negative 
hsa-
mir-
155 
2 1 2932 GSK3B GSK-3b 1 0 Negative 
hsa-
mir-
218 
0 1 2932 GSK3B GSK-3b 1 0 Negative 
hsa-
mir-
200b 
2 1 5515 PPP2CA  1 0 Negative 
hsa-
mir-
214 
2 1 5516 PPP2CB  1 0 Negative 
hsa-
mir-19a 
1 0 5525 PPP2R5A  1 1 Negative 
hsa-
mir-
424 
 
 
1 1 5527 PPP2R5C  1 0 Negative 
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miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
dst mRNA Protein 
complex 
Differential 
expressed 
SAM FDR<0.01 
Upregulated 
in Mets 
Correlaztion 
hsa-
mir-
497 
1 1 5527 PPP2R5C  1 0 Negative 
hsa-
mir-
195 
1 1 5527 PPP2R5C  1 0 Negative 
hsa-
mir-
200b 
2 1 5527 PPP2R5C  1 0 Negative 
hsa-
mir-
200b 
2 1 5567 PRKACB PKA 0 0 Negative 
hsa-
mir-
128 
1 0 5613 PRKX PKA 0 1 Negative 
hsa-
mir-19a 
1 0 5613 PRKX PKA 0 1 Negative 
hsa-
mir-
148a 
1 1 5663 PSEN1 PS-1 1 0 Negative 
hsa-
mir-
152 
1 1 5663 PSEN1 PS-1 1 0 Negative 
hsa-
mir-98 
1 0 59343 SENP2 Axam 1 1 Negative 
hsa-
mir-
142-3p 
2 1 6907 TBL1X TBL1 1 0 Negative 
hsa-
mir-
181c 
1 1 6907 TBL1X TBL1 1 0 Negative 
hsa-
mir-
199b-
5p 
1 1 79718 TBL1XR1 TBL1 0 0 Negative 
hsa-
mir-
424 
1 1 79718 TBL1XR1 TBL1 0 0 Negative 
hsa-
mir-
497 
1 1 79718 TBL1XR1 TBL1 0 0 Negative 
hsa-
mir-
363 
2 1 79718 TBL1XR1 TBL1 0 0 Negative 
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miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
dst mRNA Protein 
complex 
Differential 
expressed 
SAM FDR<0.01 
Upregulated 
in Mets 
Correlaztion 
hsa-
mir-
199a-
5p 
2 1 79718 TBL1XR1 TBL1 0 0 Negative 
hsa-
mir-
195 
1 1 79718 TBL1XR1 TBL1 0 0 Negative 
hsa-
mir-
148a 
1 1 79718 TBL1XR1 TBL1 0 0 Negative 
hsa-
mir-
181c 
1 1 79718 TBL1XR1 TBL1 0 0 Negative 
hsa-
mir-
200b 
2 1 79718 TBL1XR1 TBL1 0 0 Negative 
hsa-
mir-
152 
1 1 79718 TBL1XR1 TBL1 0 0 Negative 
hsa-
mir-
214 
2 1 79718 TBL1XR1 TBL1 0 0 Negative 
 
 
B) WNT signaling path2 miRNA-mRNA interactions negatively correlated 
miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Entrez 
Gene 
mRNA Protein 
complex 
Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Correlaztion q-value
hsa-
mir-
19a 
1 0 23002 DAAM1 Daam1 1 1 Negative 5.72E
hsa-
mir-
18a 
1 0 23500 DAAM2 Daam1 1 1 Negative 1.65E
hsa-
mir-
18b 
1 0 23500 DAAM2 Daam1 1 1 Negative 2.54E
hsa-
mir-
135b 
1 0 8321 FZD1 Frizzled 1 1 Negative 4.60E
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miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Entrez 
Gene 
mRNA Protein 
complex 
Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Correlaztion q-value
hsa-
mir-30c 
1 1 2535 FZD2 Frizzled 1 0 Negative 3.64E
hsa-
mir-30c 
1 1 7976 FZD3 Frizzled 0 0 Negative 0.007554
hsa-
mir-
20b 
1 0 8322 FZD4 Frizzled 1 1 Negative 9.19E
hsa-
mir-98 
1 0 8322 FZD4 Frizzled 1 1 Negative 1.96E
hsa-
mir-
106a 
1 0 8322 FZD4 Frizzled 1 1 Negative 2.97E
hsa-
mir-
199b-
5p 
1 1 8323 FZD6 Frizzled 1 0 Negative 4.08E
hsa-
mir-
424 
1 1 8323 FZD6 Frizzled 1 0 Negative 4.25E
hsa-
mir-
497 
1 1 8323 FZD6 Frizzled 1 0 Negative 4.40E
hsa-
mir-
199a-
5p 
only MA2 1 8323 FZD6 Frizzled 1 0 Negative 7.34E
hsa-
mir-
195 
1 1 8323 FZD6 Frizzled 1 0 Negative 8.80E
hsa-
mir-
128 
1 0 8324 FZD7 Frizzled 1 1 Negative 1.26E
hsa-
mir-
20b 
1 0 8324 FZD7 Frizzled 1 1 Negative 1.51E
hsa-
mir-
106a 
1 0 8324 FZD7 Frizzled 1 1 Negative 4.51E
hsa-
mir-
135b 
1 0 5602 MAPK10 JNK 0 1 Negative 5.40E
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miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Entrez 
Gene 
mRNA Protein 
complex 
Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Correlaztion q-value
hsa-
mir-
200b 
only MA2 1 5601 MAPK9 JNK 1 0 Negative 3.76E
hsa-let-
7c 
1 1 5601 MAPK9 JNK 1 0 Negative 9.77E
hsa-
mir-
199b-
5p 
1 1 6093 ROCK1 ROCK2 1 0 Negative 4.73E
hsa-
mir-
199a-
5p 
only MA2 1 6093 ROCK1 ROCK2 1 0 Negative 8.80E
hsa-
mir-
145 
only MA2 1 6093 ROCK1 ROCK2 1 0 Negative 1.19E
hsa-
mir-
148a 
1 1 6093 ROCK1 ROCK2 1 0 Negative 0.000025
hsa-
mir-
152 
1 1 6093 ROCK1 ROCK2 1 0 Negative 4.97E
hsa-
mir-
135b 
1 0 9475 ROCK2 ROCK2 0 1 Negative 6.84E
hsa-
mir-
130b 
1 0 9475 ROCK2 ROCK2 0 1 Negative 8.68E
hsa-
mir-
301b 
1 0 9475 ROCK2 ROCK2 0 1 Negative 0.006123
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A) Adherens junction path1 miRNA-mRNA interactions negatively correlated 
miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Entrez 
Gene 
mRNA Protein 
complex 
Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Correlaztion q-value 
hsa-
mir-
20b 
1 0 10810 WASF3 WAVE 1 1 Negative 2.21E-05
hsa-
mir-
130b 
1 0 8976 WASL WAVE 0 1 Negative 4.75E-05
hsa-
mir-
106a 
1 0 10810 WASF3 WAVE 1 1 Negative 7.24E-05
hsa-
mir-9 
0 0 6714 SRC SRC 1 1 Negative 0.000128
hsa-
mir-98 
1 0 8976 WASL WASP 0 1 Negative 0.002439
hsa-
mir-
301b 
1 0 8976 WASL WASP 0 1 Negative 0.003306
hsa-
mir-32 
1 0 8976 WASL WASP 0 1 Negative 0.00947
 
 
A) VEGF signaling path1 miRNA-mRNA interactions negatively correlated 
miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Entrez 
Gene 
mRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Correlaztion q-value 
hsa-mir-98 1 0 208 AKT2 0 1 Negative 0.006165 
hsa-mir-
135b 
1 0 11261 CHP1 1 1 Negative 5.1E-11 
hsa-mir-
204 
1 0 11261 CHP1 1 1 Negative 9.46E-05 
hsa-mir-
221 
1 0 3791 KDR 1 1 Negative 1.5E-08 
hsa-mir-
222 
1 0 3791 KDR 1 1 Negative 7.81E-08 
hsa-mir-
142-3p 
2 1 5530 PPP3CA 1 0 Negative 6.01E-16 
hsa-mir-
145 
2 1 5530 PPP3CA 1 0 Negative 1.2E-13 
hsa-mir-
30c 
1 1 5530 PPP3CA 1 0 Negative 5.35E-12 
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miRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Entrez 
Gene 
mRNA Differential 
expressed 
SAM 
FDR<0.01 
Upregulated 
in Mets 
Correlaztion q-value 
hsa-mir-
26a 
1 1 5532 PPP3CB 1 0 Negative 6.44E-08 
hsa-mir-
26b 
1 1 5532 PPP3CB 1 0 Negative 4.4E-07 
hsa-mir-
30c 
1 1 5532 PPP3CB 1 0 Negative 0.000163 
hsa-mir-
142-3p 
2 1 5534 PPP3R1 1 0 Negative 9.2E-09 
hsa-mir-
26a 
1 1 5534 PPP3R1 1 0 Negative 5.26E-08 
hsa-mir-
26b 
1 1 5534 PPP3R1 1 0 Negative 3.57E-07 
hsa-mir-
181c 
1 1 5534 PPP3R1 1 0 Negative 8.75E-05 
hsa-mir-
30c 
1 1 5534 PPP3R1 1 0 Negative 0.000133 
hsa-mir-
199b-5p 
1 1 5829 PXN 1 0 Negative 1.43E-09 
hsa-mir-
199a-5p 
2 1 5829 PXN 1 0 Negative 2.54E-08 
hsa-mir-
145 
2 1 5829 PXN 1 0 Negative 3.45E-08 
hsa-mir-
218 
0 1 5829 PXN 1 0 Negative 4.31E-05 
hsa-mir-
424 
1 1 9047 SH2D2A 1 0 Negative 3.55E-07 
hsa-mir-
497 
1 1 9047 SH2D2A 1 0 Negative 3.7E-07 
hsa-mir-
195 
1 1 9047 SH2D2A 1 0 Negative 7.45E-07 
hsa-mir-9 0 0 25759 SHC2 1 1 Negative 0.000608 
hsa-mir-
20b 
1 0 7422 VEGFA 0 1 Negative 0.001788 
hsa-mir-
106a 
1 0 7422 VEGFA 0 1 Negative 0.00594 
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Table A4 
Let-7c targets enrichment through DAVID 
Category Term Count % PValue 
KEGG_PATHWAY hsa04510:Focal adhesion 42 2.616822 3.24E-06 
KEGG_PATHWAY hsa04512:ECM-receptor interaction 22 1.370717 4.07E-05 
KEGG_PATHWAY hsa04310:Wnt signaling pathway 31 1.931464 1.16E-04 
KEGG_PATHWAY hsa04520:Adherens junction 19 1.183801 3.56E-04 
KEGG_PATHWAY hsa04360:Axon guidance 26 1.619938 6.31E-04 
KEGG_PATHWAY hsa04810:Regulation of actin cytoskeleton 37 2.305296 8.66E-04 
KEGG_PATHWAY hsa04070:Phosphatidylinositol signaling system 17 1.05919 0.001823 
KEGG_PATHWAY hsa05200:Pathways in cancer 49 3.05296 0.002683 
KEGG_PATHWAY hsa04020:Calcium signaling pathway 30 1.869159 0.00345 
KEGG_PATHWAY hsa00562:Inositol phosphate metabolism 13 0.809969 0.005223 
KEGG_PATHWAY hsa05414:Dilated cardiomyopathy 18 1.121495 0.007423 
KEGG_PATHWAY hsa00310:Lysine degradation 11 0.685358 0.008857 
KEGG_PATHWAY hsa05412:Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
15 0.934579 0.014803 
KEGG_PATHWAY hsa05210:Colorectal cancer 16 0.996885 0.015651 
KEGG_PATHWAY hsa04270:Vascular smooth muscle contraction 19 1.183801 0.024109 
KEGG_PATHWAY hsa04530:Tight junction 21 1.308411 0.037042 
KEGG_PATHWAY hsa05110:Vibrio cholerae infection 11 0.685358 0.04396 
KEGG_PATHWAY hsa04144:Endocytosis 26 1.619938 0.057737 
KEGG_PATHWAY hsa04722:Neurotrophin signaling pathway 19 1.183801 0.058201 
KEGG_PATHWAY hsa05222:Small cell lung cancer 14 0.872274 0.065042 
KEGG_PATHWAY hsa00510:N-Glycan biosynthesis 9 0.560748 0.076836 
KEGG_PATHWAY hsa05416:Viral myocarditis 12 0.747664 0.084698 
KEGG_PATHWAY hsa04330:Notch signaling pathway 9 0.560748 0.085052 
KEGG_PATHWAY hsa05217:Basal cell carcinoma 10 0.623053 0.085893 
KEGG_PATHWAY hsa05212:Pancreatic cancer 12 0.747664 0.0916 
 
 
